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ABSTRACT
Venous stasis is associated with leucocyte & endothelial activation as well as local
growth factor response in chronic venous distasease (CVD). There is no good data on
the response of this increased activation to treatment. The theme of this thesis was to
show changes in leucocyte/endothelial activation as well as microcirculatory stasis in
response to medical, surgical and compression therapy. Thus these may act as objective
measures of response to treatment.
Vascular endothelial growth factor (VEGF) is being investigated extensively in various
arterial scenarios I demonstrated high plasma levels of among patients with CVD for the
first time. Levels in patients were about 60% higher (82pg Vs 52 pg in controls). This
may represent an (reparative!) angiogenic response existing along with the leucocyte
inflammatory response. I used a model of medical treatment (60 days oral flavonoid
therapy) and demonstrated significant change in plasma VEGF (50% reduction i.e. 98
pg to 57 pg/dl), ICAM (32%), VCAM (29%) & lactoferrin (36%) levels in patients.
Thus I showed that endothelial cell activation (ECA) as well as VEGF might be used as
an objective surrogate marker in CVD. I propose that amelioration of endothelial
activation may be a mechanism of action for these compounds.
I studied the response of these parameters to surgical treatment of varicose veins in 20
patients. I showed that there is an increased plasma lactoferrin at 4 weeks that goes
below starting base line levels at 6 months (865 Vs 870 Vs 519). VEGF levels
continued to increase (65 Vs 83 Vs 134 pg/dl) in these patients and this may represent
vascular remodelling. Although not all of them are easily explainable, the
microcirculatory parameters were shown to have a definable response to therapy.
I used a new apparatus (Laser capillary anemometer) to assess the response of the
velocity of blood in the microvasculature of patients with venous, arterial or mixed
disease. I demonstrated that compression increases velocity of blood in the sub-papillary
plexus & lower levels of compression (20 mm Hg) are more effective in increasing
velocity in patients with mixed disease. This may explain the basis for using
compression therapy in these patients.3
Thus I have shown that various parameters of microcirculation may be used to assess
the response to therapy in CVD. Future uses of these findings may include design of
new and novel therapeutic approaches and to prognosticate for the development of skin
changes and ulceration of the leg in CVD.4
Figure 1 Illustrates both the leucocyte priming as well as presence of factors in the serum that
mediate it in CVD. Micrographs of polymorphonuclear granulocytes showing tetrazolium
crystal formation after nitroblue tetrazolium reduction (A,B,C) and projection of pseudopods
(D,E,F). Control blood of individuals without symptoms (A,D), patient whole blood (B,E), and
native granulocytes incubated in patient plasma (C,F). Bar represents 10 m. Magnification is
same for all patients. From Takase S et al with permission.
15
Figure 2 depicts the interaction between the leucocytes and the endothelium that has become so
important in the understanding of tissue damage in CVD. The reduced arterio-venous pressure
gradient (PA-PV) due to lower flow rates leads to leucocyte margination (decreased shear/
physical characteristics of the leucocyte). This leads to increased cell adhesion molecule
expression. There is initial weak adhesion followed by stronger adhesion. Different adhesion
molecules are involved in these processes. These leucocytes eventually diapedese. These
activated leucocytes may cause tissue damage locally either directly or by cytokine release
triggering a chemotactic reaction for other white cells. The adhesion molecule expression has
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All the experimental work described in the thesis is original and was undertaken by me,
as a member of the research team at the vascular laboratory at the department of surgery
UCL- Medical School between 1996 and 1998. The thesis is based entirely on original
observations carried out by me. The work descried in this thesis ‘Objective assessment
of the microcirculatory response in venous disease to therapy’’ stems from ideas
developed jointly by Mr. PD Coleridge Smith and myself. Neither this thesis nor any
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PART I
INTRODUCTION12
Figure 3 Leonardo Da Vinci provided drawings of the vascular system around 1452.
This figure is a reproduction of one of them.13
1.1 Development of the Understanding of CVD
The clinical presentations of CVD have been recognised since antiquity. Relics suggest
that the ancients had noted the presence of venous ‘swellings’ on the lower limbs and
that they regarded them as abnormal. The Ebers papyrus of 1550 BC is the first
recorded evidence of varicose veins regarding them as ‘serpentine windings’. A Greek
illustration from Athens dated fourth century BC shows the medial side of a massive leg
with what appears to be a varicose vein.
2 Presently the changes in the microcirculation
of the skin in patients with chronic venous disease (CVD) can now be studied with the
help of recent advances in technology.
Figure 4. Leonardo Da Vinci’s detailed drawing of the tributaries at the sapheno
femoral junction.14
Following this, from the 10th to the 18th century, various physicians, including Haly
Abbas, Avicenna and Fallopio, attributed ulceration of the legs to the accumulation of
black bile, bad humors, menstrual blood and faeculant humors, and that ulceration in the
legs served a useful purpose in getting rid of these vile substances,
3 such that if an ulcer
healed it was deliberately broken down. However, Maitre Henri de Mondeville realized
that compression bandages helped ulcer healing (drove out evil humors), Ambroise Paré
also realised this in 1533.
4
Figure 5. An illustration of a ‘venous ulcer’, perforator veins and associated varicosities
of below knee veins by John Gay (1866)15
Figure 6.The first recorded drawings of venous valves by Saloman Alberti circa 1585
Trendelenberg (1891) described ligation of the long saphenous vein in the upper third of
the thigh. The operation of flush ligation of the sapheno-femoral junction has since been
wrongly ascribed to him. Keller and Mayo wrote about stripping of the long saphenous
vein in 1905. The work on vascular anastomoses that earned Alexis Carrel his Nobel
Prize included attempts at vein transplantation for deep venous reconstruction. Homans
in 1916 clearly established the relationship between previous deep vein thrombosis,
recanalisation, valve destruction and ulceration of the Leg. Homans described two types
of ulcers; varicose ulcers associated with superficial varicose veins and generally cured
by removal of these veins, and ‘post-phlebitic’ venous ulcers, which were intractable to
palliative treatment and generally incurable by removal of varicose vein alone. Linton
5
and Cockett have since drawn attention to incompetence of the communicating veins of
the calf as a potential cause of venous ulceration. Linton in 1938 described the anatomy
and pathological significance of the perforating veins of the leg and performed sub-
fascial ligation of incompetent perforators to control venous ulcers. Cockett in 1955
hypothesized that transmission of high pressure to the skin through incompetent
perforating veins led to skin changes characteristic of venous insufficiency. He
described extra-fascial ligation of perforating veins believing that preservation of the
deep fascia was important in preserving effective calf pump function.
6 Palma used the
femoro-femoral bypass operation for treating iliac vein obstruction and published it
three years later.16
PATHOPHYSIOLOGY-DEVELOPMENT OF CONCEPTS
Interest in micro-circulatory aspects of CVD mostly stems from the skin complications
caused by it. The prevailing theory about venous ulceration has been that of some sort
of ‘impaired circulation’ leading to diminished nutrition. John Homans of Harvard first
Figure 7 The white cell trapping hypothesis according to Coleridge Smith et al. This
theory draws on earlier studies that showed increased leucocyte-endothelial interaction,
capillary micro-thromboses, leucocyte activation and sequestration in CVD.
proposed the theory of venous stasis in 1916.
7 He coined the term postphlebitic
syndrome to describe the skin changes in CVD. He stated ‘’over-stretching of the vein
walls and destruction of the valves……interferes with the nutrition of the
skin……therefore, skin, which is bathed under pressure with stagnant venous blood will
form permanent open sores or ulcers’’.
Blalock showed that the o2 content of blood from the femoral vein in CVD was higher
than that from the contra lateral side. This led to the (not conclusively proven)
hypothesis regarding arterio-venous shunting of blood in CVD.
8
Vein Valve Damage
There are suggestions that venous hypertension causes a shear stress dependent
leucocyte- endothelial interaction, which has the manifestation of chronic inflammation.























vein wall and the parenchyma of the valves. There may be elastin and collagen damage




Leucocytes are also implicated in the skin changes seen in CVD. Thomas, working with
Dormandy reported that 25 % fewer white cells left the dependent foot of the patients
with venous hypertension.They concluded that this was due to trapping of leucocytes in
the microcirculation secondary to venous hypertension.They sepeculated that these had
become activated and caused damage to the microcirculation and the overlying skin.
10
The white-cell trapping theory has established itself as the most plausible theory
amongst contemporary phlebologists. Schmid-Schonbein showed that the likelihood of
the white cell to adhere to the endothelium increased with decreasing shear stress (as
would be seen in venous hypertension due to the decreased arterio-venous gradient i.e.
PA-PV across the capillary)
11. They also showed that the leucocyte being larger and less
deformable than the erythrocytes are pushed to the periphery in the capillaries as the red
cells overtake them. It has also been shown that cellular adhesion molecule (CAM)
expression is encouraged by leucocyte-endothelium interaction. Thus the contact
between the leucocyte and the endothelium is increased in CVD. This fact led
investigators to think, and prove, that some leucocytes were sequestered in the leg
during venous hypertension
12.
The types of leucocytes directly involved in the skin changes have remained
controversial. T-lymphocytes, macrophages and mast cells have been identified. Skin
biopsies have shown that macrophages and lymphocytes predominate in the
liposclerotic skin.
13 It is possible that ‘massive’ activation of these mononuclear cells
may precipitate skin ulceration.Cytokines have since been shown to be involved
actively in this process of leucocyte activation-adhesion-migration-tissue damage
sequence. Interleukin-1 (IL-1) and tumor necrosis factor (TNF) are two of the more
widely studied
14. Both cytokines reduce fibrinolytic activity of the monocytes that may
be contributory to the fibrin cuffs seen in CVD. ……
…ark…………………………………18
Flow may be non-uniform in CVD. There may be micro-thromboses; this may lead to
organized localized heterogeneous perfusion. There is peri-capillary oedema and
erythrocytes extravasation. The exact steps in the mechanism of these changes are
unknown. Continuing leucocyte mediated injury along with the reparative response
suggested by my work may be important contributory factors.
15
1.2 Epidemiology of CVD
Venous disease of the legs is common, hence the justification for the extensive research
devoted to CVD. CVD may affect up to 20% of the total population,
16,
17 a risk that
increases with age. The prevalence of healed and/or active leg ulceratiuon in the
population is approximately 1%.
18
In one study from London age and female sex were independent risk factors for varicose
veins and phlebitis. Thrombosis and pulmonary embolism were both significantly
associated with the presence of diabetes, female sex, and increased age. A quarter of the
sample had varicose veins, and that nearly a third had had venous disease of some kind
at some time. This suggested that venous disease may place a heavier burden on health
resources than had been realised
19.
The Edinburgh Study
The Edinburgh study was a cross sectional study of a random sample of 1566 subjects
18 to 64 years of age. It reported telangiectasis in 80 % of men and 85% of women.
Varicose veins were present in 40% men and 16% women. Ankle oedema was seen in
7% men and 16% women. Active or healed venous leg ulcers occurred in
approximately1% of the general population.
Analysis of varicose veins in Edinburgh population (Lee et al 2003) provided the
following results of inter-relationships between a range of lifestyle factors and risk of
varicose veins. This was to identify which factors may be implicated in the aetiology.
An age-stratified random sample of 1566 subjects (699 men and 867 women) aged 18 to
64 years from 12 general practices throughout Edinburgh was used. A detailed self-
administered questionnaire was completed, and a comprehensive physical examination19
determined the presence and severity of varicose veins. Self-reported evidence
suggested a familial susceptibility. Future genetic studies may be warranted.
20 The
slightly higher age-adjusted prevalence of varicose veins in men than in women (39.7%
versus 32.2%) was not explained by adjustment for an extensive range of lifestyle risk
factors (male odds ratio [OR] 2.11, 95% confidence interval [CI] 1.51–2.96). In both
sexes, increasing height showed a significant relationship with varicose veins (male OR
1.50, 95% CI 1.18–1.93 and female OR 1.26, 95% CI 1.01–1.58). Among women, body
mass index was associated with an increased risk of varicose veins (OR 1.26, 95% CI
1.02–1.54). No consistent relationship with any lifestyle factor was shown. It was also
concluded that Using RD > 0.5 as a cut-off point decreases the specificity and risks
defining more normal veins as incompetent, whereas using RD > 1.0 as a cut-off point
decreases the sensitivity and risks defining more incompetent veins as normal. There are
obvious limitations in using presence of reflux in individual vein segments as a test for
the presence or absence of “venous disease.” Accepting these limitations, calculations of
sensitivity and specificity tended to support the use of 0.5 seconds as the cut-off point
for RD in the below knee popliteal vein segment as a test for venous disease. In the
upper LSV, however, there was little difference in the sensitivity and specificity
between RD >0.5 and RD >1.0.
European Studies
The French study reported in 2004
21 documented the prevalence of varicose veins, skin
trophic changes, and venous symptoms in a sample of the general population of France.
It also looked at their main risk factors and assessed relationships between them. This
cross-sectional epidemiologic study was carried out in the general population of 4
locations in France: Tarentaise, Grenoble, Nyons, and Toulon. Random samples of 2000
subjects per location were interviewed by telephone, and a sub-sample of subjects
completed medical interviews and underwent physical examination, and the presence of
varicose veins, trophic changes, and venous symptoms was recorded.
Prevalence of varicose veins, skin trophic changes, and venous symptoms was not
statistically different in the 4 locations. In contrast, sex-related differences were
observed: varicose veins were found in 50.5% of women versus 30.1% of men (P <
.001); trophic skin changes were found in 2.8% of women versus 5.4% of men (P _20
NS), and venous symptoms were found in 51.3% of women 51.3% versus 20.4% of
men (P < .001). Main risk factors for varicose veins were age and family history in both
sexes, and pregnancy in women. Female sex was a significant factor only for non-
saphenous varicose veins. Varicose veins, age, and pitting edema were the most
significant risk factors for trophic skin changes. The risk factors for venous symptoms
were female sex, varicose veins, and prolonged sitting or standing. A negative
relationship with age was found in women.
Cost Considerations
In the UK the total cost to the National Health Service is substantial. Data from the
Riverside study in London suggested that between £230 and £600 million is spent
annually to care for patients suffering with venous ulcers.
22 Much of this is spent on
care in the community, with 30% of community nursing time spent on treating leg
ulcers. Even a small improvement in healing and recurrence rates may produce
substantial savings. Furthermore, the indirect costs arising from leg ulcer disease, for
example, time lost from work, permanent disability and early retirement, are even
higher. It has been estimated that, in the UK, five hundred thousand working days are
lost per year due to this condition.
23
Prevalence Studies outside UK
The prevalence of CVD is much lower in African and Asian or Australasian aborigine
populations although immigrant subjects from these regions have the same risk as the
population of their host country. Sedentary habits, obesity, tight clothing may provide
part of the explanation.
The first major study into the epidemiology of varicose veins was the US National
Health Survey of 1935-6, which, in a questionnaire of 2.8 million people, estimated that
varicose veins were present in 1.75 million of the total population of the United States.
This survey was repeated in 1959-61, which suggested a point prevalence of 2.25% for
severe varicose veins (0.8% men, 3.5% women). A similar study in the UK based on
interviews gave a prevalence of 2.25% for varicose veins (1.41% men, 3.74% women),
and in Denmark a survey of patients attending hospital with varicose veins found an
incidence of 1.7% of males and 2% of females in one year. However, Borschberg
(Basel survey) has criticized these surveys, which concluded that statistically acceptable21
evidence on the prevalence of varicose veins could not be drawn from them. There have
since been several major regional surveys into both varicose veins and venous
ulceration: in a study from Sweden
24 the point prevalence of leg ulceration was
estimated at 6.4 per 1000 in subjects. In a further study from Sweden,
25 the period
prevalence per year from a retrospective analysis of medical records was found to be
two to four per thousand, and a more recent Swedish study has found the point
prevalence to be 3.05 per 1000.
26 The Tecumseh Community Health Study in Michigan
suggested that 24 million Americans had "significant" varicose veins (7.4% men and
16.6% women), with 5% having skin changes and 0.5% having active or healed ulcers.
In Czechoslovakia, 6.6% of men and 14% of women had varicose veins, and 1% of the
population over 15 was found to have present or past leg ulceration. The Basel III study
found a prevalence of 4.2% for severe varicose veins and 1% for active and healed
ulcers in a highly selected population of industrial workers, and in New Zealand
Beaglehole et al.
27 found varicose veins in 36.3% of Maori men and 47.4% of Maori
women, compared to 21.5% of men and 40.4% of women in the white population.
Overall, it would appear that there is a prevalence of varicose veins of approximately
2%, although local surveys have shown higher levels. Data from the Framingham study
supports this.
28
Prevalence of Venous Leg Ulceration
There have been several studies on the prevalence of active ulceration. In Ireland, the
prevalence of current ulcers was found to be approximately 1.5% of the population. In
Australia the point prevalence of active leg ulcers of greater than four weeks duration
was found to be 1.05-1.1 per 1000 of the population.
29,30 Sixty-seven percent of these
ulcers had venous pathology, 27% had arterial disease, and the rest suffered from
diabetes, rheumatoid arthritis and other miscellaneous conditions. In Scotland the point
prevalence of active leg ulceration was found to be 1.48 per 1000 of the population, and
in England the point prevalence of current ulcers was found to be 1.8 per 1000.It has
also been estimated that for every patient with an ulcer there are 20-30 patients with the
characteristic skin changes of lipodermatosclerosis, which precede ulceration.
31
Overall, Callam, reviewing the literature, suggests a point prevalence of 0.1-0.2% for22
active ulceration in Western Europe, with 1% of the population suffering from
ulceration at some time in their lives.
32
Sex Distribution
It is generally believed that varicose veins and ulcers are more common in women. All
the above mentioned studies with the exception of the Basel III study (carried out in
factory workers with relatively few women) have shown a female preponderance,
ranging from 1.5:1 in the Swedish and Czech studies, to 2:1 in the studies from
Australia, Ireland and England. Females may also be more prone to varicose veins as
pregnancy is often thought to be a risk factor for their development. In 1942 Lake had
observed that in a group of 563 women that 67% of childless women and 80% of
women with children had varicose veins. It is estimated that between 8 and 20% of
women develop varicose veins during pregnancy.
33 It has been shown that multiple
pregnancies increase the prevalence of varicose veins.
34 The role for progestogen
receptors is discussed in the chapter on pathology.
Figure 8 Results of DUPLEX confirmed reflux in the lower limbs of a cross sectional
study of 1566 subjects. Proportion of participants either leg, by age. Data is grouped
reflux of 0.5 seconds or more duration and reflux of more than 1.0 seconds. This graph
is from the Edinburgh Vein study and shows the increasing prevalence of reflux with
age23
However, in patients with symptomatic veins GSV reflux combined either with SSV
reflux and/ or perforator reflux has been shown to correlate with severity of symptoms
and skin changes (The Edinburgh Vein Study)
17.
Age Distribution
The Basel III study has shown an age-related increase in the prevalence of ulceration
from nil under the age of 35 to 4.8% in women over the age of 50. Data from the other
studies show similar trends. The cross sectional Edinburgh study of DUPLEX
examination of lower limbs also found increasing venous insufficiency with age.
17
Figure 9 Shows the prevalence of DUPLEX confirmed venous reflux in a cross-
sectional survey of 1566 subjects ranging in age from 18 to 64 years, randomly selected
from 12 general practices. It remains unknown as to what percentage of these subjects
would progress to clinical chronic venous disease.
The US National Health Survey of 1961 noted varicose veins in 24% of whites
compared to 10.4% of colored people; Mekky assessed two groups of females in
England and Egypt, finding 32% of English workers had varicose veins compared to
5.8% of Egyptians.
35 Similarly Maffei found a significant difference between whites24
(49%) and non-whites (35.8%) in Brazil. Beaglehole, who concludes that varicose veins
are commoner in Caucasian western populations., has summarized the available data
36.
Inheritance
It is widely believed that varicose veins have a familial bias. However, varicose veins
are extremely common, and accordingly most sufferers are aware of other family
members with varicose veins. Several studies have found a positive association
between varicose veins and family history,
, though all these studies are open to bias in
that relatives were not examined. However, Belcaro found a positive association in a
small study using Doppler examination in both parents and offspring.
37 According to
one study the risk of developing varicose veins for the children (in later life) was 90%
when both parents suffered from this disease, 25% for males and 62% for females when
one parent was affected, and 20% when neither parent was affected.
124 Cytogenetic
abnormalities have been described in familial varicose vein tissue. Cytogenetic
investigation of primary cell cultures from fragments of varicose veins of patients
showed metaphases with structural abnormalities, clonal trisomies of chromosomes 7,
12, and 18, and monosomy of chromosome 14 only in cases with the familial type,
while the sporadic cases had no similar chromosome aberrations
38.
1.3 Applied Venous Physiology of the Lower Limbs.
60-75% of the blood in the circulatory system is located in the veins. Unlike the
splanhnic veins the skeletal muscle veins are not known to have abundant sympathetic
nervous supply. These are however responsive to circulatory catecholamines. There are
considerable changes in the venous pressure in the lower limbs in the erect posture. The
pressure remains fairly constant at the hydrostatic indifferential point just below the
diaphragm. When upright, there is loss of approximately 500mls of blood into the
venous circulation. The extra loss of interstitial fluid is collected by the lymphatic
system. Reversal of flow in the vein is essential for venous valve closure. A velocity of
approximately 30 cm/sec woul usually cause valve closure. Venous valve imaging by
advanced US imaging has demonstrated pulsatile flow with regular opening and closure
cycles. The cross-sectional area across the valve is 35% smaller even in the fully opened25
state. Two flow streams are generated during forward flow. The first one is a proximally
directed jet. The second is a vortex flow into the valve cusp. There is suggestion that
valve closure occurs when the vortex flow exceeds the proximally directed jet flow.
39
Pressure in the superficial and deep veins is similar during periods of ‘quiet standing.
The 1 mm or so higher pressure in the deep veins may keep the perforator valves closed.
It is thought that the perforator valves may protect the skin and underlying tissues from
the extreme venous pressures generated during muscular contraction (100-130 mm Hg).
Their exact role, however, is the subject of much debate.
In the heel-strike position the plexuses under the heel are compressed and blood finds its
way into the calf. From there muscular contractions (aided by the function of the valves)
drive the blood into the deep veins.
THE CALF MUSCLE PUMP & ORTHOSTATIC VENOUS PRESSURES
The principal participants in the pumping mechanism are the veins of the calf within the
calf muscles, gastrocnemius and soleus. These usually contain about 250ml of blood.
Additional muscle pumps are also recognised in the thigh and foot. The latter has a
much smaller capacity (about 25ml), but is probably responsible for return of most
blood from the foot. It may have a 'pump-priming' effect on the calf muscle pump. The
calf pump is often referred to as the peripheral heart. If the calf muscles are not
contracted periodically it may result in syncope in an erect subject.
Venous flow is affected by the contractile force of the heart, static filling pressure and
gravity. The pressure in the venules being 15-20 mmHg and 0-6 mmHg in the right
atrium During calf contraction, the pressure in and around all the structures contained
within the deep fascia becomes raised resulting in all the intra-muscular veins becoming
completely compressed resulting in the blood that is present in these veins being
emptied by the calf muscle pump into the outflow tract which is the popliteal vein. The
large veins within the gastrocnemius and soleus muscles form the main chamber of the
pump but all the other deep veins participate. Distal deep venous valves prevent axial
reflux and valves in the communicating veins prevent reflux from the deep venous
system to the superficial venous system. (With continuous exercise, the calf blood
volume is reduced by 1.5 - 2.0 ml/100ml mainly as a result of the compression of the26
veins in the pump chamber and the average expelled volume is approximately 30 - 40
ml/100 ml, that is, a significant proportion of all the blood within the pump. The pump
will normally expel this volume in four or five contractions though one single sustained
contraction can expel as much). As the exercise rate increases, the muscle blood flow
may increase to 20 - 30 ml/100ml/min, that is, an additional load of 600 ml/min on the
calf pump. The calf must contract about 20 times every minute to expel this increased
blood flow. At a normal walking pace of 80 steps/minute, each calf contracts about 40
times/minute so the calf muscle pump can easily deal with the high blood flow of
exercise hyperaemia. The popliteal vein is a large bore vein which offers virtually no
resistance to outflow. The gradient of 10 - 15 mmHg between the small veins and the
heart is sufficient to ensure venous blood flow in the supine position. The increase in
gradient produced by the calf muscle pump during contraction is sufficient to ensure an
adequate rapid venous return to the heart during vigorous erect muscle exercise.
As the calf muscles relax, valves cephalad to the muscle pump close and prevent reflux
of blood from more proximally in the axial veins. The valves in the communicating
veins open and allow normal blood flow from the superficial to the deep venous system.
In addition, inflow from the lower extremity capillary beds re-primes the calf muscle
pump for a subsequent contraction. At the moment when the calf muscles relax their
contained veins are empty, at zero pressure and as yet unfilled by arterial inflow. As the
veins are collapsed, they are unaffected by hydrostatic pressure. On the other hand, the
superficial veins are full and subjected to hydrostatic pressure plus the remnant of
cardiac generated pressure. The pressure gradient between the two compartment may
become 100 - 110 mmHg resulting in blood immediately flowing from the superficial to
the deep compartment through the many communicating veins (Bjordal et al, 1970).
This empties the superficial compartment and reduces its pressure (Pollack et al, 1949).
Therefore the function of the calf muscle pump is vital in ensuring venous return from
the lower limbs during exercise and the reduction of the superficial venous pressure thus
removing the damaging effects of the hydrostatic pressure.
PHYSIOLOGICAL INVESTIGATION OF ‘VENOUS EMPTYING’ OF THE LOWER
LIMBS27
The effectiveness of the calf muscle pump can be investigated by several methods. The
ambulatory venous pressure measurement technique measures deep venous pressure
directly by placing a needle in a dorsal foot vein and connecting it to a standard pressure
transducer and a recording device. The baseline dorsal foot vein pressure is
approximately 80-90 mmHg in subject standing upright with no calf muscle movement.
This pressure is predominantly hydrostatic and is directly related to the distance from
the needle canulation site to the right atrium. The high resting distal venous pressures in
normal subjects in the upright position is due to the lower extremity venous valves
being partially open. The venous pressure may transiently rise further after calf muscle
contraction reflecting the presence of physiologic reflux before valve closure. As the
calf veins are emptied by the contraction of the calf muscle pump, the pressure steadily
decreases and as the calf veins empty there is a functional shortening of the hydrostatic
fluid column as valves close in the axial veins at progressively lower levels. When the
hydrostatic fluid column is maximally shortened and the veins maximally emptied a
new baseline pressure is obtained, the ambulatory venous pressure. This is generally
reached after ten successive up and down tiptoe movements. This pressure reflects the
point where the forces promoting venous return are balanced by arterial inflow and
inflow from the superficial veins to the deep system. The ambulatory venous pressure is
generally below 40 mmHg in normal subjects.
Other Aspects of the Venous Circulation
When the subject is in the supine position, the respiratory cycle plays an important part
in the venous return from the lower extremities. In the supine position, the pressure in
the foot vein of the subject represents the increment of pressure that remains after the
dissipation of kinetic energy generated from the heart by the resistance of the arterioles
and capillaries. This foot vein pressure in the supine position is approximately 15
mmHg. The right atrial pressure is normally between 0 and 2 mmHg so the venous
return to the heart in the supine position is generated by a pressure gradient of 13-15
mmHg. During inspiration, the volume of the veins of the thorax increases and the
pressure decreases in response to reduced intrathoracic pressure. Expiration leads to the
opposite effect, with decreased venous volume and increased pressure. The venous
response to respiration is reversed in the abdomen, where the pressure increases during28
inspiration because of the descent of the diaphragm, and decreases during expiration as
the diaphragm ascends. Increased abdominal pressure during inspiration decreases
pressure gradients between peripheral veins in the lower extremities and the abdomen,
thus reducing flow in the peripheral vessels. During expiration, when intra-abdominal
pressure is reduced, the pressure gradient from the lower limbs to the abdomen is
increased and the flow in the peripheral veins rises correspondingly. The respiratory
effects are usually associated with clear phasic changes in venous flow in the
extremities. These can be detected by various instruments, including many forms of
plethysmography and Doppler flow detectors. The respiratory changes in venous
velocity may be exaggerated by respiratory manoeuvres, such as the Valsalva
manoeuvre, which increases intra-thoracic and abdominal pressures and decreases,
abolishes, or even reverses flow in some peripheral veins. Also, the respiratory effects
on venous flow may be diminished in the lower limbs of individuals who are chest or
shallow breathers and whose diaphragm may not ascend sufficiently to change intra-
abdominal pressure.
In the fully upright position, the expiratory promotion of venous flow is not enough to
overcome gravitational hydrostatic forces and promote adequate venous return. The
contraction of the calf muscles is required to overcome this gravitational force. In the
upright position, the column of blood between the heart and the foot exerts a
gravitational force known as the hydrostatic pressure. The pressure in the foot vein then
becomes the sum of (15 mmHg)the approximate foot vein pressure in the supine
position plus the hydrostatic pressure. This hydrostatic pressure is exerted by the
column of blood between the foot and the level of the manubrium sterni, the point used
as the zero reference for CVP measurement.
1.5 Biology of Chronic Venous Disease
Endothelial/ leucocyte activation is being increasingly recognised as an important
marker event that could be used to prognosticate the development of complications in
many scenarios.
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The aetiology of skin damage in patients with chronic venous disease is incompletely
understood. In 1987 Moyses et al
18
reported a 15 and 20% reduction in the number of
white cells leaving the feet in eight healthy subjects during a 45 minute period of sitting.
Thomas et al16 found a larger fall (of 24%) in a group of ten patients with chronic
venous insufficiency compared to normal control subjects (5%) following 60 minutes of
leg dependency. After the subjects were allowed to lie supine, the white cells returned
to the circulation. Coleridge Smith et al. using video microscopy showed that the
number of visible capillaries fell during a period of venous hypertension, suggesting
that increased venous pressure reduced capillary perfusion and hence the capillary flow
rate. The white cell trapping hypothesis proposed that raised venous pressure led to
decreased flow, This causes leucocyte margination, activation, adhesion, and extra-
vascular migration. It was proposed that the release of proteolytic enzymes and free
radicals from activated leucocytes resulted in tissue damage. This is supported by
histological evidence of white cell infiltration of the tissues
41 in skin biopsies.
Bollinger
42 using capillary fluorescence microscopy showed that there were areas of
skin with no apparent blood flow in patients with chronic venous insufficiency, which
was restored when elastic stockings were applied. He suggested that some of the
capillaries were not functioning because of thrombosis. He also demonstrated increased
diffusion of fluorescein out of capillaries in patients with chronic venous insufficiency,
indicating that capillaries in chronic venous insufficiency are much more permeable
than normal to this molecule, suggesting abnormal endothelial function. Using
simultaneous fluorescence and light capillary microscopy Franzeck et al. described the
appearances of capillary loops that did not appear to be perfused, suggesting capillary
thrombosis to be a feature of chronic venous insufficiency
43. Coleridge Smith et al also
showed using video microscopy that the number of visible capillaries fell following a
period of venous hypertension, suggesting that increasing venous pressure reduced the
capillary perfusion pressure and hence the capillary flow rate.
It is well known that low capillary flow is a potent initiator of white cell adhesion
44 45-46
and Schmid-Schonbein has shown that the likelihood of a leucocyte adhering to a vessel
wall is inversely related to the shear force exerted on it.
11 On the basis of these
observations Coleridge Smith et al. put forward the white cell trapping hypothesis,
17
postulating that the fall in the count of capillaries in the leg skin of patients with chronic30
venous insufficiency on dependency was due to reversible adherence of white blood
cells to the endothelium. The hypothesis postulates that an increase in venous pressure
during standing or walking causes a reduction in capillary flow rate, resulting in
trapping of white blood cells in the leg. The trapped white cells plug the capillaries
resulting in areas of ischaemia, and also become activated releasing proteolytic enzymes
and toxic metabolites (free radicals) that damage the capillaries, and chemotactic
substances that attract more white cells. Activated white cells have been shown to be
mediators of tissue damage in a number of organs including the heart
47,48 brain, lung
and kidney.
148,49 Monocytes release cytokines interleukin-l (IL-I) and tumour necrosis
factor-alpha (TNF-alpha) when activated. These may also activate endothelial cells
resulting in increased vascular permeability.
50 The latter may be the mechanism by
which fibrinogen passes into the pericapillary spaces and forms fibrin cuffs.
Skin biopsies taken from three groups of patients with chronic venous disease (no skin
changes; LDS only; LDS and ulceration) showed that there was a low number of white
cells in the skin of patients without LDS, while in patients with LDS but no ulceration,
the number of white cells in the skin was increased eight-fold, and in patients with
ulceration, there was a 40-fold increase in the number of white cells in the skin.
51 . A
more recent study has confirmed increased numbers of white cells in the skin of patients
with LDS. Immuno-histochemical features suggest that they are mainly macrophages
and lymphocytes.
52
The molecular mechanism of leucocyte activation, leucocyte-endothelial adhesion and
extra vascular migration has been the subject of much recent study. Various adhesion
molecules are expressed by circulating leucocytes and endothelial cells in response to
diverse physiological and pathological stimuli, leading to firm adhesion of leucocytes to
the endothelium with subsequent degranulation or extra vascular migration.
Experimental work to study white cell activation in venous disease was undertaken by
Shields who investigated neutrophil activation by measuring neutrophil degranulation
products lactoferrin and elastase in both normal subjects following experimental
venous hypertension and patients with chronic venous disease. Neutrophils posses two
types of granules, primary and secondary, which contain various chemical substances.31
Upon activation these are released into phagocytic vacuoles and some is spilled into the
plasma. Lactoferrin is an iron binding glycoprotein found in secondary granules of
neutrophils and has been used as an indicator of neutrophil activation in several disease
states including various forms of arthritis, pneumonia
53 and sepsis.
54,
55 It is produced in
response to various stimuli such as TNF-, FMLP, opsonised bacteria, C5a coated
bacteria/immunoglobulins and lipopolysaccharides, and has various functions
Neutrophil Elastase is a 29KD protein which is stored in the primary granules
56 and
released during the process of phagocytosis or when neutrophils are activated by other
stimuli such as soluble immune complexes, C5a or endotoxins.
57 It is chemotactic,
degrades fibrinogen
58 and has been implicated in the tissue destruction seen in venous
disease by causing endothelial cell injury.
59 In a series of experiments Shields et al
showed that there was a rise in plasma lactoferrin levels in normal subjects in response
to venous hypertension. Patients with varying severity of venous disease all had raised
lactoferrin levels compared to age and sex matched controls
161. Similarly plasma
elastase was noted to be higher in patients with venous disease compared to age and sex
matched controls.
20 However, no difference was found between the various patient
groups and it was concluded that neutrophils are probably responsible for acute
inflammatory changes and for initiating vascular endothelial damage but unlikely to
account for the skin damage seen in patients with chronic venous insufficiency.
1.6 ENDOTHELIAL CELL ACTIVATION (ECA)
The endothelium is extremely heterogenous and varies from one anatomical site to
another. Not all endothelial cells exhibit histocompatibility locus A (HLA) class II
molecules.
60 ECA was first used as a term in 1960 when it was noted that endothelial
cells showed both a loss of integrity (leakiness, cellular oedema)as well as increased
amounts of intracellular organelles.
61 Willms-Kretschmer et al implied in this paper that
there were functional consequences to the altered morphology.
The functions of the endothelium normally include maintainence of selective
permeability, transduction of blood borne signals, regulation of vasucular tone,
antithrombogenic properties, regulation of leucocyte adhesion as well as regulation of
vascular growth. Agents causing ECA are diverse. These include cytokines (notably IL-
1 & TNF), Bacterial endotoxins (lipopolysaccharides) , complement, viral infections32
and immune complex deposition. There are two distinct types of endothelial cell
activation viz. type-I ECA and type-II ECA.
Type-I ECA (endothelial cell stimulation) does not require denovo protein synthesis or
gene upregulation. This response may occur within seconds of a stimulus being applied.
There is retraction of the endothelial cells from each other and the subendothelium is
exposed. There is increased expression of P-selectin, release of Von Willebrand factor
and secretion of platelet activating factor (PAF).
Type-II ECA requires a period of time (usually up to 4-6 hours in vitro) to be estalished.
It involves gene activation, transcription and increased protein synthesis.. Increased
transcription signalling involves leucocyte adhesion molecules (E-selectin, ICAM-1,
and VCAM-1), cytokines (IL-1, IL-6, and IL-8), monocyte chemoattractant protein
(MCP) and tissue factor. At the same time thrombomodulin and other significant
molecules are lost from the endothelial surface.
Processes Involved In ECA
These are shown in Figure 12 and include loss of vascular integrity, expression of
leucocyte adhesion molecules, secretion of cytokines, prothrombotic changes and
upregulation of HLA molecules. Loss of integrity involves retraction of the cells from
each other. This allows proteins and cells to pass from the lumen to the outside. The key
leucocyte adhesion molecules are E-Selectin, P-Selectin and the integrins. The
endothelium is both a source of cytokines as well as a target for these. The cytokines
include IL-1, IL_6, IL-8, TNF, CSF and MCP-1 amongst others.
The prothrombotic changes seen in ECA include alteration of its normal anti-platelet,
anti-coagulant and fibrinolytic effects. The decreased fibrinlytic effect is probably
mediated through increased production of PAI-1 (Plasminogen activator inhibitor-1)
that counters the normal tisssue plasminogen activator. VW factor is one of the
molecules expressed in ECA; it is also an acute phase protein. Other coagulation
pathways affected include expression of anti-thrombin III as well as heparan sulfate.33
Table 1 shows the various integrin adhesion molecules along with their ligands.
Integrin Other Name Ligand
α1β1 CD49a-CD29 Laminin (collagen)
α2β1 CD49b-CD29, gpIa-IIa Collagen (Laminin)
α 3β1 CD49c-CD29 VCAM-1,fibronectin
α 5β1 CD49e-CD29,fibronectin receptor Fibronectin
α 6β1 CD49f-CD29, laminin receptor Laminin
α 8β1
α vβ1 CD51-CD29 Fibronectin
α sβ2 CD11a-CD18,LFA-1 ICAM-1,ICAM-2,ICAM-3
α Mβ2 CD11b-CD18, Mac-1 ICAM-1,ICAM-3,fibrinogen,C3bi
α xβ2 CD11c-CD18,p150,95 Fibrinogen,C3bi
α HBβ3 CD41a,gpIIb-IIIa Fibrinogen,fibronectin, , , Von Willebrand
Factor
α Vβ3 CD51-CD61 Von Willebrand
Factor,laminin,thrombospondin,fibronectin
















Reduced shear rate in microcirculation
favours white cell margination
'White cell trapping' hypothesis
Figure 10 illustrates the white cell activation hypothesis. From Coleridge Smith PD.
Microcirculation in venous disease. Landes Bioscience 199835









60 minutes sitting 15 minutes supine
Time in minutes
White cell loss (%)
Figure 11 illustrates the white cell trapping hypothesis. It illustrates the trapping of the
leucocytes in the venous side of the circulation on standing up on dependency of the legs and
their subsequent release on assuming the supine position. From Coleridge Smith PD.
Microcirculation in venous disease. Landes Bioscience 1998.a
Tissue factor and vesicles with increased prothrombinase acttivity are also
affected.Human endothelial cells in culture normally exhibit Class I major
histocompatibility complex (MHC-I) like HLA-A, B and C). Stimulation of cultured
endothelial cells results in increased expression of class I but not class II molecules
(HLA-DR, DQ and DP)
¥. In vivo only certain endothelial cells (notably post-capillary
venules, veins and some arteries) exhibit class II molecules. In chronic rejection and
inflammatin, however, the expression of these molecules is increased in many tissues
affected by these processes.
Intracellular processses in ECA
Altered gene transcription is involved in the transduction of signals in ECA. From the
endothelial cell surface the message is carried intra-cellularly by a transcription factor
nuclear factor B (NF-B). Gene upregulation during ECA include binding site for NF-
¥ Human Leucocyte Antigen; DR DQ DP36
B in their promotor area. NF-B is stored as an inactive form in the cytoplasm and is
activated by removal of an inhibitory subunit IB.
1.7 Adhesion Molecules in CVD
Leucocytes express adhesion-promoting receptors that mediate cell-cell and cell-matrix
interaction. These interactions are crucial for the direction and control of leucocyte
traffic, migration through tissues, and the development of immune and nonimmune
inflammatory responses
There are four main groups of adhesion molecules viz. Integrins, Immunoglobulin super
family, Cadherins and Selectins
. The integrins are trans-membrane cell surface
proteins that bind to cytoskeletal structures and communicate extra-cellular signals.
They have  and  subunits, their classification being according to the  subunit. In
association with different  subunits about 21 different combinations are known (see
table 1). Their functions are varied. Certain of the integrins function as extra cellular
matrix receptors, others mediate leucocyte–endothelial cell adhesion or bind primarily
to matrix proteins. They may be important in inflammation, wound healing and
development. Table 2 gives the details of the immunoglobulin super family. Previous
work suggests that the leucocyte population in the human consists of “primed" and "un-
primed" group. Leucocytes most likely to bind to endothelium represent the "primed"
group, which express the highest levels of CD11b and L-selectin. Therefore, the fall in
the activation of the circulating cells is the result of the more activated cells adhering to
the endothelium. Surface expression of CD11b and L-selectin may remain low even
after the venous hypertensive insult is withdrawn. A rise in the soluble L-selectin levels
in the plasma was noted, confirming it had been shed, a process that precedes CD11b
expression and firm adhesion.
These findings, considered together, provide strong evidence of leucocyte activation and
trapping in the microcirculation. Naturally occurring blocking antibodies to
CD11b/CD18 receptors have been reported, and it may be that patients with long-
 Lectins (to select) are sugar binding proteins with high selectivity for the sugar moiety. First described
in 1888 as agglutinins.37
Figure 12 depicts the various changes invloved in endothelial cell activation.
VWF=VonWillebrand’s factor, HS=Heparan Sulfate, TM=Thrombomodulin, PAF=platelet
activating factor, PAI-1=Plasminogen activator inhibitor-1. (From Hunt & Jurd by
permission).
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Figure 13 is a photomicrograph of the skin of the leg in LDS. It shows increased number of
capillaries in the dermis (C). A= epidermis, B=sub-papillary dermis. (Photograph courtesy of H
Pardoe MS FRCS)
Table 2 shows the adhesion molecules of the Immunoglobulin super family.39
standing chronic venous disease release a circulating inhibitory factor that binds to and
blocks CD11b/CD18 receptors on the activated leucocytes, thereby preventing adhesive
interaction. There appears to be no difference in response to venous hypertension in the
two groups (superficial and/or deep) of patients with venous disease. There is no
definite explanation of why skin changes develop in one group of patients and not in
others. Presumably, other aspects of the response of the tissues to leucocyte adhesion
are involved in the development of skin damage.
1.8 Investigation of Chronic Venous Disease
Objectives Of Investigations
These tests are to confirm the presence of obstruction or reflux (or both), localise the
sites of obstruction or reflux and quantify the abnormality. The investigations start out
with a history and examination.
Duplex-Scan confirms the anatomic localisation of obstruction and reflux in the
majority of cases. It detects the sites of deep to superficial reflux. Ascending or
descending venography is rarely required. MR scan may be required to give the exact
anatomic pattern in some cases.
Quantitative analysis of of reflux could be measured from duplex criteria which could
be used to obtain para meters like reflux flow-volumes. Air plethysmography can add
by information to differentiate between venous obstruction, venous reflux and calf
muscle pump dysfunction. Some authorities use ambulatory venous pressure more than
the other criteria.
Phlebography
The purpose of ascending venography is both to confirm the presence as well as the
extent of outflow obstruction. Ascending phlebography is performed by injecting the
dye into a foot vein after applying a tourniquet at the ankle. Proximal passage of the dye
is delayed either by putting the patient in a semi upright position or by using a second40
Table 3 Compares sensitivity and specificity of the various clinical tests to hand held Doppler
examination (Kim et al)
Ref
tourniquet at the thigh. Deep to superficial reflux may be shown by asking the patient to
actively plantar flex the ankle (functional ascending phlebography). Descending
phlebography is used to demonstrate both the extent as well as the site of reflux. Iso-
osmotic dye is injected into the femoral vein with the patient in the 60 semi-upright
(head-up) position. Repeated boluses of contrast are used. Reflux in the common
femoral, superficial femoral, deep femoral and popliteal veins as well as the SFJ may be
demonstrated. Asking the patient to do a valsalva and active plantar flexion are
performed to demonstrate reflux. The reflux is graded according to the sites
involved
62. There has been no significant correlation between these grades and the
development of skin changes/ leg ulceration. Direct varicography may be used for
recurrent veins and/or veins in the region of the SPJ. Most workers utilize these
techniques uncommonly presently.
Continuous Wave Doppler
This is perhaps the simplest most easily performed investigation at the bedside. Based
on the principle first described by the Austrian physicist Christian Johann Doppler
(1803-53).This test utilizes an ultrasound beam emitted by a piezoelectric crystal.
















C= sound velocity in flow
D= angle of incidence of sound from the flow direction
The hand held instruments are designed so that the reflected sound is in the audible
frequency range of about 20,000 Hz. The emitted frequencies are usually 5-8 MHz. See
table 2 for comparison of handheld dopple with clinical examination. One of the main
limiting factors for hand held Doppler is its lack of anatomic selectivity especially at the
SPJ. Reflux in the Giaccomini or gastrocnemius veins can give false positive results
64.
Photoplethysmography
(Greek:"plethysmo", to increase, an "graphos" to write) is the recording of changes in
the content of blood in the tissues. It is also known as ‘light reflection rheography’ and
depends on the ability of blood to reduce the amount of light reflection form the tissues.
It is difficult to quantitate the amount of blood and attempts to do so have shown no
correlation.
Figure 14 Shows principal of PPG and a typical trace obtained from the lower limb at base line
and after ankle dorsiflexion.
Venous ‘refill time’ has a strong linear correlation with venous pressure
measurements
63. For testing usually 10 tiptoe or foot dorsiflexion movements are used.
Normal venous refill time is >25 sacs. With venous insufficiency the reduced refill
times may be corrected by placement of strategically placed tourniquets. This may





provide better interpretation of data. While the exact place for PPG continues to evolve
in clinical practice, correction of prolonged refill times with a superficial tourniquet is
indicative of a predominantly superficial vein issue. This may be correctible with an
interventional procedure.
Strain gauge plethysmographs consists of mercury filled silastic loop placed around the
leg with just enough stretch for good contact. The length of the strain gauge and hence
its electrical resistance is increased by increase in the circumference of the leg. It has
mainly been applied to the diagnosis of DVT and outflow obstruction. Air
plethysmography is used by many workers to quantify some parameters of CVD.
Air Plethysmography
This allows quantitative non-invasive measurement of venous reflux and calf muscle
ejection. It is performed using a PVC ‘chamber’ that surrounds all of the lower leg
(capacity circa 5 L). After calibrating the machine the patient is asked to do tiptoes and
various parameters are measured as depicted in the diagram. Air plethysmography
allows non-invasive quantitative measurement of venous reflux and calf muscle pump
ejection. The PVC chamber (5 L) covers the lower leg from ankle to knee. The system
is primed to 6 mmHg and then calibration is performed using a 100 ml syringe. The
various parameters assessesed in clude the following
A. VV is the increase in leg volume as a result of standing (100-150 mls normal).This is
obtained following a stable baseline supine measurement. The subject is upright with
the weight on the opposite leg and supporting himself on an orthopaedic frame.
B. VFT90 is time taken to achieve 90% of the filling
PARAMETERS OBTAINED BY AIR PLETHYSMOGRAPHY UNITS
VV (Venous volume) measured after a baseline reading ml
VFT 90(Venous Filling Time) time to reach 90% VV sec
RV (Residual Volume) after 10 tiptoe movements ml
VFI (Venous Filling Index)= 90%VV/ VFT 90 ml/sec
EV (Ejection Volume) ml
EF (Ejection fraction)= (EV/ VV)  100 %
RVF (Residual Volume Fraction)=(RV/ VV) 100 %43
Figure 15 Illustrates the principal of Air-plethysmography and the various variables that can be
calculated from this technique (Redrawn after Nicolaides AN, Sumner DS. ‘Investigation of
Patients with Deep Vein Thrombosis and Chronic Venous Insufficiency’.
C. Venous filling index (VFI) =90%VV/ VFT90. This is expressed in ml/sec. A VFI of
less than 2 ml/sec confirms absence of significant venous reflux. A VFI of more than 7
mls/sec is associated with a high rate of skin changes and ulceration. Suitable tourniquet
tests will point to the probable site of reflux.
D. EV (Ejected Volume) is determined by asking the patient to do a single tiptoe with
the weight on both legs. The patient is then asked to return to the original postion when
the reading is made.
E. EF (ejection fraction) = (EV/VV) ×100.
F. The residual volume (RV) and RVF (residual volume fraction) determines the
amount of blood left behind after ten tiptoe movements. RVF= (RV/VV) ×100. The
RVF shows a linear correlation with ambulatory venous pressure. It is an effective non-









An abnormal RVF (>40%) may be the result of i. reflux ii.decreased EF or iii. a
combination of both of these. In recurrent deep vein thromboses obliteration of venous
channels with decreased EV and EF may occur. In these patients valvuloplasty may not
be very successful.
Table 4 Values of Ambulatory Venous Pressure P (mm Hg)
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Ambulatory Venous Pressure
AVP remain the gold-standard for measurement of venous function and to validate other
investigational techniques. AVP have been used since the observation in the 1940s that
foot venous pressures increase on standing still and drop dramatically on flexing the calf
muscles.
The test is performed by canulating a foot vein with a 21G ‘butterfly’ needle. This is
connected to a transducer. The patient holds himself upright with an orthopaedic frame
without putting any weight on the limb from which the measurements are taken. This is
done because the contraction of calf muscles can cause artifacts in the readings. 10
tiptoe movements are performed at the rate of 1/sec. The patient remains still again at
the end of the exercise as resting pressures are again recorded. The exercise is repeated
after inflating a tourniquet at the ankle level to occlude the superficial veins. The test
may also be repeated with the tourniquet placed at successive higher levels on the lower
limb. Pressure may actual rise following tip-toe movements in patients with venous
outflow obstruction. The most useful measurements are the mean ambulatory pressure
((P) measured towards the end of the 10 tip-toe movements) in the steady state and the
90% refill time (90%RT)
64.
Type of Limbs No ankle cuff Ankle cuff inflated
Normal 15-30 15-30
Primary Varicose Veins 25-40 13-30
Varicose Veins/ incompetent perforators 40-70 25-60
Deep venous insufficiency/ proximal
occlusion
55-85 50-80
Competent popliteal/ proximal occlusion 25-60 10-6045
There is a strong direct relationship between the incidence of ulceration and the value of
P. It is one of the important tests for measuring the efficacy of calf muscle pump. The
90% refill time (90% RT) is also very useful . In the presence of deep vein obstruction
the value of P may increase during exercise (exercise hyperemia).
Duplex Scanning
Duplex scanning was first used in the 1980’s for diagnosis of DVT. Duplex
(incorporating B-mode imaging) and colour flow imaging are some of the most useful
and commonly utilised investigations for CVD. Duplex imaging allows anatomical
localisation of the reflux and also allows for its quantitation. Usually a 7.5 imaging
MHz probe is used with a 3.0 MHz pulsed Doppler.
With the lower limb in a non-weight bearing position reflux velocities and the diameter
of the vein are determined. The refluxing volume in ml/sec can be determined. For
quantitative measurements a ‘’Hokanson device’’ and a presssure cuff may be used to
ensure unifrom inflation/ deflation and standard pressures (70mmHg). Because the
subject is standing up the cross-section of the vein is taken as circular. Samples are
taken at the common femoral vein, 2-4 cms distal to the junction at the femoral vein and
2-4 cms from the junction at the long saphenous vein with the vessel axis of about 45°.
Compression of the calf muscles is used to detect the reflux. The short saphenous
system is examined with the patient standing up and facing away. The probe is placed
longitudinally after identifying the veins in the transverse axis. Longitudinal imaging of
the popliteal vein, spaheno-popliteal junction and the short saphenous vein are
obtained
64.
It has been shown that leg ulceration does not occur with refluxing volumes of
<10ml/sec. Refluxing flow of >15ml/sec is associated with high incidence of skin
changes/ ulceration
65. This is irrespective of whether this reflux flow is in the superficial
or in the deep part of the venous system.46
Figure 16: represents tracings of ambulatory venous pressure and its response to calf muscle contraction
in normal (red) and venous insufficiency (green). The 90% refill time (VRT) is markedly different
between the two sets. Decrease in pressure in venous insufficiency would be typically significantly lower
than in subjects with no venous insufficiency.
% Change in pressure= (P1-P2/ P1) * 100
P1=initial pressure

























































Table 5: Incidence of leg ulceration in relation to AVP (Nicolaides)
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Table 6: Incidence of ulceration in relation to the residual volume fraction (RVF)(Nicolaides)
64
Table 7 incidence of sequelae of venous disease in relaion to VFI (Nicolaides)
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The preceding measurements may be quite tedious since accuratged gating of the
Doppler pulse is required and hence colour Duplex is often used instead to detect
abnormal flow. Colour duplex is coded so that the hue and intensity are related to the
direction and intensity of the Doppler shift. This allows immediate recognition of
abnormal retrograde flow. Although this may be quantitated (to a degree) by software,
colour is most often used for qualitative measurement of flow incontemporary practice..
For colour flow imaging (CFI) the grey-scale image is optimised by adjustments made
for tissue attenuation ad then the colour is switched on. Using manual calf compression
the detection of reflux both at the SFJ as well as the SPJ has become a relatively simple
matter. Colour flow Doppler has been shown to be as accurate as conventional Duplex
and in addition it can detect abnormal flow in the calf veins. Colour flow imaging has
also shed much light on understanding the flow phenomena in the calf perforators.
There is deep to superficial flow initially with muscular contraction in ‘incompetent
perforators’. The perforating veins eventually close, however, with increasing muscle
contration and occlude the flow more or less completely. During relaxation of the
muscles the flow is from superficial to the deep system.49
Figure 17 is a photograph of a leg with severe lipodermatosclerosis. There is evidence
of an ulcer.50
1.9 Pharmacotherapy in CVD
Currently no pharmacologic agent restores venous competence in CVD. It is even
doubtful wether any medical treatment exerts major effects on the haemodynamics in
CVD. Thus the aetiologic mechanisms in CVD i.e. venous hypertension cannot be
reversed using the present paradigms.
Drugs that may act on the microcirculation in established CVD and ameliorate its
effects may therefore be important. These may counteract some or all of the
mechanisms that have been proposed at various times to act at the microcirculatory
level. Thus drugs affecting increased capillary permeability, micro-vascular slugging,
cytokine release and leucocyte activity has been utilized. Drugs affecting fibrin
deposition in the pericapillary space have also been used. A wide variety of drugs have
been used with varying results. These include the following
i. ‘Phlebotropics’
a. Benzopyrones
1. Alpha Benzopyrones (Coumarin)
2. Gamma Benzopyrones (Flavonoids)
Flavones/ Flavonols (Diosmin, Rutosides)
Flavanes/ Flavonones (Hesperidin, Catechin)
b. Saponins (e.g. Horse Chestnut extract, Escin)
c. Other Plant Extracts (Ginkgo Biloba)
d.Synthetics e.g. Ca Dobesilate
ii. Rye-Ergot derivatives





viii. Non-steroidal anti-inflammatory agents
ix. Diuretics
x. Anti-platelet agents
Pentoxifylline (Trental®, Hoechst, Hounslow, UK), which inhibits the effects of TNF-α
and IL-1,
66 has been shown by some workers to have some effect on ulcer healing when
used in conjunction with compression therapy.
67 A recent Cochrane review suggested
some efficacy of Pentoxifylline treatment especially when used without compression
therapy. Twelve trials involving 864 participants were included. The quality of trials
was variable. Eleven trials compared pentoxifylline with placebo or no treatment; in
seven of these trials patients received compression therapy. In one trial pentoxifylline
was compared with defibrotide in patients who also received compression. Combining
11 trials that compared pentoxifylline with placebo or no treatment (with or without
compression) demonstrated that pentoxifylline is more effective than placebo in terms
of complete ulcer healing or significant improvement (RR 1.70, 95% CI 1.30 to 2.24).
Significant heterogeneity was associated with differences in sample populations (hard-
to-heal samples compared with "normal" healing samples). Pentoxifylline plus
compression is more effective than placebo plus compression (RR 1.56, 95% CI 1.14 to
2.13). Pentoxifylline in the absence of compression appears to be more effective than
placebo or no treatment (RR 2.25, 95% CI 1.49 to 3.39). A comparison between
pentoxifylline and defibrotide found no statistically significant difference in healing
rates.More adverse effects were reported in people receiving pentoxifylline (RR 1.56,
95% CI 1.10 to 2.22). Nearly three-quarters (72%) of the reported adverse effects were
gastrointestinal. The authors’ conclusions were that Pentoxifylline is an effective
adjunct to compression bandaging for treating venous ulcers and may be effective in the
absence of compression. The majority of adverse effects were gastrointestinal
disturbances.
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Prostaglandin E1, which prevents activation of neutrophils, has also been shown to be
of some benefit in patients with venous ulceration, as have free radical scavengers
applied topically to ulcers.
69 In a recent report a randomized, placebo-controlled, single52
blind study in which 87 patients who had venous leg ulcers homogeneous for
dimensions and characteristics were treated for 20 days with an infusion of
prostaglandin E-1 or placebo, in association with topical therapy. The dimension and the
number of the ulcers were determined at the beginning of the treatment and then every
20 days up to 4 months, or until total recovery. The main outcome of the study was the
recovery percentage of the ulcers at the end of the 120-day period of observation and
the referred healing time. The reduction in the extension of ulcers from the baseline
measurement to the last observation was also evaluated. It was observed that the the
reduction in the size of the ulcers was faster in the patients treated with PGE-1. In this
group, 100% of the ulcers healed < or = 100 days, whereas in the placebo group, only
84.2% did so by the end of the 120-day observation period (P < .05). The estimated
healing times of 25%, 50%, and 75% of the patients treated with PGE-1 were 23, 49,
and 72 days, respectively, compared with 52, 80, and 108 for the patients in the placebo
group. Only one serious event occurred in the treated group. This study demonstrated
some effectiveness of PGE-1 in reducing the healing time of venous ulcers.
70 (The
effects observed were not large and longer term follow-up is lacking).
The effect of an analogue of PgE1 has been investigated in a study in 44 patients with
venous ulcers. PGE1 has been shown to cause reduction of leucocyte activation, platelet
aggregation inhibition, and small vessel vasodilatation as well as reduction of vessel wall
cholesterol levels. Patients were randomized to receive either the active compound or
placebo by daily intravenous infusion over a period for 6 weeks
71. Improved venous ulcer
scores were observed in patients treated with the active compound at the end of the study
period. The duration of the investigation was too short to be able to assess the influence of
PgE1 on the rate of ulcer healing. Unfortunately this method of treatment requires the use
of an intravenous infusion and is quite intensive.
Two other studies have investigated the use pentoxifylline (Trental, Hoechst, Germany) in
the management of patients with venous ulceration
72 73. Pentoxifylline is thought to
inhibit cytokine mediated leucocyte activation, reducing leucocyte endothelial interaction
and superoxide free radical production. Both studies have shown a beneficial effect on the
rate of ulcer healing, but in the second where much more effective compression was
applied; the influence of Trental was more modest. This is a treatment with a definite
efficacy, but of small magnitude. Its exact role in the management of patients with venous
ulceration remains unclear.53
Prostacyclin analogues (Iloprost, Schering Berlin) have been used with some success in
the systemic treatment of leg ulcers. Iloprost is thought to affect leucocyte activation,
platelet aggregation, small vessel dilatation as well as fibrinolysis. In a double-blind
randomized trial (with placebo controls) involving 44 patients, the healing was more (8 of
20 Vs 2 of 22) in the Iloprost group. In addition the clinical parameters improved in the
non-placebo group significantly.
74 A more recent study of 98 consecutive patients
confirmed these findings
75.
The flavonoids have been extensively studied and merit discussion. Antibiotics are often
used for acute exacerbation of inflammation associated with infection in the ulcers.
Drugs used for recanalisation of acute obstruction such as. Plasminogen activators and
oral anticoagulants are not discussed here. Non-steroidal anti-inflammatory drugs are
mainly used for thrombophlebitis and acute exacerbation of LDS. Diuretics are used
only sparingly to control chronic oedema. Their haemoconcentrating effect may
encourage thrombosis. Relatively recently objective microcirculatory criteria are
increasingly used for assessment of both conservative and operative treatment.
i. Flavonoids in Venous Disease
Flavonoids are a broadly distributed class of naturally occurring plant products. Because
of their widespread occurrence in edible plants such as fruits, vegetables and grains,
they are an integral part of the human diet. Many compounds traditionally used for
treating inflammatory conditions have flavonoids as active components. Daflon, which
is a ‘micronised’ preparation of flavonoids, has been used in the treatment of varicose
veins & haemorrhoids.
76
The leaves of ‘Baphia nitida ‘ have been used in folk medicine for the treatment of
inflamed and infected umbilical cords in Nigeria. Phytochemical analysis of the leaves
detected tannins, flavonoids and saponin glycosides. This anti-inflammatory effect has
been tested experimentally. Flavonoid rich preparation of the leaf, obtained by a
chromatographic process, was formulated into an ointment and tested at three dose
levels for anti-inflammatory activity against croton oil and heat induced inflammation
on ears of mice and depilated backs of rats, respectively. Both provide evidence for54
the ability of this fraction to inhibit the inflammatory condition on the rodents. The
activity was found to be dose related, and the mouse ear model was found to be the
more sensitive of the two test s used. Hydrocortisyl cream was used as a positive control
reference in this experiment.
77
Pharmacokinetics
In a study involving Pharmacokinetic parameters of diosmin performed after oral
administration to healthy volunteers, diosmin and its aglycone, diosmetin, were
determined by HPLC (high performance liquid chromatography) and LC-MS (Liquid
chromatography-mass spectrometry). At the level of sensitivity of this method, no
parent compound was present in the plasma but only its aglycone, diosmetin. Analysis
of the pharmacokinetic parameters showed that the drug was rapidly absorbed.
Diosmetin presents a long plasma elimination half-life ranging from 26 to 43 hours.
Data show the total absence of urinary elimination for both diosmin and its aglycone
diosmetin, while its minor metabolites are eliminated in the urine, mainly as
glucuronic acid conjugates. The presence of degradation products such as alkyl-




Flavonoids have several anti-inflammatory actions. In varicose veins increase in
glycosaminoglycan levels in the vein wall is known in varicose disease. This reflects a
deregulation of the normal matrix biosynthesis by the cells of varicose vein wall,
especially smooth muscle cells. Some flavonoid drugs are capable of correcting these
deviations by decreasing proteolytic attack on fibrous proteins and decreasing the
accumulation of proteoglycans and hyaluronan.
79
Changes in venous haemodynamics have not been convincingly demonstrated. It is
possible that the clinical effects of Flavonoids are mainly at the microcirculatory level.
80
Capillary permeability
In a hamster cheek pouch model, in comparison with vehicle, Flavonoids significantly
inhibited the macromolecular permeability increasing effect of histamine, bradykinin (p55
< 0.001) and LTB4 (Leukotriene B4; p < 0.001). At reperfusion, after 30 min
ischaemia, Flavonoid significantly decreased the observed macromolecular permeability
(p < 0.01). Flavonoid-treated animals also tended to have a lower number of leukocytes
adhering to the venular endothelium (104.8 +/- 11.0 vs. 75.8 +/- 9.7/6 mm2; p > 0.05).
These results demonstrate that oral administration of micronised purified flavonoid
fraction for 25 days at 20mg/kg body weight/day has a protective effect on leakage of
macromolecules after application of permeability-increasing substances and during
ischaemia-reperfusion in the cheek pouch microvasculature of diabetic hamsters. Data
illustrating the inhibitory effect of clinically relevant doses of micronised purified
flavonoid fraction on the inflammatory processes may serve as a basis of its mode of
action.
81
Effect in clinical capillary fragility
The efficacy and safety of this flavonoid fraction consisting have micronized diosmin
(90%) and hesperidin (10%) were studied in 100 patients with symptomatic capillary
fragility in a double blind, randomised, placebo-controlled trial. Treatment lasted 6
weeks and consisted of 2 daily tablets of either flavonoid or placebo. Patients were
examined at weeks 0, 2, 4 and 6. Compared to placebo, capillary resistance, assessed by
the negative suction cup method, was significantly higher in the flavonoid group at
week 4 (p < 0.001) and week 6 (p < 0.00 1). This resulted in a significant improvement
of symptoms of capillary fragility (spontaneous ecchymosis, epistaxis, purpura,
petechiae, gingivorrhagia, metrorrhagia and conjunctival haemorrhage) in S5682
*
treated patients (p < 0.001) flavonoid was well tolerated. The rate of side effects
spontaneously volunteered by the patients was similar in both groups. It was concluded
that flavonoid increase the capillary resistance in patients with abnormal capillary
fragility to a significant extent without major side effects.
82
Haemorrheological
An open pilot study performed to verify the variations in capillary packed cell volume
in comparison with the velocity in 24 patients with third-stage chronic venous
insufficiency before (day 1) and after (day 28) a 28-day treatment with Daflon 500 mg
a micronized purified flavonoid fraction consisting of diosmin, 450 mg, and
* Flavonoid preparation56
hesperidin, 50 mg, per tablet) 1 g/day, and then 14 days (day 42) after cessation of
treatment. Ankle skin micro-circulation was evaluated by dynamic capillaroscopy.
Values of relative capillary packed cell volume were calculated by a densitometric
method, and red blood cell velocity was calculated using the cross-correlation
simplified method. Relative capillary packed cell volume (mean +/- SD) significantly
(p = 0.001) increased from day 1 (64.10 +/- 9.34%) to day 28 (72.89 +/- 5.74%) and
then decreased until day 42 (66.84 +/- 7.48%). In the same patients, red blood cell
velocity (mean +/- SD) significantly (p = 0.041) increased from day 1 (0.26 +/- 0.14
mm/sec) to day 28 (0.35 +/- 0.11 mm/sec) and then remained stable until day 42 0.33
+/- 0.16 mm/sec). Two possible explanations can account for this apparent
discrepancy: first, dissociation between viscosity and velocity due to the Fahraeus-
Lindqvist effect (sigma effect)
†; and secondly, increased deformability of red blood
cells leading to an increased red blood cell velocity despite an increased packed cell
volume. It can be concluded that Daflon 500 mg seems to have a beneficial
haemorheological effect, resolving the stasis with an increase in red blood cell velocity.
A concomitant increase in relative packed cell volume and red blood cell velocity after
therapy suggests an improvement of the flexibility of red blood cells.
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Free Radicals & Oxidation
Flavonoids have been used in the treatment of vascular endothelial damage. They are
known to be excellent scavengers of oxygen free radicals. It has been suggested that
Daflon 500 mg could interact with free radicals, which could have a deleterious effect
in ischaemic tissues( particularly in the retina).
84.
The nitric oxide radical (NO) probably plays an important role in this mechanism. In
studies of the NO scavenging effects of flavonoids, they were found to be very potent
NO scavengers. The anthocyanidins were found to be more effective scavengers than
the hydroxyethylrutosides, which correlated with their therapeutic activity. The values
of their scavenging rate constants are only 30 times less active than that very potent
† Under most circumstances, blood flow can be modeled by the Navier-Stokes equations. Whole blood
can often be assumed to be an incompressible Newtonian fluid. However, this assumption fails when
considering flows within arterioles. At this scale, the effects of individual red blood cells becomes
significant, and whole blood can no longer be modeled as a continuum. When the diameter of the blood
vessel is slightly larger than the diameter of the red blood cell the Fahraeus–Lindqvist effect occurs and
there is a decrease in wall shear stress. However, as the diameter of the blood vessel decreases further, the57
endogenous NO scavenger, haemoglobin. It is speculated that NO scavenging plays a
role in the therapeutic effect of the flavonoids.
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In an animal model intravenous injection of Daflon 500 mg (25 and 50 mg/kg) reduced
the hyperglycaemia induced by injection of alloxan in rat. This effect of Daflon 5 00 mg
was linked to its ability to scavenge active oxygen radicals, demonstrated in vitro using
human neutrophils or mouse peritoneal macrophages stimulated by zymosan. The free
radical scavenger effect of Daflon 500 mg is observed at concentrations ranging from
10(-7) M
‡ to 10(-4) M, with half-maximal effect between 10(-6) M and 10(-5) M. Thus,
Daflon 500 mg behaves as a potent protective agent against inflammatory disorders.




Flavonoids have been demonstrated to inhibit beef heart mitochondrial succinoxidase
and NADH-oxidase activities. The primary site of inhibition is suggested to be in the
complex I (NADH-coenzyme Q reductase) portion of the respiratory chain. The order
of potency for inhibition of NADH-oxidase activity was robinetin, rhamnetin, eupatorin,
baicalein, 7, 8-dihydroxyflavone, and norwogonin with IC50
 values of 19, 42, 43, 77,
277 and 340 nmol/mg protein, respectively. Flavonoids with adjacent tri-hydroxyl or
para-dihydroxyl groups exhibited a substantial rate of auto-oxidation, which was
accelerated by the addition of cyanide (CN-). Flavonoids possessing a catechol
configuration exhibited a slow rate of auto-oxidation in buffer that was stimulated by
the addition of CN-. The addition of superoxide dismutase (SOD) and catalase in the
auto-oxidation experiments each decreased the rate of oxygen consumption, indicating
that O2- and H2O2 are generated during auto-oxidation. In the CN
 (-)-stimulated
oxidation experiments, the addition of SOD
 also slowed the rate of oxygen
consumption. These findings demonstrate that the CN-/flavonoid interaction generated
O2- non-enzymatically, which could have biological implications.
red blood cells have to squeeze through the vessel and often can only pass in single file. In this case, the
inverse Fahraeus–Lindqvist effect occurs and the wall shear stress increases.
‡ M= Molar
 IC50=Half maximal inhibitory concentration for experimental samples
 Cyanide
 SDO=Super Oxide Dysmutase58
Leukocyte activation
Studies exist to suggest that pre-treatment with Daflon 500 mg prior to the induction of
4 h of tourniquet ischaemia significantly lowers the number of adherent leukocytes.
This observation is linked to the protective effect of flavonoids in the treatment of
oedema, as decreased activation is also associated with a decreased platelet and
complement system activation, leading to a lowered release of histamine and decreased
leukocyte-dependent endothelial damage.
Inflammatory Mediators
The arachidonic acid derivatives form part of the chemical/ biological factors associated
with activation of the inflammatory reaction. The mediators include are (prostaglandin
[PG], leukotrienes [LT], or thromboxanes [TX]), vasoactive amines (histamine or
serotonin), and oxygen free radicals (superoxide ion, O2-, or hydrogen peroxide,
H2O2). In peri-venous inflammation, these mediators play a prominent role in
favouring vasodilatation (histamine),increasing membrane permeability (PGE2,
histamine, free radicals) and providing a chemotactic signal for specialised cells, i.e.,
neutrophils, macrophages, lymphocytes (LTB4, free radicals). Flavonoids can act at
various levels, possibly independently. Daflon 500 mg (100 mg/kg, orally) may reduce
oedema formation and inhibit the synthesis for PGE2 (78.5%), PGF2 alpha (45.2%) and
TXB2
§ (59.5%).
Effect on Cytokine Release
The growth of two human lymphoid tissue derived cell lines, IM-9 and Molt-4 cells
**
together with normal lymphocytes have been studied in the presence of several plant
natural products. Amongst the 11 test compounds studied, the flavonoids (fustin,
taxifolin, phloretin) and the polyphenol tannic acid were found to be potent inhibitors.
They exerted varying degrees of inhibition on Molt-4 cell and normal lymphocyte cell
proliferation but not on the non-malignant (IM-9) cells. . The IL-2 level was also
enhanced in the Molt-4 but inhibited in normal lymphocytes. However, its level
remained unchanged in the IM-9 cells. The amount of IL-2 secreted could be directly
correlated to the percentage cell growth inhibition for only Molt-4 cells.
§ TXB2=Thromboxane B2
** MOLT-4/ IM-9 =Experimental cell lines59
Effect on arterial smooth muscle
Flavonoids relaxed the contractions induced by nor adrenaline, KCl orphorbol 12-
myristate, 13-acetate in rat aortic strips, the order of potency being: flavonols
(quercetin, kaempferol, pentamethylquercetin) >flavones luteolin, apigenin) > flavanols
(+)-catechin, (-)-epicatechin) which correlates with the reported order of potency to
inhibit protein kinase C. The relaxant effects were slightly potentate by isoprenaline and
those of pentamethylquercetin, kaempferoland apigenin by sodium nitroprusside. It is
concluded that the main vasodilatory mechanism of flavonoids seems to be the
inhibition of proteinkinase C. Inhibition of cyclic nucleotide phosphodiesterases or
decreased Ca2+ uptake may also contribute to their vasodilatory effects. It is not known
if this effect contributes to the clinical effects in patients with CVD.
Effects on venous wall composition
Varicose vein walls differ from normal venous walls by an important loss of their
collagen content and increase of their glycosaminoglycan content, essentially of
hyaluronan. The decrease in fibrous protein content can be attributed to increased
proteolytic (collagenolytic) activity as well as to free radicals. Glycosaminoglycan
increase reflects a deregulation of the normal program of matrix biosynthesis by the
cells of varicose vein wall, essentially smooth muscle cells. Some flavonoid drugs re
capable of correcting these deviations by decreasing proteolytic attack on fibrous
proteins and the accumulation of proteoglycans and hyaluronan. These effects, due to
interactions between flavonoid rugs and the cells and fibrous proteins of the venous wall
may differ according to the nature of such drugs. These differences are based on the
conformation of these drugs and their interaction with the triple helical structure of
collagen fibres as well as with the cell membranes.
Clinical Efficacy of Flavonoids
The wheal vanishing (WV) time has been used to assess the effect of therapy with
Daflon ®on capillary filtration in subjects with mild-moderate venous hypertension.
The WV time, which was comparable in the two groups at the beginning of the study
decreased significantly in the treated group. No change was observed in the WV time
in the placebo group. Subjective symptoms of venous disease measured with an
analogue scale improved following treatment with hydroxyethylrutosides [foot oedema60
(p < 0.005), ankle oedema (p < 0.001), and paraesthesia (p < 0.01)]; only night cramps
were reported less in patients receiving the placebo (p < 0.05). Pitting oedema and
eczema also improved significanlty.
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Controlled Clinical Studies
The efficacy of Daflon 500 mg was investigated in three double-blind, randomized trials
using strain gauge plethysmography to provide quantitative information on venous
hemodynamics in patients with chronic venous insufficiency. In total, 183 patients were
treated with Daflon 500 mg versus a control group of equal number of patients. Daflon
500 mg produced a significant decrease in venous capacitance, venous distensibility,
and venous emptying time (P < 0.001). In addition, these changes were accompanied by
improvement in clinical symptoms and a decrease in the supramalleolar circumference.
Clinical side effects were rare and led to treatment withdrawal in only three patients. It
was concluded that Daflon 500mg could be of benefit to patients with chronic venous
insufficiency.
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A study, similar to one mentioned earlier was performed to evaluate the effect of
hydroxyethylrutosides on capillary filtration in subjects with mild to moderate venous
incompetence—superficial varicose veins and/or deep venous disease and ankle
oedema—using the vacuum suction chamber (VSC) device applied to the internal peri
malleolar region and the wheal vanishing (WV) time. Subjects entered in to the study
were randomised to receive either hydroxyethylrutosides (1 g twice daily for 4 weeks)
or placebo for fmy weeks. The two groups entering and completing the study were
comparable. Microcirculatory parameters (laser-Doppler resting flux, the veno-arteriolar
response, transcutaneous PO2 and PCO2) remained constant during the fmy week study
in both groups. The WV time, which was comparable in the two groups at the beginning
of the study decreased significantly [from a median 55 min (interquartile 95-50 min), to
a median45 minutes (interquartile 65-40 min) in the treated group, p < 0.01]. No change
was observed in the WV time in the placebo group. Subjective symptoms measured
with an analogue scale improved following treatment with hydroxyethylrutosides [foot
oedema (p < 0.005), ankle oedema (p < 0.001),and paraesthesia (p < 0.01)]; only night
cramps were reported less inpatients receiving the placebo (p < 0.05). Furthermore, the
changes observed in WV time correlate well with an improvement in symptoms.61
Effects on Tco2 & Laser Doppler Parameters
A 3-month, double-blind, randomised, parallel-group study carried out in 104 patients
who received Daflon® in varying doses. The parameters studied were transcutaneous
tension of oxygen and Laser Doppler flow measurements. These patients were divided
into 3 groups according to the daily dose: 1 tablet (group 1, n = 34), 2tablets (group 2, n
= 33), on 4 tablets (group 3, n = 37). All patients (mean age 43.7 +/- 13.1 years; 100
females, 4 males) included in the study were affected by mild CVI. They were followed
for 90 days with visits at 1month (day 28) and 3 months (day 90). At inclusion, there
were no significant differences between groups as regards biometrics data, meantcpO2
(group 1, 62.7 +/- 4.5 mm Hg; group 2, 64.0 +/- 3.3 mm Hg; group 3,64.1 +/- 3.5 mm
Hg), mean tcpCO2 (group 1, 40.7 +/- 2.5 mm Hg; group 2, 39.3 +/- 2.9 mm Hg; group
3, 40.0 +/- 2.5 mm Hg) and laser Doppler parameters. Fourteen patients withdrew from
the study (group 1, n = 4; group 2, n = 3; group 3, n = 7): 9 for reasons not related to
treatment, 3for adverse events, 2 because they were lost to follow-up. From day 0 today
90, mean tcpO2 significantly increased (p < 0.001) in each group (group 1, 3.0 +/- 2.1
mm Hg; group 2, 2.9 +/- 2.1 mm Hg; group 3, 2.5 +/-1.6 mm Hg), mean tcpCO2
significantly decreased (p < 0.001) in each group (group 1, 2.6 +/- 2.0 mm Hg; group 2,
1.7 +/- 1.9 mm Hg; group 3, 2.2 +/-1.5 mm Hg). No significant differences were
observed between groups. Laser Doppler parameters remained unchanged from day 0 to
day 90 in the 3groups. Symptoms (discomfort, pain, heaviness, burning sensation) and
signs (oedema) of CVI as well as perimetric measurements of calf and supramalleolar
area were significantly improved in all the 3 groups. During this 3-month study, Daflon
500 mg improved oximetric measurements and did not alter laser Doppler parameters.
These data suggest that Daflon 500 mg, at the early stages of CVI can act favourably on
the microcirculatory disturbances also involved in the patho-physiology of more severe
stages of CVI.
ii.Benzopyrones
The gamma-benzopyrones include ‘flavones’ and ‘flavonols’ (diosmine, rutin). The
alpha-benzopyrones include coumarin and dicoumerols among others.
iii.Hydroxyrutosides
Hydroxyrutosides are a class of drug derived from plant glycosides (chemically gamma-
benzopyrones). They initially gained favour 20 years ago when experimental studies62
indicated that they reduced capillary permeability following burns in dogs. A number
of clinical studies evaluating their effect on a variety of symptoms associated with CVI
followed. In general these indicated that hydroxyrutosides appeared to be marginally
more effective than placebo in reducing aching, tiredness, muscle cramps and other
symptoms, which one might imagine, are difficult to evaluate objectively. The drugs do
appear to be more effective than placebo in reducing oedema
87; the clinical relevance of
this is uncertain. One study of venous ulcer healing seemed to show an increased
number of healed ulcers after 2 weeks of treatment with hydroxyrutosides compared
with placebo, but this difference disappeared after 4 weeks of treatment. A study on the
effect of rutosides on symptoms in 112 patients with venous insufficiency included with
ulceration. All took rutosides for eight weeks, only one showed any evidence of
improvement
88 . The use of hydroxyrutosides in venous disease appears to have
significant symptomatic value
89,90, 91, but there is no objective evidence of a beneficial
effect on venous ulcers.
The efficacy and tolerability of O-(beta-hydroxyethyl)-Rutosides (HR) in elderly
patients (aged over 65 years) with chronic venous insufficiency or varicose veins was
studied in a multi-centre, double-blind, randomised, placebo-controlled trial. Of the 104
patients entered into the trial, data from 102 were available for analysis of tolerability
and from 86 for efficacy. Treatment as for 6 months, with monthly examinations. Three
different dosages were used due to slight differences in the registered dosage in various
countries: (1) 250 mg 4 times daily (1 g/day), UK, n = 19 patients; (2) 300 mg 3 times
daily (900 mg/day), FRG and Belgium, n = 55, and (3) 300 mg 4 times daily (1,200
mg/day), The Netherlands, n = 30. Each centre had its own placebo control group. The
HR-treated group (n = 41) showed a significantly greater reduction in the total symptom
score, 5.7 +/- 2.4 to 2.3 +/- 1.8, than in the placebo group, 4.4 +/- 3.0 to 3.0 +/- 2.4 (p <
0.01). Of the 5 studied symptoms there was also a significant (p < 0.05) improvement in
leg cramps, heavy legs and restless legs. No significant differences between the two
groups were seen for aching pains and paraesthesia. A small reduction was also seen in
ankle and calf circumferences, which became significant at the end of the trial (p <
0.05). Pitting oedema of the leg (p < 0.01) and eczema of the leg (p < 0.05) also
improved significantly greater than in the control.The drug seemed to be well tolerated.
Diosmin is chemically 3.5.7trihydroxy-4-methoxyflavone-7-rhamnoglucoside. This63
has been used in continental Europe for some time. Reported effects include increased
venous tone, lymphatic drainage and decreased micro-vascular permeability.
iv. Dicoumarols
These are powerful oral anticoagulants and unlike the gamma-benzopyrones have
different and widespread pharmacological applications.
v.Coumarin
Coumarin has been used for lymphoedema in Europe. They may induce proteolysis of
the high molecular weight proteins present in lymphoedema. Unlike the Dicoumarols
they donot modify blood coagulation. Some preparations are hepatotoxic.
vi.Aescin (Horse chestnut extract)
Results with this compound have proved disappointing. In 125 female patients with
CVD ankle circumference was not reduced after 2 months of treatment.
92 There is no
published evidence of ulcer healing or prevention of recurrences with this compound.
vii.Calcium Dobesilate
In one study this synthetic drug decreased the calf circumference and leg volume
significantly compared with placebo. However any published evidence for ulcer healing
or prevention of recurrences is lacking.
viii.Fibrinolytic Therapy
The concept of an oxygen diffusion barrier causing skin hypoxia proposed by Browse
and Burnand has influenced attempts at treatment of chronic venous insufficiency by
pharmaceutical means. They demonstrated that fibrinolytic activity was markedly
reduced in patients with venous disease
93,
94,
95. These observations led to attempts to
reverse the damaging cutaneous effects of ambulatory venous hypertension by
enhancing fibrinolysis. The effect of stanozolol, an anabolic steroid with pro-fibrinolytic
properties, was evaluated in 14 patients with long-standing LDS, without active
ulceration
96. After three months, all showed clinical improvement both subjectively and
objectively (by mapping the area of LDS). Serum parameters of fibrinolytic activity
improved in all cases. Subsequently a 6 month double-blind crossover trial on 23
patients with long-standing LDS, which had not responded to compression hosiery, was64
conducted
97. All patients continued with stockings during the trial. The area of
liposclerotic skin fell during treatment with both stanozolol and placebo. Leg volume as
measured by plethysmography increased on the steroid, presumably as a result of fluid
retention. Skin biopsy analysis suggested but did not prove that tissue fibrin was
reduced by stanozolol treatment; foot vein pressure reduction on exercise was improved
to the same extent on both active and placebo treatment. All but one patient described
subjective improvement during the trial but was unable to differentiate between the
active and placebo periods. The exception to this was in pain relief that was
significantly better while taking the active component.
Overall, the results seem to have been unspectacular, indicating a possible small benefit
from fibrinolytic treatment rather than a major advance in therapy. This impression was
confirmed in a further double blind crossover study of 60 patients performed in UCL
98.
Stanozolol combined with stockings caused a reduction of liposclerotic skin area of
28% over 6 months. However, when the separate contributions of the two treatment
elements were calculated using multivariate analysis, the effect attributable to
stanozolol alone was not statistically significant.
Fibrinolytic treatment for venous ulceration has been evaluated in one trial of 75
patients
99. Patients were allocated to receive either stanozolol or placebo for up to 420
days, with conventional compression treatment in all cases. In an interim report, the
authors found complete healing in 26 of 40 ulcers in the stanozolol group and 27 of 44
in the placebo group, indicating no benefit from active over placebo treatment.It appears
thatone may say that fibrinolytic enhancement may be of minor benefit in the
symptomatic treatment of LDS, but that it does not appear to improve ulcer healing.
ix. Diuretics
Diuretics have a lmited role in the treatment of chronic vein disease. They may be useful
in the short term for controlling osedema mostly associated with other co-morbidities.
x. Anti-platelet agents
They have mainly a preventative role. Results of meta-analysis show that aspirin
reduces the risk of pulmonary embolism and deep-vein thrombosis by at least a third
throughout a period of increased risk. Hence, there is now good evidence for65
considering aspirin routinely in a wide range of surgical and medical groups at high risk
of venous thromboembolism.66
1.10 Compression therapy - Mechanism of
Action & the microcirculation
Compression treatment has been used for the treatment of venous leg ulcers since
antiquity. Despite its successful and widespread use the exact mechanism of its action
remains unknown. There are several relative and absolute contraindications for
compression therapy. These may include local infection and sometimes significant
cardiac failure. Fontaine type III and IV stage (rest pain, gangrenous changes) arterial
occlusive disease is also a contraindication. In lesser degrees of arterial disease
(Fontaine I and II i.e. asymptomatic, intermittent claudication) the policy is less clear
with no scientific evidence to back up any recommendations. This assumes special
importance in case of leg ulcers of mixed arterial and venous aetiology. Several factors
contribute to the relative effectiveness of compression therapy. Ulcer size, duration,
limb joint mobility and general mobility were significant independent factors in
multivariate analysis
100. In a related study the impact of socio-economic status was
limited.
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Studies of the macro-circulation fail to provide adequate explanation for the mechanism
of action of compression therapy in CVD. The microcirculation may be important in
this regard. In this thesis a study of the microcirculatory response to compression
therapy is included. The pressure exerted by the bandage is proportional to the tension
of the bandage (T) and inverse of the radius of curvature (R) of the skin surface i.e.
Laplace’s law: P=T/R. Hence if even tension is maintained while applying a bandage
the pressure exerted would be higher at the ankle and lower at the thigh level. It is
important to blot out concavities e.g. those around the malleoli. The stretched bandage
exerts the resting pressure while the working pressure is exerted by muscle contraction
with change in size of the leg. The latter is intermittent and is exerted by walking.
Compression therapy may not make the valves competent at the lower pressures
ordinarily used i.e. 30-40 mm Hg. It can increase the stroke volume and decrease the
mean residual filling volume of the leg during walking. Refilling rates and times may67
Table 8 Comparison of classifications of elastic support in Europe
also be improved.
102 It may increase intra-tissue pressure with increased resorption of
oedema. The effect of this magnitude of changes in the macro-circulation on ulcer
healing is unclear. Some studies have reported increased fibrinolysis following
compression therapy.
It has been shown that compression actually increases flux of blood through the skin.
This may increase the shear force between the leucocytes and the endothelium and thus
provide a possible mechanism of action for the stockings. Hence Mondeville’s
suggestion in 1309 that compression works by driving out evil humors may not have
been far off the mark.
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Various types of bandages may be used. Long stretch elastic bandages are easier to use
and last longer they have a high resting pressure. The walking pressure however, is not
high. Calibrated bandages may help the patient to check the compression by means of
deformation of small built in ‘’squares’’
Previous Studies Of Compression & The Microcirculation
Studies undertaken previously have established several facts regarding response of
macro-circulation and the microcirculation to compression therapy. These include the
following (i) compression restores venous valvular competence at a lower pressure i.e.
circa 40 mmHg in about a quarter or less of patients. (ii) Higher pressures may simply
lead to complete collapse and closure of the veins (iii) patients with CVD have a higher
rate of flux of blood through their micro-circulations compared to controls (iv) Flux
increases in the skin of patients with CVD with increasing compression. This is
especially evident at pressures between 30-60 mmHg. In general higher pressures are












I 14-17 15-21 10-15 18-21 18.37-21
II 18-24 23-32 15-20 15-20 25.12-32.25
III 25-35 34-46 20-36 20-36 36.37-46.5
IV >35 >49 >36 >36 >58.8768
Sarin et al studied the effect of compression on valvular competence in controls and
patients
.104 They used a water-filled cuff around the knee with the long and short
saphenous veins as well as the popliteal veins scanned through the cuff. Vein diameter,
vein patency and reflux was determined at increasing pressures in increments of 10 mm
Hg. This study suggested that the beneficial effect of compression might not after all be
due to a simplistic correction of venous reflux. It may be that some of the answers lie in
the microcirculatory response to compression.
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Effects of compression have been widely studied on the venous haemodynamics of the
lower limb. In patients with CVD the ambulatory foot vein pressure is raised. It would
be reasonable to assume that application of compression stockings will restore this
index to normal. The time required for the foot vein pressure to return to resting levels
after the end of exercise is an indicator of the degree of reflux in a limb. This may be
measured either by direct vein pressure or indirectly by air plethysmography, strain
gauge plethysmography, foot volumetry etc. Air plethysmography may permit a more
detailed analysis of the calf muscle pump, however, this has not demonstrated reduced
venous refilling times after the application of stockings. It seems probable that stockings
and compression bandaging may benefit the overall haemodynamics of the limb to some
degree.
Laser Doppler fluxmetry measures both the sub papillary (thermoregulatory) shunt flow
as well as the nutritional flow in the papillary capillary loops. Its findings are broadly
comparable to those of capillary microscopy. The technique is non-invasive and simple
to use and is a useful tool in the assessment of diseases that affect the microcirculation.
Although the laser Doppler flux in subjects in the supine position was higher in
liposclerotic skin, as has been reported previously, the blood cell velocity in patients
with liposclerotic skin was substantially lower than that in control subjects. The
increased laser Doppler flux was attributable to an increase in the combined cross-
sectional area of the capillaries. Previous histological studies have shown that the
number of capillary loops seen on histological section of liposclerotic69
Table 9 shows diametrs of the veins at zero and at 40 mm Hg external presure with those still
demonstrating reflux distinguished from those that did not. Reflux was abolished in only a
proprtion of the samples at 40 mm Hg. The diameters following compressio were smaller than
initial diameter in all the cases. Adapted from PD Coleridge Smith ‘Microcirculation in Venous
disease’ 2
nd edition 1998)
skin is increased compared with normal skin. This may partly represent multiple cross
sectioning through elongated and distended capillaries.
It has been reported that the capillaries in liposclerotic skin are dilated and coiled.
35,36
It is therefore not surprising that there should be an increased volume of moving blood
cells in the skin. It has been reported that plasma viscosity, erythrocyte sedimentation
rate, and fibrinogen are increased in patients with post thrombotic syndrome, but the
hematocrit level is not significantly different from control subjects. The increased
volume of moving blood cells shown in this study is consistent with the observation that
capillaries are dilated and coiled in liposclerotic skin as shown by studies with capillary
microscopy and histological examination. The microangiopathy of liposclerotic skin
seems to comprise not just of structural changes but also a disturbed microcirculatory
flow pattern.
The decrease in blood cell velocity may increase the likelihood of white blood cells in
capillaries or venules interacting with the endothelium. It has been shown both in vivo
and in vitro that at low shear rates, interaction of leucocytes with the endothelium is
much more likely than at higher shear rates. Because the shear rate is a function of the
flow velocity, leucocyte adhesiveness is inversely proportional to the velocity of blood
flow. It is possible that white blood cells play a significant role in the venules
interacting with the endothelium.
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17 9(7-10) 14 5.8(5-6.4) 21 4.6(3.9-5.9)70
Figure 18 shows the effect of skin compression on laser doppler flux, velocity and concentration
of blood cells in the microcirculation of the skin. The figure at the top shows data obtained in
the supine position while that on the bottom shows data from upright position. From PD
Coleridge-Smith ‘Microcirculation in Venous disease 2
nd edition 1998, with permission)

……
 LDF=Laser Doppler flow, BCV= Blood Cell Velocity, CMBC=Concentration of Moving Blood Cells71
On application of compression there is an increase in the laser Doppler flux in patients
with liposclerotic skin. In the horizontal position, the peak flow occurs in the region of
10 to 20 mm Hg, which corresponds with what one might expect the capillary pressure
to be with a patient lying in this position. When the patient moves to the sitting position,
the peak flow occurs at 50 to 60 mm Hg, which again corresponds with the expected
capillary pressure with a patient sitting erect because of the increased hydrostatic
pressure.
Compression in the range of 20 to 30 mm Hg, commonly achieved by use of
compression stockings, is sufficient to double the laser Doppler flux of a patient in the
sitting position. In addition it is also suggested that still higher levels of compression (of
the order of 40 to 60 mm Hg) may be effective in the treatment of patients with venous
disease, without resulting in cessation of blood flow to skin in the patient in the sitting
position. It has been shown that compression bandaging reaching pressures of 45 mm
Hg results in rapid healing of venous ulcers,
45 and this is consistent with the suggestion
that the findings of increased laser Doppler flux on compressing the skin are related to
the mechanisms of the effect of compression on venous disease. Clearly there is no
fundamental difference in the response to compression in liposclerotic skin compared
with normal skin, although the effect is less marked in control subjects. It can be seen
that local compression of the skin, without compression of the whole limb, results in
significant alteration in the local microcirculatory blood flow. There is an increase in
blood cell velocity in response to compression. Such an increase in velocity may reduce
the likelihood of white blood cells interacting with the endothelium. This finding could
have an important bearing on the mechanisms of action of compression.
One of the major shortcoming of these studies was thet the laser flux measures flow
both in the nutritive as well as the ‘non-functional’ part of the microcirculation. The
latter may be relatively unimportant in skin nutrition and leucocyte mediated damage.
There is also the question of patients with mixed arterial and venous disease. The
response in these patients may be very different.72
1.11 Surgical/ Interventional Treatment of
Chronic Venous Disease
Surgery for varicose veins involves tying off incompetent communications between the
deep and the superficial venous systems, stripping of lengths of vein and multiple
phlebectomies. ‘Strategic’ ligation of incompetent veins and operations to restore valve
patency in the superficial venous system remain to be proven. Superficial vein disease
alone is responsible for leg ulceration in about half of all cases. Studies have shown that
surgery in these instances can lead to a high healing rate in the short to medium term
106.
No studies of the long-term outcome are available. There is some evidence of the
efficacy of both laser vein ablation (& radiofrequency)
118 as well as foam sclerotherapy.
More long term data is not available.
It has been shown recently that selecting patients for superficial vein surgery with AVP
criteria can improve venous function significantly post-operatively
107. The significance
of perforator vein surgery remains to be proven conclusively. Part of the reason for this
is the fact that perforator incompetence and indeed some DVI seem to improve with
superficial venous surgery alone.
Surgery to the deep veins is still practiced in relatively few centres. More recent studies
have suggested that both primary venous insufficiency, as well as post-thrombotic CVD
may be suitable for deep vein reconstruction
108. The procedures utilized are
valvuloplasty (Open, trans-commissural, angioscopic guided), vein segment
transposition and vein segment auto-transplantation. Bypass procedures for obstructive
disease (circa 10% of CVD) include the Palma procedure and femoro-popliteal (venous)
bypass operations as well as more proximal bypasses including the vena cava. However
these procedures are suitable only for a relative minority.
Varicose Vein Surgery
Traditionally issues in varicose vein surgery have focused on the role of Duplex scans,
whether or not to strip the GSV, method of stripping used, preventing recurrent varicose
veins and medico-legal problems. More recent developments are laser vein surgery,
foam sclerotherapy and other similar treatments.73
The accuracy of DUPLEX and its comparison to other tests is discussed in section 1.4.
Most surgeons would use DUPLEX scan for (i) Recurrent varicose veins (ii) Short
saphenous varicosities (iii) suspicion of DVI (iv) Any other uncertainty about the origin
of the varices.
The case for performing DUPLEX for all cases has been put forward. Studies have
shown that leaving the GSV in situ leads to a higher rate of recurrence. The mid-thigh
perforator has been implicated in many of these recurrences. The GSV is duplicate in
many instances and reconnection to these may be responsible for other cases. Bruising
of the thigh is a frequent sequel of GSV strip. Gentler stripping techniques including
inversion techniques have been advocated. The perforate Invaginate stripper (PIN
stripper) has been used in an effort to reduce exit wound scar length as well as to
reduce the trauma of stripping. Studies have not, however shown any conclusive
difference between PIN technique and conventional stripping.
LEG ULCERS AND THE ROLE OF SUPERFICIAL VENOUS SURGERY
Various studies have documented the role of the superficial venous system in aetiology
of leg ulceration.). It has been shown that superficial venous surgery will heal the vast
majority of leg ulcers. In sick patients this may even be performed under local
anaesthesia. If there is no associated DVI then the use of post-operative compression
stockings may not be necessary. There is no long-term data regarding what happens to
Table 10 Venous ulceration-morphology of the venous insufficiency
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these ulcers eventually. My own pilot study included in this thesis looks at some long
term data. In one published study 122 limbs underwent surgery for SVI. Cumulative











Shami 59 DUPLEX - 53 47 (32) N.A.
Lees 25 DUPLEX - 52 48 (12) N.A.
Weingarten 148 DUPLEX - 9 80 (55) N.A.
Van Rij 120 DUPLEX/
APG
2 67 31 (28) N.A.
Grabs 111 DUPLEX - 51 43(38) 1474
healing rates at 6, 12 and 18 months were 57, 74 and 82 per cent respectively. It was
observed that the larger ulcers also healed but took longer. None of these patients had
DVI and none of them were prescribed post-operative leg compression.
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Thus direct treatment of the cause of venous ulceration in these often very infirm
patients would avoid the morbidity and prolonged immobilization of procedures such as
skin grafting. In this report the healing rates were equally good with either GSV or SSV
incompetence causing leg ulceration. It is also reported in that a fixed ankle joint




The incidence of pure perforator incompetence is very low. Most often it is associated
with superficial, deep or combined chronic venous disease. Reverse flow in these
perforators may be restored to normal by correction of the SVI when there is no
associated DVI. Hence most patients in this group have healed ulcers following
saphenous surgery alone.
*Bimalleolar/ Posterior calf
Table 11 Distribution of superficial venous reflux and ulceration
in legs(per cent).
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There is uncertainty regarding the role of combined/perforator surgery in patients with
simultaneous superficial, deep and perforator disease. No studies have shown
conclusively that perforator surgery either on its own or in tandem with saphenous
surgery is better than saphenous surgery alone. The role of perforator interruption
Site of Ulcer





Long Saphenous (n=93) 62 (67) 21 (23) 10 (11)
Short Saphenous (n=13) 7 6 -
Long and short spahenous
(n=16)
10 5 175
(surgery or other interventions) in patients with DVI but no obstruction continues to be
investigated.
Sub-fascial Endoscopic Perforator Surgery (SEPS)
This is a technique for ligating calf perforators that avoids both a long incision as well
as its placement in diseased skin of the leg in CVD. SEPS is technically effective at
eradicating calf perforators and produces less complications than open surgery.
Although SEPS and saphenous surgery produce good initial venous ulcer healing, there
is no hard evidence to support its use in preference to conservative management or
saphenous surgery alone. SEPS may actually worsen the situation if used in the
presence of deep venous obstruction. In this situation the calf perforators are thought to
act as safety valves for relieving the high pressures within the deep venous system.
111
Chemical Ablation & Radiofrequency Ablation of Perforators
Ultrasound guided Radiofrequency ablation may give similar results to SEPS with
experience.
112 Careful guided sclerotherapy may also yield good results in perforator
vein closure.
113 Good quality long term data is lacking regarding these procedures.
DEEP VENOUS RECONSTRUCTION
These include valvuloplasty, vein valve transplantation/ implantation, valve support
devices and vein segment transposition. Results of bypass surgery for iliac vein
occlusion are reported to be favourable. Below the inguinal ligament, reflux is regarded
as the primary pathologic problem leading to symptoms in patients afflicted with
chronic venous insufficiency (CVI). In 1968 the first valve repair 1 was performed on a
patient with incapacitating pain and oedema of the lower extremity and severe reflux of
the femoral system. After repair of the incompetent superficial femoral vein and
interruption of perforators, the patient was relieved of his CVI symptoms and remained
free of them until his death 13 years later. The postoperative venogram confirmed
patency and competence of the repair. The first series of valve reconstruction was
reported in 1975, and good clinical results were achieved in 80% with a follow-up of 5
years. Since a technique for direct surgical correction of reflux was developed, other
procedures have been introduced for reflux, including valve substitution by
transposition and transplantation. Despite reports of encouraging clinical results by76
several centres, considerable controversy and uncertainty persists regarding the
durability and long-term effectiveness of valve reconstruction procedures. Furthermore,
although haemodynamic studies show improvement after valve reconstruction, these
tests do not normalize in all cases, even with successful relief of symptoms.
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Kistner and Masuda published their long term results (Mean follow-up 10 years) with
venous reconstruction surgery
114. One of the most striking findings in this long-term
study is the strong correlation of valve competence, verified by descending venography
or duplex scanning, with successful clinical outcome. All limbs that were converted to
an asymptomatic state demonstrated either complete valve competence or mild
incompetence. Valve competence was more frequently achieved in the valve repair
procedure as opposed to the valve transposition procedure and correlated with the better
clinical results found in the group undergoing repairs. Valve competence was found up
to 16 years after valvuloplasty and confirms the long-term durability of the valve repair
operation. The importance of having a competent proximal valve is also seen in those
who had recurrence of symptoms, because the most frequent finding in them was
recurrent reflux in the proximal valve.
……………………………….
In the patients where the results were poor, this occurred within 6 years in all patients
but one and within 4 years in the PVI (primary venous insufficiency) group. This
suggests that future studies of valve operations shoauld give long-term valid results after
an observation time of 4 to 6 years. This long-term study reflects the importance of
thorough workup of the patient with CVI to find patients with repairable proximal
valves. Descending phlebography is necessary to discover which patients have
repairable vessels caused by PVI. In those who have pure PVI incompetence,
valvuloplasty can be expected to yield good long-term results in a high percentage of
patients. The results of this series represent what has been accomplished with repair of a
single valve in the SFV, or proximal transposition surgical procedure. Results may be
improved by better techniques of repair or repair of multiple valves or reconstruction in
different sites such as the popliteal vein. The overriding finding of the series was that
the individual who is relieved of major amounts of axial reflux in te CVI extremity
experiences dramatic clinical improvement. In these cases the surgeon is only able to
provide a measure of improvement to try to restore the patient to a compensated state
rather than a totally curative solution. The fact that one third of the entire group were77




Maleti and colleagues have presented a series of 40 patients with neo-valve
reconstruction creating flaps using the thickened vein wall. They report some
encouraging early results especially with a modified technique. Further results are
awaited.
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Table 12 depicts a standardized outcome of surgery for the purpose of study design and
reporting. It is recommended that no clinical outcome grade be assigned until at least 6 months
after operation.
1.12 REPORTING STANDARDS OF OUTCOME
The clinical outcome after surgery for CVD must be standardized for various
procedures to be compared amongst themselves as well as comparison between
different institutions. A venous severity score
116 has been validated and it was found
that venous severity scores are significantly higher in advanced venous disease,
demonstrating correlation with anatomic extent. Both venous clinical severity scores,
VCSS and CEAP clinical score, were equally sensitive and significantly better for
Clinical outcome after surgery
+3 Asymptomatic, no symptoms of chronic venous disease, improvement of VRT to normal or
at least +5 seconds, improvement in AVP to normal or at least -10 torr
+2 Moderate improvement, mild symptoms of chronic venous disease, improvement of VRT to
normal or at least +5 seconds, improvement in AVP to normal or at least -10 torr
+1 Mild improvement, clinical improvement or improvement in vascular laboratory test results
(VRT or AVP)
0 Unchanged, no change clinically or by vascular laboratory test results
-1 Mild worsening; worsening of symptoms of chronic venous disease or vascular laboratory
tests (VRT or AVP)
-2 Significant worsening, worsening of symptoms and worsening of vascular laboratory test
results (VRT or AVP)
-3 Marked worsening, same as - 2 accompanied by either new or worsening ankle claudication
AVP, Ambulatory venous pressure.78
measuring changes in response to superficial venous surgery than was the CEAP
clinical class. Although the assignment of CEAP clinical class might be adequate for
daily clinical purposes, venous severity scoring systems should be used in clinical
studies to quantify venous outcome
117.
Comparison of CEAP clinical score and VCSS
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Ulcer duration Ulcer duration






The venous severity scoring (VSS) system has been proposed by the American Venous
Forum Ad Hoc Committee on Venous Outcomes Assessment as a useful and reliable
method for outcome quantification, comparison of different management approaches,
and reports in the management of chronic venous disease (CVD). The proposed system
has three elements: venous clinical severity score (VCSS), which is a modification to
replace CEAP clinical score; venous segmental disease score (VSDS), which is a
(VDS), a modification of the original CEAP disability score. The purpose is to use these





Chronic venous disease (CVD) is associated with leucocyte and endothelial activation
as well as a local growth factor response. This increased activation may respond
favourably to various forms of therapy in CVD. The Hypothesis tested in this work is
that there are measurable changes in leucocyte/endothelial activation and
microcirculatory blood flow in CVD in response to medical, surgical and compression
therapy. Thus these may act as objective measures of response to treatment.
It has been shown that there is increased expression of VEGF in skin tissue with CVD.
Therefore it is possible that plasma vascular endothelial growth factor (VEGF) would
also be raised in patients with CVD. If this is proven then plasma VEGF may be used in
subsequent studies to monitor response to therapy. This may be accomplished by
measuring plasma levels in both patients as well as normal subjects. There may be
potential diagnostic, prognostic and therapeutic applications of this.
Physiological assessments following therapy have both limitations as well as logistical
difficulties for more widespread use. Previous studies from this department have shown
that plasma levels of VCAM, ICAM-1, vW factor & Lactoferrin are elevated in patients
with CVD. Therefore treatment of the venous disease by a number of methods may
normalise changed expression of leucocyte/ endothelial activation. Flavonoids
(especially purified micronised fraction) have been shown to be of symptomatic benefit
in CVD. They may ameliorate the increased neutrophil activation/ degranulation and
endothelial activation. Therefore plasma levels of VCAM, ICAM-1 VW-factor and
Lactoferrin may be significantly reduced following therapy with oral purified
micronised flavonoid fraction.
Compression therapy is effective in CVD by means of an as yet unproven mechanism.
There is no evidence that compression treatment renders incompetent valves competent.
Compression may affect the microcirculation directly by changing the microcirculatory
skin blood flow in patients with pure CVD as well as in those with mixed arterial and
CVD. This may lead to change in shear at the venular/ capillary endothelial interface
and thus possibly help in ameliorating the effects of CVD. Measuring the red cell
velocity in microvasculature of patients with venous, arterial or mixed disease before
and after compression may show demonstrable changes in this parameter.81
In summary the hypothesis tested in this thesis is that alteration in microcirculatory
flow; endothelial activation, VEGF activity & increased neutrophil degranulation
activity described in CVD would show a measurable response to therapy.82
PART III-
METHODOLOGY83
3.1 Protocol For Quantifying Lower Limb Venous Reflux Using Duplex
Ultrasound Scanning
Colour duplex ultrasonic mode imaging, B-mode (brightness mode) imaging and
spectral Doppler mode measurements were performed using the Acuson 128XP/10v
(Acuson, Mountain View, California, USA) computed sonography system with ART
(acoustic response technology) using a 5- or 7.5- MHz linear array transducer.
Patient preparation
The ultrasound examination is done with the patient in the standing position so that the
veins are under hydrostatic pressure as in pathological conditions. The limb to be
examined should be externally rotated and completely relaxed and non-weight bearing
with all the weight transferred to the contralateral limb.
Venous segments that are as close to the gaiter area as possible without interfering with
the cuff position were examined: the SFV in the distal thigh, distal popliteal vein
segment, proximal PTV segments, LSV at knee level and proximal SSV segment.
Measurements at the valve cusps were avoided due to the presence of turbulent flow and
all measurements were carried out on segments just above or below the cusp. In the
quantification of blood volume flow within a vein, the size of the pulsed Doppler gate
should insonate the entire vessel in order to account for all the blood cells which travel
at different velocities with the slowest velocities present towards the vessel walls and
the fastest present in the centre of the vessel.
The long saphenous vein and superficial femoral vein were examined with the patient in
the standing position and facing the examiner, with the leg to be examined slightly
flexed and externally rotated with the body weight supported by the contralateral limb.
The sapheno-popliteal junction, short saphenous vein and popliteal vein are examined
with the patient standing and facing away from the examiner with the knee on the side
being examined slightly flexed so as to relax the popliteal fossa and the weight
distributed on the contralateral limb. A pneumatic calf cuff with a width of 12cm that
could be rapidly inflated and deflated automatically to a pressure of 120mmHg was
placed around the calf and used to induce reverse flow. A standardised measuring
method was adopted throughout in all the vein segments examined after augmentation84
Figure 19 .The top photograph shows turbulent reflux at the SFJ. The middle photograph is a
higher resolution B-Mode image depicting the valve cusps at the SFJ. The lower photograph
shows a colour flow image of the SFJ.( All photographs courtesy of John Farrah PhD).
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of blood flow by the standardised cuff inflation method in the calf. A standardised rapid
cuff inflation and deflation unit constructed in our laboratory (Middlesex Hospital
Vascular Laboratory, 1995) with a calf cuff width of 12cm was used to augment flow in
the vessels (see section 2.7). The cuffs were inflated for approximately 3 seconds with
the deflation requiring only 0.3seconds. A B-mode 2D image of the vein segment of
interest was obtained after insonation of the vessel with plenty of scanning gel applied
between the transducer and the skin to avoid distortion of the underlying superficial
vessels that may be compressed with the transducer.
In order to obtain the B-mode image and the frozen spectral Doppler display the patient
is investigated in the standing position with the leg to be examined slightly flexed and
externally rotated with the body weight supported by the contralateral limb and a
pneumatic calf cuff with a width of 12cm that could be rapidly inflated and deflated to a
pressure of 100mmHg placed around the calf to induce reverse flow as described by the
standardised method above. The vessel of interest is insonated with the transducer and a
frozen B-mode image is obtained to measure the vessel diameter followed by a frozen
spectral Doppler display obtained after calf compression and release which has captured
both the antegrade and retrograde flow.
To calculate reflux or retrograde volume blood flow
A reflux time of 0.5 secs or more in the popliteal vein was was taken as an abnormal
reading.
The formula used to calculate the reflux volume blood flow is
Q = TAV x area x T
where, Q = reflux volume flow (ml), TAV = time averaged velocity (metres / sec), Area
= cross-sectional area (mm
2) at the Doppler sample gate and T = a multiplier to
express flow within the duration of reflux (seconds).
The formulae (D
2/4 or r
2) where D is the cross-sectional diameter of the vein in mm
obtained from the B-mode 2D imaging mode and r is the radius of the vein in mm is
used to calculate the cross-sectional area of the vein and the TAV and T can be
calculated from the axial Doppler reflux velocity waveforms on the frozen spectral
Doppler strip as described earlier.86
Protocol for Venous reflux test by photoplethysmography (ppg)
The model PPG13 Vasculab
® Photoplethysmograph (PPG) (Medasonics, Mountain
View, California) was used in this thesis. It serves as a preamplifier and power supply
and was used with the model PH77 PHOTOPULSE
® photoplethysmograph sensor
Methodology
The subject was examined in the sitting position with the lower limbs dependent and
with the transducers attached using a double-sided tape 5cm proximal to the medial
malleolus. A stable trace was established, and the subject was asked to perform a series
of 10 dorsiflexions and plantarflexions at the ankle to activate the calf muscle pump.
This produced an emptying phase in which the falling content of haemoglobin resulted
in increased amounts of light reaching the photodetector. The subject was then asked to
rest and the refilling phase recorded. If the test showed an abnormal response, a
tourniquet cuff (5 cm dia) was placed above the knee and inflated to about 80-
110mmHg (depending on the size of the thigh) to occlude the superficial veins in the
thigh and the test repeated as described above. If the test still showed an abnormal
response, it is repeated with below knee cuffs inflated to 40-60 mmHg to occlude the
calf veins. If a torunquet was required at the ankle level a 2.5 cm tourniquet was used.
Data Analysis
The time taken for the trace to return to the baseline level was referred to as the PPG
refilling time. It was measured by placing the start cursor at the end of the exercise
phase and the end cursor at the end of the refilling phase where the trace started to level
off. In normal subjects, this refilling time is greater than 20 seconds whereas abnormal
subjects with incompetent veins will have refilling times of less than 20 seconds.
Protocol for measuring resting ankle brachial pressure indices (ABPI).
The subject is examined in the supine position after lying relaxed in a comfortable
ambient temperature room for 10 minutes.
Measuring arm pressures
A standard 12 inch sphygmomanometer cuff
 or other suitable cuff (depending on size
of limb) is placed around the arm just above the elbow. The brachial pulse is located
 Standard Adult cuff 16  30 cms, small adult 12 * 22 cms, large adult 16 * 36 cms, thigh cuff 16 * 42
cms.87
with a hand-held bi-directional Doppler (Dopplex
®, Huntleigh Healthcare) by
positioning the 8MHz probe over the brachial pulse after applying gel and holding and
manoeuvring the Doppler probe at a 45 degree angle between the forefinger and thumb
until a good Doppler signal is obtained. The cuff is inflated until the Doppler signal
disappears and slowly deflated until the signal returns. The pressure at that point is
noted as this is the brachial systolic pressure. The same procedure is repeated in the
other arm.
Measuring ankle pressures
The sphygmomanometer cuff is placed around the leg just above the ankle and using the
Doppler probe as described above, both the dorsalis pedis artery as well as the posterior
tibial artery pulse is located. The cuff is inflated until the Doppler signal disappears and
slowly deflated until it returns. The pressure at this point is noted as the ankle systolic
pressure. The higher of any readings obtained are used for calculation. Both pedal ankle
systolic pressures are measured and recorded.
Data Analysis
To calculate the ankle brachial pressure index (ABPI), the ankle systolic pressure
reading is divided by the brachial systolic pressure using the higher of the brachial
pressures and the higher of the ankle systolic pressures in the calculation. Normal ankle
brachial pressure index is equal to or greater than 0.90 in a non-diabetic individual.
3.2.1 Human soluble ICAM-1 Immunoassay
Adhesion molecules mediate the interaction of cells with the extracellular matrix and
with other cells. The immunoglobulin superfamily of proteins contains a large class of
adhesion molecules with multiple immunoglobulin-like domains. ICAM-1 (CD54) is a
member of this family (1, 2). It is a 90 kDa type-I transmembrane glycoprotein with five
Ig-like extracellular domains. The most important ligands for ICAM-1 are the â2
integrins LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) , which are expressed on
leucocytes . ICAM-1 thus mediates the adhesion of leucocytes to ICAM-1-expressing
cells. ICAM-1 also binds fibrinogen , hyaluronan , Rhinoviruses, Plasmodium88
falciparum-infected erythrocytes and CD43 (sialophorin) . ICAM-1 is either a
transmembrane protein (mICAM-1) or soluble (sICAM-1) . mICAM-1 is expressed on
endothelial and epithelial cells, lymphocytes, monocytes, eosinophils, keratinocytes,
dendritic cells, hematopoietic stem cells, hepatocytes and fibroblasts.
Regulation of ICAM-1 expression is cell specific. Up-regulation generally is by
inflammatory cytokines (TNF-á, IFN-ã and IL-1) and down-regulation generally is by
anti-inflammatory agents ( e.g.glucocorticoids) . One important, well-characterized
function of ICAM-1 is immune-cell trafficking. At sites of inflammation, inflammatory
cytokines induce up-regulation of ICAM-1 expression on vascular endothelial cells and
activation of leucocyte integrins (LFA-1 and Mac-1). This leads to adhesion of
leucocytes to the local endothelium, an essential step in migration of leucocytes to the
site of inflammation. sICAM-1 has been reported in serum (10), cerebrospinal fluid and
bronchoalveolar lavage. sICAM-1 likely arises by proteolytic cleavage of mICAM-1;
synthesis from an alternatively spliced message has not been found . In general,
elevated levels of serum sICAM-1 appear to be associated with inflammatory conditions
and certain malignancies . It has, however, been pointed out that in inflammatory
conditions, where the ligands LFA-1 and Mac-1 are likely to be activated, binding and
clearance of sICAM-1 might be enhanced, so that a reciprocal relationship between
sICAM-1 levels and inflammation also is possible .
The Parameter human sICAM-1 Immunoassay is a 2 hour solid phase ELISA that is
designed to measure sICAM-1 in cell culture supernatants, serum and plasma. It
contains recombinant human ICAM-1 and antibodies raised against the recombinant
factor. This immunoassay has been shown to quantify recombinant and natural human
sICAM-1 accurately. Results obtained using natural human sICAM-1 showed linear
curves that were parallel to the standard curves obtained using the recombinant
Parameter kit standards. These results indicate that the Parameter Immunoassay kit can
be used to determine relative mass values for natural human sICAM-1.
Principle Of The Assay
This assay employs the quantitative sandwich enzyme immunoassay technique. A
monoclonal antibody specific for sICAM-1 has been pre-coated onto a microplate.
Standards, samples, Controls and Conjugate are pipetted into the wells and any sICAM-89
1 present is sandwiched by the immobilized antibody and the enzyme-linked
monoclonal antibody specific for sICAM-1. Following a wash to remove any unbound
substances and/or antibody-enzyme reagent, a substrate solution is added to the wells
and colour develops in proportion to the amount of sICAM-1 bound. The colour
development is stopped and the intensity of the colour is measured.
Assay Procedure
All reagents and samples are brought to room temperature before use. It is
recommended that all samples, Standards and the sICAM-1 Control be assayed in
duplicate. The following protocol as recommended by the manufactures (R&D Systems
Abingdon UK) was used
1. Prepare all reagents, working Standards, samples, and Control as directed in the
previous sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch
containing the desiccant pack, reseal.
3. Add 100 µL diluted Conjugate to each well.
4. Add 100 µL Standard, sICAM-1 Control*, or sample* to each well with sufficient
force to ensure mixing.
5. Cover the plate with a plate sealer provided and incubate at room temperature for
1.5 hours.
6. Aspirate or decant each well and wash, repeating the process five times for a total of
six washes. Wash by filling each well with Wash Buffer (300 µL) using a multi-channel
pipette, manifold dispenser or autowasher. Complete removal of liquid after each wash
is essential to good performance. After the last wash, aspirate or decant the contents and
remove any remaining Wash Buffer by tapping the inverted plate firmly on clean paper
towels.
7. Immediately add 100 µL Substrate to each well. Cover the plate with a new plate
sealer and incubate at room temperature for 30 minutes.
8. Add 100 µL of Stop Solution to each well. The Stop Solution should be added to the
wells in the same order as the Substrate.
9. Determine the optical density of each well within 30 minutes, using a microplate
reader set to 450 nm. If wavelength correction is available, set to 620 or 650 nm. If
wavelength correction is not available, subtract readings at 620 or 650 nm from the90
readings at 450 nm. This subtraction will correct for optical imperfections in the plate.
Readings made directly at 450 nm without correction may be higher and less accurate.
Calculation Of Results
The mean absorbance values for each set of duplicate Standards were calculated. A
standard curve was constructed by plotting the mean absorbance for each Standard on
the y-axis against the concentration on the x-axis and drawing a best-fit curve through
the points on the graph. The concentration of each unknown sample was determined by
calculating the concentration of sICAM-1 corresponding to the mean absorbance from
the standard curve. For samples and the sICAM-1 Control, the concentration determined
from the standard curve was multiplied by the dilution factor. The sICAM-1 Control
was run in each assay. If the values obtained were not within the expected range, as
stated on the Control vial label, the assay results were considered invalid.
3.2.2 Human sVCAM-1 Immunoassay
Human Vascular Cell Adhesion Molecule-1 (VCAM-1) is a 100 - 110 kDa, 715 amino
acid (aa) type I transmembrane glycoprotein typically characterized by the presence of
seven C2-type immunoglobulin (Ig) domains .Its extracellular region is 674 aa in length,
followed by a 22 aa transmembrane segment and a 19 aa cytoplasmic tail . In the
extracellular region, there are multiple N-linked glycosylation sites (the predicted
molecular weight is 80 kDa), and each C2 domain is closed by a disulfide bridge. There
is considerable interspecies VCAM-1 homology, with mouse and rat VCAM-1 showing
approximatley 75% aa identity to human VCAM-1. Notably, the short 19 aa
cytoplasmic tail is absolutely conserved, mouse to human to rat. Cells expressing mouse
VCAM-1 bind both mouse and human leucocytes, and this reflects their high degree of
aa identity. A number of variants of VCAM-1 are known to occur, all of which are
likely the result of alternate gene splicing. In particular, a human six Ig domain
molecule is known, and in rabbits, an eight Ig domain form has been identified.
There is also a three C2 domain, 43-kDa GPI-linked form of VCAM-1. Although it
binds known VCAM-1 ligands (or co-receptors), its function is unclear. Cells known to
express VCAM-1 include neurons, endothelial cells, smooth muscle cells, fibroblasts91
and macrophages. Soluble VCAM-1 has been identified in culture supernatants, blood,
and cerebrospinal fluid. The exact mechanism by which VCAM-1 is generated is
unknown; it may, however, involve both proteolytic processing and alternate splicing.
Functionally, VCAM-1 binds to both α4β1 (VLA-4) and α4β7 (LPAM-1) integrins.
These integrins (or VCAM-1 ligands) are expressed on a variety of cells, with VLA-4
found on all leucocytes with the exception of neutrophils (17, 19, 20). Because of this,
VCAM-1/VCAM-1 ligand interactions are undoubtedly key events in the rate and
timing of leucocyte extravasation. Other roles proposed for VCAM-1 include the
regulation of osteoclastogenesis via a cell-to-cell contact mechanism, and the induction
of sickle cell adherence to vascular endothelial cells during hypoxemia. The Parameter
human sVCAM-1 Immunoassay is a 2 hour solid phase ELISA that is designed to
measure sVCAM-1 in cell culture supernatants, serum and plasma. It contains
recombinant human sVCAM-1 and antibodies raised against the recombinant factor.
This immunoassay has been shown to quantitate recombinant and natural human
sVCAM-1 accurately. Results obtained using natural human sVCAM-1 showed linear
curves that were parallel to the standard curves obtained using the recombinant
Parameter kit standards. These results indicate that this immunoassay kit can be used to
determine relative mass values for natural human sVCAM-1.
Principle Of The Assay
This assay employs the quantitative sandwich enzyme immunoassay technique. A
monoclonal antibody specific for sVCAM-1 has been pre-coated onto a microplate.
Standards, samples, Controls and Conjugate are pipetted into the wells and any
sVCAM-1 present is sandwiched by the immobilized antibody and the enzyme-linked
monoclonal antibody specific for sVCAM-1. Following a wash to remove any unbound
substances and/or antibody-enzyme reagent, a substrate solution is added to the wells
and color develops in proportion to the amount of sVCAM-1 bound. The color
development is stopped and the intensity of the color is measured.
Assay Procedure
All reagents and samples are brought to room temperature before use. All samples,
Standards and the sVCAM-1 Control were assayed in duplicate. The following protocol
recommended by the manufacturers (R&D Systems Abingdon UK) was used.92
1. Prepare all reagents, working Standards, samples, and Control as directed in the
previous sections.
2. Remove excess microplate strips from the frame and store in the resealed foil pouch
with the desiccant pack.
3. Add 100 µL diluted Conjugate to each well.
4. Add 100 µL Standard, Control*, or sample** to each well with sufficient force to
ensure mixing.
5. Cover the plate with a plate sealer provided and incubate at room temperature for
1.5 hours.
6. Aspirate or decant contents from each well and wash by adding 300 µL of Wash
Buffer per well. Repeat the process five times for a total of six washes. After the last
wash, aspirate or decant the contents and remove any remaining Wash Buffer by
tapping the inverted plate firmly on clean paper towels.
7. Immediately add 100 µL Substrate to each well. Cover the plate with a new plate
sealer and incubate at room temperature for 20 minutes.
8. Add 100 µL of Stop Solution to each well. The Stop Solution should be added to the
wells in the same order as the Substrate.
9. Determine the optical density of each well within 30 minutes, using a microplate
reader set to 450 nm. If wavelength correction is available, set to 620 nm. If wavelength
correction is not available, subtract readings at 620 nm from the readings at 450 nm.
This subtraction will correct for optical imperfections in the plate. Readings made
directly at 450 nm without correction may be higher and less accurate.
Calculation of Results
The mean absorbance values for each set of duplicate Standards were calculated. A
standard curve was constructed by plotting the mean absorbance for each Standard on
the y-axis against the concentration on the x-axis and drawing a best-fit curve through
the points on the graph. The concentration of each unknown sample was determined by
calculating the concentration of sVCAM-1 corresponding to the mean absorbance from
the standard curve. For samples and the sVCAM-1 Control, the concentration
determined from the standard curve was multiplied by the dilution factor. The sICAM-1
Control was run in each assay. If the values obtained were not within the expected
range, as stated on the Control vial label, the assay results were considered invalid.93
3.2.3 Human VEGF Immunoassay
††
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor
(VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein
with potent angiogenic, mitogenic and vascular permeability-enhancing activities
specific for endothelial cells. The amino acid sequence of VEGF exhibits primary
structural, as well as limited amino acid sequence, homology with that of the A and B
chains of PDGF. All eight cysteine residues involved in intra- and inter-chain disulfide
bonds are conserved among these growth factors. A cDNA encoding a protein having a
53% amino acid sequence homology in the PDGF-like region of VEGF has been
isolated from a human placental cDNA library. This protein, named placenta growth
factor (PlGF), is now recognized to be a member of the VEGF family of growth factors.
Based on its homology with VEGF, PlGF was also proposed to be an angiogenic factor.
A gene encoding a polypeptide with homology to VEGF has been discovered in the
genome of the orf virus (OV), a parapoxvirus that affects sheep, goats and sometimes
humans.
VEGF is expressed by numerous rodent and human tumor cells, including human lung
adenocarcinoma, bladder carcinoma, fibrosarcoma, HL60 promyelocytic leukemia, GS-
9L glioma, and U937 lymphoma cells (6 - 10). In normal tissues, VEGF expression has
been found in activated macrophages (11), keratinocytes (12), renal glomerular visceral
epithelium and mesangial cells (13, 14), hepatocytes (15), smooth muscle cells (16),
Leydig cells (17), embryonic fibroblasts and bronchial and choroid plexus epithelium
(18, 19). The expression of VEGF is upregulated by phorbol ester, TGF- and in hypoxia
(6 - 10, 18). In contrast to the widespread distribution of VEGF, the expression of PlGF
mRNA is limited to placental tissue, choriocarcinoma cells and cultured endothelial
cells .In the conditioned media of human choriocarcinoma cells (JAR and JE-3), the
occurrence of VEGF/PlGF heterodimers has also been observed . The gene for human
VEGF is organized into 8 exons. As a result of alternative splicing, at least 4 transcripts
encoding mature monomeric VEGF containing 121, 165, 189, and 206 amino acid
†† The broad term 'VEGF' covers a number of proteins from two families, that result from alternate splicing of mRNA
from a single, 8 exon, VEGF gene. The two different families are referred to according to their terminal exon (exon 8)
splice site - the proximal splice site (denoted VEGFxxx) or distal splice site (VEGFxxxb). In addition, alternate
splicing of exon 6 and 7 alters their heparin binding affinity, and amino acid number (in humans: VEGF121,
VEGF121b, VEGF145, VEGF165, VEGF165b, VEGF189, VEGF206. An alternative classification is VEGF A,B,C and
PIGF.94
residues (VEGF121, VEGF165, VEGF189, and VEGF206), each preceded by a 26
amino acid residue signal peptide, have been detected. VEGF121 and VEGF165 are
diffusible proteins that are secreted into the medium. VEGF189 and VEGF206 have
high affinity for heparin and are mostly bound to heparin-containing proteoglycans in
the extracellular matrix. VEGF contains a potential N-linked glycosylation site and the
natural protein is a glycoprotein. E. coli-expressed, recombinant human VEGF is
indistinguishable from natural VEGF in its in vitrobiological actions, suggesting that the
carbohydrate moiety may not be required for activities. VEGF is a highly conserved
protein that has cross-species activity. Between human, rat or bovine VEGF, 84 - 94%
sequence identity has been observed. Two receptor tyrosine kinases have been described
as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase) , and KDR (kinase-insert-
domain-containing receptor) proteins have been shown to bind VEGF with high affinity
. The mouse homologue of KDR was named Flk-1, for fetal liver kinase-1. Mouse Flk-1
shares 85% amino acid sequence identity with human KDR Flt-1 and KDR/Flk-1 are
members of the superfamily of RTKs (receptor tyrosine kinases) that also include the
receptors for PDGF, M-CSF and SCF. In addition to the membrane-spanning Flt-1, a
cDNA encoding a soluble truncated form of Flt-1 has been cloned from a human
vascular endothelial cell library. The mRNA for the soluble receptor is apparently
generated by alternative splicing .Recombinant soluble Flt-1 binds VEGF with high
affinity and inhibits VEGF actions on vascular endothelial cells. Thus, it is possible that
natural soluble Flt-1 may act as a VEGF antagonist in vivo. Using a dominant-negative
Flk-1 mutant, Flk-1 has been shown to be involved in the VEGF-mediated transduction
of signals that are important for angiogenesis and vasculogenesis. As assessed by
Northern blot analysis and/or in-situ hybridization, Flt-1 was found to be expressed in
both endothelial and non-endothelial cells, while KDR/Flk-1 expression was reported to
be restricted to endothelial cells. In vitro, VEGF is a potent endothelial cell mitogen. In
cultured endothelial cells, VEGF can activate phospholipase C and induce rapid
increases of free cytosolic Ca2+. VEGF has been shown to stimulate von Willebrand
factor release from endothelial cells and induce expression of tissue factor activity in
endothelial cells as well as in monocytes. VEGF has also been shown to be chemotactic
for monocytes and osteoblasts (31). In vivo, VEGF can induce angiogenesis as well as
increase microvascular permeability. As a vascular permeability factor, VEGF acts
directly on the endothelium and does not degranulate mast cells. It promotes95
extravasation of plasma fibrinogen, leading to fibrin deposition that alters the tumor
extracellular matrix.
The modified extracellular matrix subsequently promotes the migration of macrophages,
fibroblasts and endothelial cells. Based on its in vitro and in vivo properties, VEGF is
expected to play important roles in inflammation and during normal and pathological
angiogenesis, a process that is associated with wound healing, embryonic development,
and growth and metastasis of solid tumors. Elevated levels of VEGF have been reported
in synovial fluids of rheumatoid arthritis patients and in sera from cancer patients.
Bioassays for VEGF, based on its proliferative effects on endothelial cells, are time-
consuming and not completely specific for VEGF. The Quantikine VEGF Immunoassay
is a 4.5 hour solid phase ELISA designed to measure VEGF165 levels in cell culture
supernates, serum, and plasma. It contains Sf21-expressed, recombinant human
VEGF165 and antibodies raised against the recombinant protein. Results obtained for
naturally occurring human VEGF and recombinant human VEGF121 showed linear
curves that were parallel to the standard curves obtained using the Quantikine kit
standards. These results indicate that this kit can be used to determine relative mass
values for natural human VEGF.
Principle Of The Assay
This assay employs the quantitative sandwich enzyme immunoassay technique. A
monoclonal antibody specific for VEGF has been pre-coated onto a microplate.
Standards and samples are pipetted into the wells and any VEGF present is bound by
the immobilized antibody. After washing away any unbound substances, an enzyme-
linked polyclonal antibody specific for VEGF is added to the wells. Following a wash
to remove any unbound antibody-enzyme reagent, a substrate solution is added to the
wells and color develops in proportion to the amount of VEGF bound in the initial step.
The color development is stopped and the intensity of the color is measured.
Assay Procedure
All reagents and samples are brought to room temperature before use. All samples,
Standards and the sVCAM-1 Control were assayed in duplicate. The following protocol
recommended by the manufacturers (R&D Systems Abingdon UK) was used.96
1. Prepare all reagents and working standards as directed in the previous sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch
containing the desiccant pack, reseal.
3. For Serum/Plasma Samples: Add 100 µL of Assay Diluent RD1W to each well.
4. For Serum/Plasma Samples: Add 100 µL of Standard, control or sample per well.
Cover with the adhesive strip provided and incubate for 2 hours at room temperature.
A plate layout is provided to record the standards and samples assayed.
5. Aspirate each well and wash, repeating the process twice for a total of three washes.
Wash by filling each well with Wash Buffer (400 µL) using a squirt bottle, multi-
channel pipette, manifold dispenser or autowasher. Complete removal of liquid at each
step is essential to good performance. After the last wash, remove any remaining Wash
Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
6. Add 200 µL of VEGF Conjugate to each well. Cover with a new adhesive strip.
Incubate for 2 hours at room temperature.
7. Repeat the aspiration/wash as in step 5.
8. Add 200 µL of Substrate Solution to each well. Protect from light.
For Serum/Plasma Samples: Incubate for 25 minutes at room temperature.
9. Add 50 µL of Stop Solution to each well. If color change does not appear uniform,
gently tap the plate to ensure thorough mixing.
10. Determine the optical density of each well within 30 minutes, using a microplate
reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If
wavelength correction is not available, subtract readings at 540 nm or 570 nm from the
readings at 450 nm. This subtraction will correct for optical imperfections in the plate.
Calculation Of Results
Thee duplicate readings for each standard, control, and sample were averaged and the
average zero standard optical density subtracted. A standard curve was constructed by
plotting the mean absorbance for each standard on the y-axis against the concentration
on the x-axis and draws a best fit curve through the points on the graph. The data was
linearized by plotting the log of the VEGF concentrations versus the log of the optical
density (O.D.), and the best-fit line be determined by regression analysis. This
procedure produces an adequate fit of the data. If samples were diluted, the
concentration read from the standard curve was multiplied by the dilution factor.97
3.2.4 Serum Assay for Lactoferrin
Human lactoferrin (LTF) is an 80 kDa glycoprotein which was first isolated from
human milk. LTF is found in most body fluids and secretions, e.g., in the nose, genital
tract, and tears. In the blood, LTF is secreted by neutrophils and its plasma
concentration is positively related to the total pool of neutrophils and to the rate of
neutrophil turnover. Because of its ability to strongly bind iron, LTF is considered to be
bactericidal. In a number of cases of inflammation, LTF is released into the extracellular
medium from secondary granules of neutrophilic leucocytes. Its extracellular
concentration can therefore be used as an index of neutrophil activation, especially in
blood samples containing anti-myeloperoxidase antibodies.
Principle Of The Procedure
The BIOXYTECH® Lactoƒ-EIA™ method is an enzyme-linked immunosorbent assay
(ELISA). Lactoferrin is captured by a monoclonal antibody (MAb) that is coated on
wells of a sectional microplate. A second LTF-MAb labeled with biotin is added to the
well and binds with the captured LTF forming a “sandwich.” A solution of streptavidin-
peroxidase is then added. Streptavidin has a high affinity for biotin and once bound, its
horseradish peroxidase (HRP) label is available for color development by addition of
the substrate, o-phenylenediamine (OPD). This color development at 450 nm is
proportional to the quantity of LTF in the sample.
Assay Procedure
The actual assay for LTF is performed in the following fashion
· Perform a serial dilution of the 100 ng/mL Standard to the following concentrations:
50, 25, 12.5, 6.2, 3.1 and 1.6 ng/mL.
· Pipet 100µL Standard or sample to the appropriate well.
· Cover the wells with a Plate Sealer and incubate at 37°C for one hour. (± 5 minutes).
Anti-LTF incubation
· Prepare the required volume of diluted Anti-LTF Solution (4) (table 2).
· Empty the microplate.
· Wash wells 5 times with diluted Wash Buffer (3).
· Blot residual liquid on absorbent paper.98
· Pipet 100 µL of diluted anti-LTF Solution into each well.
· Cover the wells with Plate Sealer and incubate at 37°C for 1 hour. (± 5 minutes)
Streptavidin-HRP incubation
· Prepare the required volume of Streptavidin-HRP solution (5) (table 2).
· Empty the microplate.
· Wash wells 5 times with diluted Wash Buffer (3).
· Blot residual liquid on absorbent paper.
· Pipet 100 µL of diluted Streptavidin-HRP into each well.
· Cover the wells with Plate Sealer and incubate at 37°C for 15 minutes.
Colorimetric measurement
· Prepare the required volume of OPD solution (table 3).
· Empty the microplate.
· Wash wells 5 times with diluted Wash Buffer (3).
· Blot residual liquid on absorbent paper.
· Pipet 100 µL of prepared OPD solution into each well.
· Cover the wells with Plate Sealer and incubate at 37°C until the absorbance of the 100
ng/mL
Standard reaches about 1-1.5 (approximately 5 to 10 minutes).
· Add 50 µL of Stop Solution (8) to each well.
· Read the absorbance at 450 nm.
Calculations are performed in a standard fashion.
3.2.5 Serum Assay for VW Factor Activity
von Willebrand factor (vWF) is a complex multimeric adhesive glycoprotein
synthesized by endothelial cells and megakaryocytes. It is a carrier for factor VIII
 and
acts as an adhesive protein in haemostasis. It mediates the adhesion of platelets to the
subendothelium (glycoprotein Ib). It may also be involved in platelet/platelet interaction
(glycoprotein IIb/IIa). It binds collagen and possibly other endothelial structures.
Decreased levels of vWF are seen in Von Willebrand’s disease. This may be caused by
other coexisting diseases (Von Willebrand’s Syndrome).99
Increased levels of vWF antigen/activity indicate damage to the endothelium. However
short term increase in vWF areseen after exercise, adrenaline or DDAVP infusion,
pregnancy and venous hypertension. These may indicate endothelial activation rather
than damage.
PRINCIPLE OF THE PROCEDURE
ELISA utilising a monoclonal antibody which recognises a functional epitope on the
vWF molecule.This is a reproducible, easy-to-use, sensitive and cost effective assay. It
detects low vWF activity to aid diagnosis of vW disease as well as elevated vWF
activity to aid assessment of endothelial damage in cardiovascular disease. During the
first incubation specific vWF antigen in the serum binds to the antibody coating the
wells. The wells are washed to remove unbound components. A horseradish-
peroxidase/-labelled anti-human vWF binds to the surface bound antigen in the second
phase. After a further washing substrate solution is added and detects specifically-bound
Anti-body. The stop solution is used to terminate the reaction. The amount of conjugate
bound is measured in absorbance units.
The kit components include 12x8 well microtitre plate strips coated with monoclonal
antibody, calibrator and controls, diluent concentrate (for samples, controls and
conjugate), wash buffer concentrate, substrate, substrate buffer, stop solution.
ASSAY PROCEDURE
1. Add 100µl of standard or sample to wells
2. Incubate at room temperature for 60 minutes
3. Wash
4. Add 100µl of anti-vWF conjugate
5. Incubate at room temperature for 60 minutes
6. Wash
 vWF monomer is a 2050 amino acid protein. Every monomer contains a number of specific domains
with a specific function; domains D’/D3 act as carrier for factor VIII. Domain A1 binds to collagen and100
7. Add 100µl of substrate
8. Incubate at room temperature for 5 minutes
9. Wash
10. Add 100µl of stop solution. Read absorbance at 450nm
3.3 Laser Doppler Anemometer for Measuring Blood Cell
Velocities In Perpendicular Capillary Loops
There are several methods available for measuring blood cell velocity within single
capillaries they are all image-based techniques and can only measure flows in vessels
lying parallel to the surface. Since the measurement is derived from the image, a good
high contrast image is necessary. This is not always possible to obtain in many subjects
and using standard video equipment restricts the maximum range of measurement to the
order of 2 mm/s. Velocity measurement using the laser Doppler technique is well
established and there are many applications in the study of fluid flow. The technique
was first demonstrated in 1964. Because of the relatively high cost of the necessarily
precise optics, its use is generally restricted to measurements that would otherwise be
impossible or impracticable. Typical applications include studies of velocity and
turbulence profiles of liquids and gases in complex systems.
The application of laser Doppler to measuring flows in microscopic biological vessels
has been published by several groups. The first in vivo application was the measurement
of the velocity of blood cells in an 80-micron diameter retinal artery of an albino rabbit,
using laser light backscattered at a known angle. In 1974 Mishina et al. described a dual
beam Laser Doppler Microscope
119. This was used to demonstrate the measurement of
velocity in a 70-micron diameter venule in the web of a frog's foot by transmission
through the tissue. Another laser Doppler microscope anemometer was used to measure
velocity profiles in arterioles 65-98 microns in diameter. This system used the beam
scattered at a known angle through the tissue to detect blood cell velocity. The
Heparin & platelet GPIb-receptor. There are also C1 & ‘cysteine knot’ domains.101
measurements compared well with those from a previously obtained calibrated particle
velocity meter technique.
Later Einav et al
120 described a fringe mode transmittance laser Doppler microscope.
Measurements of the velocity profile across a rectangular channel gave good accuracy
and reproducibility better than 1% All the above techniques depend on the angle of
incidence or the angle of scattering of the laser beam. Some of All the above techniques
measure velocities parallel to the tissue surface, which like the imaging techniques
restricts measurements to such sites as the nail-fold or forearm. Following on from the
first instrument of Riva et al., was the development of laser Doppler perfusion monitors.
In these systems the laser light is delivered and collected by two optic fibres. The laser
light radiates out into the tissue is diffusely scattered and shifted by the flows in the
multitude of vessels within the measuring volume of about 1 cubic mm. These systems
produce an exponentially shaped Doppler shift spectrum that is processed to give
arbitrary values proportional to average velocity and average blood cell concentration.
The output requires linearisation to correct for changes in blood cell concentration. The
linearisation is only effective for part of the physiological range typically encountered.
The output is dependent on the morphology of the tissue, i.e. the distribution of vessel
dimensions and directions.
The ‘’CAM1 Capillary Anemometer’’ was developed to overcome the limited velocity
range, image quality, and limited tissue sites of the imaging techniques, the high cost
and complexity of the dual beam laser Doppler microscopes, and the unknown probe
volume, arbitrary values, and non-linearity of the laser Doppler perfusion monitors.102
Figure 20 shows diagrammatically the anatomy of the skin capillaries that are assessed by
capillary microscopy.
Figure 21 the lower photograph shows a view of the skin capillaries obtained at capillary
microscopy. The capillaries are elongated, tortuous and glomeruloform. This is unlike th
straight capillaries seen in normal skin. This is shown in the top photograph (Authors’ own
photographs)103
3.4 DESCRIPTORS & STATISTICAL METHODS
Because of the relatively small number of patients the data was analysed using non-
parametric tests. Advice was sought from experts regarding the method of analysis used.
The median was used as descriptor of ‘average’. The description of spread mostly used
in the work in this thesis is by interquartile range. The analysis of paired data was by the
Wilcoxon signed ranks test. Unpaired data was analysed using the Mann-Whitney U test
(an equivalent test to the Wilcoxon rank two sample test).
Descriptors of Average
An average describes a ‘typical’ measurment. This representative value can summarise
the data. Commonly used parameters used the mean, the mode, the median, the
geometric mean & the weighted mean.
The Median
An ordered set is first created by arranging the values in increasing order of magnitude.
The median would divide this set into two halves with equal values above and below it.
If the number of observations is odd, the median is the
(n+1)/2 th
value in the set of observations. If n=even number then there strictly no median. In
practice the arithematic mean of the two middle observations is often used as the
median. Symmetry of the data greatly affects the median. In symmetrical data, the
median and the mean are the same. In data skewed to the right the median is lower than
the mean, in data skewed to the left the median is higher than the mean. One of the
advantages of the median is that it is not distorted by outliers.
The Arithmetic mean
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the arithmatic mean uses all the data values and is manageable algebraically. It is
however, distorted bioth by outliers as well as by skewed data.
The Mode
This is the value that occurs most frequently in the set of observations. In continuous
data the data is first grouped and then the modal group is dtermined. If each value
occurs only once there is no mode. Similarly there may be more than one mode. The
mode ignores most of the information and is not algebraically defined.
The Geometric Mean
In skewed data if logarithmic transformation makes the distribution symmetrical, the
logarithmic mean is taken. This is then back transformed to the non-logarithmic value.
This technique has obvious limitations.
Weighted Mean
If a variable x of interest has certaain values more important than others then a weight
wi is attached to each of the values xi.
W1x1+w2x2+w3x3+………..+wnxn = wixi
W1+w2+w3+….+wn wi
This can be a very useful value provided the weights are known.
Descriptors Of Spread
These give an idea about the dictribution of the data. Most analyses require this along
with an ‘average’ to describe data. Commonly used descriptors of spread include range,
ranges derived from percentiles (e.g. interquartile ranges), the variance, and standard
deviation. Like many other statistical parameters it is often best represented
graphically.105
The Range
This is stated as the difference between the largest and the smallest observations in the
set of values. In many instances these values are quoted instead. This is distorted by
outliers and increases with increasing sample size.
Ranges from Percentiles





th percentileas are called deciles. Similarly quartiles divide the data into four
equal sets. These are the 25
th, 50
th and the 75
th percentiles.
The interquartile range is the difference between the fisrt and the 3
rd qaurtiles i.e.
between the 25
th and the 75
th percentiles(see Figure 22). The interdecile range lies
between the 10
th and the 90
th percentiles and contains the central 80% of the data. The
95% central range is also a frequently used range. It ignores 2.5% of the data below
the lower limit and 2.5% abovet the upper limit.
Figure 22 Box and whiskers method of representing the interquartile range relating to the
median as well as the maximum and minimum values.
These ranges from percentiles are not algebraically defined and are difficult to use for
smaller samples.
Variance
This depicts the degree to which the data deviates from the average. Because of
mathematical reasons the calculation of variance (s
2) involves the sqaure of the






2 = (xi- x¯)2
n-1
The unit is the square of the original units. Variance is considered inappropriate for
skewed data.
Standard Deviation
This is the square-root of variance. Although it has the same limitations as the variance
it uses the same units as the original observations and is thus easier to interpret.
S =
The coefficient of variation is obtained by dividng the standard deviation by the mean
and expressing the quotient obtained as a percentage.
Paired Data Analysis For Numerical Data
This is used when the variable that is to be measured is on the same indiidual in
different circumstances. This would happen in a crossover trial amongst other
situations. In some case control studies different individuals may be mathced to each
other and the data is therefore treated as paired data. Account of dependence of the two
values is taken by taking the difference of the two paired values. This converts the data
into a single set of differences.
The Wilcoxon signed ranks test takes account of both the sign of both the signs of the
differences as well as their magnitude. It is therefore a much more powerful test than a
simple sign test. After calculating individual differences for each pair, positive or
negative signs are assigned and all zeros are left out. The differences are ranked
according to their agnitude irrespective of their signs. The smallest value is assigned 1,
the next smallest 2 and so on. Identical differences receive an average of the rank they
would have otherwise received. The null hypothesis would requie the sum of positive




To calculate the Wilcoxon statistic difference for all pairs of results is calculated first.
All n' differnces are then ranked assiging 1 to the smallest and n' to the largest. Then the
postive (T+) and the negative differences (T-) are summed up.
I. if n' </=25 then T, the test ststistic is the smaller of the two vlues T+ or T-
II. If n' >25 then the test statistic z has to be calulated using the following formula
| T- n' (n'+1) | - 1
z= 4 2
{ n' (n'+1) ((2n'+1) }
24
z is then compared to a list of values from a list of known probability distributions.
Analysis Of Un-Paired Data (For Numerical Data)
This analysis involves samples from two different groups of individuals. There is one
numerial variable of interest. The item of interest is whether the means or the
distribution of the variable in the two groups is the same. The Wilcoxon rank sum (two-
sample) test makes no assumption about the distribution and could be used here. An
alternative test is the Mann-Whitney U test.
If there is a sample of n1 observations to be compared with an independent sample of n2
observations where n1 is the smaller sample size.
i. Rank all the (n1+n2) observations ignoring the grouping.
ii. Find the total (T) of the ranks in sample 1.
If each of the sample sizes is ten or more then the test statistic a Standardised Normal
Distribution (SND) or z score, is
SND = T – n1 (n1+n2+1)/2





4.1 Vascular Endothelial Growth Factor
(VEGF) in CVD
Vascular endothelial growth factor (VEGF, vascular permeability factor) is a member of
the platelet derived growth factor (PDGF) family. It is a disulphide linked homodimeric
glyco-protein. It is a potent mitogen for endothelial cells even at very low
concentrations and significantly increases vascular permeability.
121 VEGF is important
both in angiogenesis and oedema formation.
122 VEGF acts via two different tyrosine
kinase membrane receptors, which have been identified on vascular endothelial cells
123.
Its angiogenic role in neoplasia is well established. Cells producing VEGF include
vascular smooth muscle cells, fibroblasts, keratinocytes and histiocytes.
124 . VEGF is
ubiquitous in wound repair and the inflammatory process has an important part to play
in the healing process. However abnormally increased levels over a prolonged period of
time can have local deleterious effects.
Burnand et al
125 reported on the existence of peri-capillary fibrin cuffs in patients with
CVD. Although the morphology of the microangiopathy has since been well described,
the factors that mediate its development remain unknown.
In the presence of lipodermatosclerosis there is great proliferation of the
subepidermal/dermal capillaries in the skin. Capillary microscopy has shown that the
capillaries are elongated and tortuous (Bollinger et al).
126 In advanced stages they may
look glomerular (see Figure) compared to the normally pin-shaped capillary loops.
127
Recently many growth factors including VEGF have been identified which could be
responsible for the angiogenic response in CVD
128-
129
Increased leucocyte activity may damage the skin and the vein wall itself in CVD.
130 In
the chronic stage a reparative tissue response coexist with the inflammatory response.
131
Many growth factors including vascular endothelial growth factor (VEGF) are involved
in this response. VEGF is a glycoprotein secreted by a variety of cells including smooth
muscle cells, monocytic cells and keratinocytes
132. Increased expression of VEGF is
dependent on increased transcription.
133 It has been shown previously that there is up-
regulation of VEGF expression in the skin of patients with CVD
172. This is more so in110
patients with clinical stage C4 disease
134. VEGF has been shown to stimulate NO
release in bovine, rabbit and human endothelial cells.
135 136 NO may mediate the
angiogenic effects of VEGF.
137 Excessive mounts of NO may lead to local tissue
damage.
It has been shown previously that the leg skin in CVD shows increased expression of
VEGF when studied by immunohistochemistry. The plasma levels of VEGF had not
been studied before in CVD and I undertook a study to determine these levels in CVD.
The aim of this study was to measure plasma VEGF levels in controls and patients with
CVD before and after a period of experimental hypertension to investigate the role of
this angiogenic factor in the development of chronic venous disease.
The highly tortuous capillaries in CVD are cut many times on histological sections and
these account in part for apparent increase in numbers reported by Burnand. The
resulting microcirculation is abnormal and shows many features suggesting impaired
efficiency including a diminished cutaneous hyperemic response
138. The proliferation of
the capillary endothelium has not been fully explained, although recently production of
VEGF in the epidermis has been demonstrated.
128-
139 VEGF acting on the main
capillaries in the underling papillary dermis causing them to proliferate is a likely
mechanism.
Material & Methods
The UCL Medical School Committee for Medical Ethics considered and approved the
protocol for this study. Patients attending the vascular clinic at the Middlesex Hospital
for management of lower limb venous problems were invited to volunteer. The control
group comprised 25 volunteers and included members of the staff of the Department of
Surgery or patients being treated for unrelated conditions. They had no symptoms or
signs of venous disease of the lower limb. There was no duplex evidence of chronic
venous disease. Volunteers with a history or clinical evidence of arterial disease,
diabetes mellitus, connective tissue disorders including rheumatoid arthritis, blood
disorders, infection within the previous six weeks, or medication known to alter white
cell activity were excluded from the study. All controls had CVD excluded by means of
duplex venous scan. Patients and controls who gave informed written consent were111
considered for inclusion in this study. The demographic details of subjects included are
shown in Table 13. All subjects were examined clinically for signs of venous disease by
a surgeon trained in the management of vascular diseases. Patients were divided into the
two appropriate CEAP (Clinical, Etiologic, Anatomic, and Pathologic)
134groups based
on the clinical examination. There were 15 patients in the C3 group (varicose veins and
oedema) and 15 patients in the C4 group (trophic skin changes). Patients underwent
colour duplex ultrasonography by skilled vascular technologists and
photoplethysmography (PPG) follow up. The extent of venous valvular incompetence
and post-thrombotic vein damage in the deep and superficial venous systems was
established and recorded systematically.
Table 13 Distribution of subjects according to sex and CEAP stage
A foot vein or the long saphenous vein at the ankle was canulated using an 18G canula
(Vasculon 2, Viggo-Spectramed, Helsingborg, Sweden) and blood samples were taken
from each subject before and after a period of experimental venous hypertension blood .
The subject first lay supine for 20 minutes, to minimize venous pressure in the leg.
Following this the subject stood supported, with minimal movement for 30 minutes.
This was followed by a further 10-minute period of lying supine. Blood was collected at
the end of each period, using EDTA as the anticoagulant. Plasma was separated by
spinning the sample at 2000 rpm for 10 minutes. It has shown previously that standing
produces pressures of 70 - 80 mm Hg in the foot veins
140.
Details of ELISA techniques are mentioned in the section on methodology. Assay of
VEGF165 protein was performed using a sandwich ELISA technique. A ‘Quantikine’ kit
supplied by R&D systems (4-10 The Quadrant, Barton Lane, Abingdon, Oxon OX14
3YS, UK) was used. Plasma levels were read from standard curves obtained by plotting
No. of
subjects
Age SVI DVI + (SVI) TOTAL
C0 (Controls) 8F/7M 31(23-42) - - 15
C3 12M/3F 48 (29-73) 13 2 (2) 15
C4 7F/8M 51 (32-69) 3 12 (10) 15
TOTAL 45 16 14112
mean absorbance for standards. The kit used detects 25% of VEGF protein activity in
the plasma. Detectable levels in serum are 100% by contrast. Thus the absolute levels of
VEGF165 may be higher than the levels depicted in this paper. However, detection in
both serum as well as plasma is equally reliable and the manufacturers confirm that this
kit is suitable for use with plasma samples. There are no reports to indicate significant
differences in normal individuals in the respective age groups.
Table 14 median plasma vegf levels (pg/ml)
Values in parentheses are Inter-quartile ranges. M-W: Mann Whitney u test, Wilc: Wilcoxon matched
pairs signed rank test.
The test used measures levels of VEGF165. This is one of the four 4 transcripts
encoding mature monomeric VEGF (viz. VEGF121, VEGF165, VEGF189, VEGF206).
VEGF121 andVEGF165are diffusible proteins that are secreted into the medium. The other
are mostly bound to heparin containing proteo-glycans in the matrix. Results obtained
for naturally occurring human VEGF and the recombinant VEGF showed linear curves
that were parallel to the standard curves obtained using the Quantikine kit standards.
RESULTS
The median plasma VEGF165 levels (IQR in parentheses) in controls and patients
before and after venous hypertension is shown in Table 14





















(Wilc) p=0.08 (Wilc)p=0.17 (Wilc)p=0.19 (Wilc) p=0.008113
Figure 23 Plasma VEGF levels. Comparison between patients & controls. The horizontal lines
at the top compare VEGF levels in the supine and standing positions between the two groups.
values indicated by special symbols (,) are respective values for differences between supine






















































Figure 24 Plasma VEGF levels. Comparison in CVD between patients with & without skin
changes. The horizontal markers at the top compare VEGF levels in the supine and standing
positions between the two groups. P values indicated by special symbols (,) are respective
values for differences between supine & standing positions115
DISCUSSION
It is recognised that physiological indices of venous function (e.g. air plethysmography)
predict the likely severity of venous disease but that there is considerable overlap
between the impairment of venous function in patients from different clinical groups.
This simply reflects the fact that the development of skin changes and venous ulceration
is not simply a matter of ambulatory venous hypertension producing leg ulcers, but that
the response of the tissues is also a major determinant of the severity of the clinical
syndrome. It is specifically this point that I wished to investigate since it still reflects a
poorly understood aspect of the disease that might eventually be a useful target for drug
treatment.
My control subjects were somewhat younger than either of the study groups. I
investigated the influence of age on the VEGF levels in my control subjects and could
find no correlation. A MEDLINE search of the world literature did not reveal any
studies that investigated the influence of age on plasma VEGF levels in adults. The
median VEGF levels in my control subjects were similar to those measured by the
manufacturers of the analysis kit in their human controls and I believe that these reflect
those in a normal population of healthy subjects. Nevertheless the age differences
between patient and control groups may leave the possibility that some of the
differences I have observed may be accounted for by age differences.
Foot vein cannulation was in general very well tolerated. There were atwo patients who
developed mild bruising and extravastion of blood after foot vein cannulation. No cases
of thrombophlebitis or DVT were observed.
VEGF is strongly expressed by epidermal keratinocytes during wound healing, in
psoriasis, in skin with ultra-violet burns, and in bullous diseases such as erythema
multiforme and bullous pemphigoid. All of these disorders are characterized by
increased micro-vascular permeability and angiogenesis. A large increase in VEGF
mRNA and protein levels is seen following irradiation of quiescent keratinocytes with
physiologically relevant doses of UVB. Over-expression of VEGF is116
considereddependent on de- novo protein synthesis.
141 . It appears that tissue damage in
general, especially hypoxic, can cause up-regulation of VEGF expression.
10 142
There are no large population studies of the plasma levels of VEGF measured using this
assay. However data on record in the supplier's laboratory shows a median plasma
levels at 62 pg/ml
143 in control subjects, which is very close to that in my control
subjects (52 pg/ml lying, 60 pg/ml standing). In my study, levels of VEGF were higher
in patients compared to controls in both supine and standing positions. Due to the large
scatter of the data, statistical significance was not reached until the results of all patients
with venous disease were considered together. Levels of VEGF were approximately
60% higher in the patient groups compared to the control group in both lying and
standing positions. The two patient groups showed similar levels of VEGF (Figure 24).
There was a small rise in VEGF level following 30 minutes of venous hypertension in
the control group, which did not reach statistical significance. In the patient groups there
was a similar modest rise in plasma VEGF that did reach significance due to the larger
numbers when all patients were considered together.
In chronic venous disease there is proliferation of vessels in the skin
144. This correlates
with the severity of the clinical skin damage. Until recently, the growth factors, which
mediate this, have remained unknown. It has been reported that vascular endothelial
growth factor (VEGF) and platelet derived growth factor (PDGF) expression is
increased in the skin in patients with venous disease and may be the mediator of
vascular proliferation
20
In this study my aim was to assess the association of the development of skin changes
with plasma VEGF levels. I therefore used the clinical classification of the CEAP
system to divide the patients into those with no clinically detectable skin changes and
those with lipodermatosclerosis. This allowed us to investigate the factors, which are
responsible for the development of the skin changes, which may not necessarily be the
same factors that result in venous valvular incompetence of the deep or superficial
veins.
The data from this study show that both groups of patients showed similar elevations in
plasma VEGF compared to controls. This may reflect the fact that this growth factor is117
induced in patients with venous disease in order to repair tissue damage caused by
venous hypertension. However, measurements of plasma levels may not reliably reflect
the actual tissue levels expressed in the region of tissue repair. It is unlikely that VEGF
as reflected by these plasma levels is an important factor in explaining the differences
between C3 and C4 patients.
Epidermally derived VEGF is likely to be a factor in the angiogenesis of
lipodermatosclerosis. This increased expression of VEGF is seen even before any skin
changes develop. I have shown increased serum levels of VEGF in my study in patients
with venous disease. In my study the changes in serum levels were actually more
prominent in the group with C3 disease. Studies that measure the expression of VEGF
mRNA levels could more conclusively prove the actual site of origin of the protein.
VEGF seems to act both acutely over a period of a few minutes) and chronically (over a
few hours) to increase micro-vascular permeability.
145 VEGF promotes the
extravasation of fibrinogen and deposition in the tissues as fibrin. This could represent a
mechanism for the formation of the ‘Fibrin Cuffs’ that are characteristically found in
CVD .
146
It has previously been shown that leucocyte activation occurs within 30 minutes of
experimental venous hypertension using the same model as employed in this study. This
can be shown both in control subjects as well as those with venous disease. This is
associated with evidence of endothelial activation and I believe these are the
mechanisms that initiate the skin damage caused in CVD. This may initiate a repair
process that involves increased expression of VEGF by keratinocytes and vascular
smooth muscle cells. This causes the neo-vascularization essential to any tissue repair
process. The neo-vasculature is permeable to large molecules when compared to normal
capillary endothelium and allows the perivasular accumulation of large molecules
accounting for the ‘fibrin cuff’ originally reported by Browse and Burnand. Such
perivascular cuffs are of course common in many inflammatory conditions.
It has been demonstrated that Hyaluron oligosaccharides (OHA) in the intercellular
matrix modulate the invasive and proteolytic properties of bovine micro-vascular
endothelial cells and synergize specifically with VEGF in the induction of angiogenesis118
in vitro. The synergism between OHA and VEGF probably plays a role in the regulation
of angiogenesis. This could be exploited therapeutically in situations that would benefit
from modulation of new blood vessel growth. The signalling cascade is thought to
involve inducible NO synthase, Guanylate cyclase and cGMP dependent protein kinase.
Experimentally administration of VEGF was found to cause severe hypotension in
animals. The hypotension is thought to be mediated by production of NO and is
reversible with appropriate blocking therapy with N (G)-monomethyl-L- arginine (L-
NMMA)
147148. NO can also explain the hyper-permeability induced by VEGF. An
excessive release of nitric oxide can be caused by this mechanism, and in contrast to its
usual beneficial role, this free radical may contribute to local tissue damage.
To summarize all these observations a possible scenario for the sequence of events in
skin injury in CVD may be the following. Damage to the tissues is caused by excessive
leucocyte activation. The injury itself may cause either increase in VEGF protein
synthesis or release of VEGF from depot sites. Activated platelets or macrophages
present at the site of injury may release peptide factors that in turn stimulate VEGF
release. The abundant macrophages in skin exposed to CVD are a potential source of
VEGF as well. These could be within the basement membrane or extra-cellular matrix.
Components of the extra-cellular matrix like heparin proteo-glycans are also exposed by
injury. These are known to facilitate migration and tube formation by endothelial cells. -
149 Re-synthesis of extra-cellular matrix components and migration of pericytes could
represent a mechanism of quenching the angiogenic stimulus.
150
CONCLUSIONS
In my study plasma VEGF levels were elevated in both groups of patients with chronic
venous disease, compared to control subjects. Experimental venous hypertension caused
a further statistically significant rise in VEGF levels. Increased VEGF expression may
play a role in causing tissue injury in CVD. Leucocyte mediated tissue damage could
directly release VEGF from depots in the intima or intercellular matrix. Excessive neo-
vascularization with hyper-permeable vessels could directly contribute to the skin
changes seen with CVD. Increased NO production is a possible mechanism of local
tissue damage. The source of the VEGF detected in this study is currently unclear and
studies are being undertaken to determine localisation of VEGF mRNA expression to119
confirm the origin of the protein. It remains to be seen whether early rise of plasma
VEGF will serve as a marker for developing skin changes. Although VEGF may well be
the cause of cutaneous capillary proliferation in venous disease, whether
pharmacological inhibition of this process would achieve a clinically useful effect
remains to be proven.120
4.2 Endothelial Activation Response (& Plasma VEGF
levels) in CVD to Oral Micronised Flavonoid Therapy
Endothelial cell activation by cytokines or thrombin leads to increased adhesion
molecule expression. These include ICAM-1 (binds neutrophil/ lymphocytes) and
VCAM-1 (binds lymphocytes/ monocytes). This can lead to MHC-II
‡‡ (T-cell response)
and GMP-140
 (binds platelets) expression. Binding of platelets increases the
availability of platelet activating factor and further accelerates the expression of
adhesion molecules. The circulating levels of many of these molecules are known to be
increased in patients with CVD.
151
The physical interaction between the leucocyte and the micro-vascular endothelium is
important for its function in the micro-vasculature.
152 Patients with chronic
inflammatory and septic states show increased leucocyte priming. This is also observed
in patients with CVD. The primed cells show increased surface CD62L and CD11B
130.
CD62L is involved in the initial 'rolling' movement of the leucocyte along the
endothelium. CD11B is the molecule responsible for firmer adhesion and subsequent
diapedesis. There is some evidence of inflammatory mechanisms being important in
damage to the venous valves seen in CVD
153. Following any successful treatment for
CVD, a reduction in leucocyte activation would be expected
Pharmacological treatment is widely used to ameliorate the symptoms of venous disease
in many European countries. It is hardly used in other places. One reason for these
discrepancies is the lack of controlled scientific trials establishing the role of these
compounds. At least one recent study shows increased ulcer healing rates in response to
flavonoid treatment
154. Unfortunately no 'phlebotonic' drugs exist that claim to correct
venous valvular incompetence. However many of these do affect the inflammatory
changes responsible for the skin damage.
In the chronic stages there is a tissue repair response alongside the inflammatory
response
131 and many growth factors are involved
155. Histological data suggested that
VEGF (vascular endothelial growth factor) may be responsible for the vascular
‡‡ MHC II-expressed on specialised cells including B-cells that interact with CD4+ T helper cells121
proliferation seen in the cutaneous capillaries in patients with chronic venous disease.
VEGF is one of the molecules involved physiologically in the angiogenesis of healing
as well as in tumour angiogenesis. In addition, it is a potent factor for increasing
vascular permeability
156. It is a glycoprotein secreted by a variety of cells including
smooth muscle cells, monocytic cells and keratinocytes
157. Its expression is dependent
on increased mRNA synthesis and increased transcription
158. Any tissue injury,
especially hypoxic injury could be a potent stimulus for its expression.
The response of the increased endothelial activation to any form of therapy remains
unknown. Many pharmacologic compounds have been used for treating CVD. A
purified micronised Flavonoid fraction (DAFLON500, Servier Laboratories France)
has been used in Europe for the treatment of CVD for some time. “DAFLON” consists
of 90% Diosmin (3',5,7 trihydroxy -4'- methoxyflavone 7 rhamnoglucoside; C28 H32
O15) and 10% hesperidin flavonoids (3',5, 7 trihydroxy -4'- methoxyflavanone 7
rhamnoglucoside; C28 H34 O15). The use of pharmacological treatment is variable,
mainly because of lack of good controlled trials. There is some evidence of increased
healing rate of venous ulcers with flavonoid therapy.
159
Daflon comprises 450 mg of diosmin and 50 mg of hesperidin per tablet. The
'micronisation' of the effective components is claimed to increase its bio-availability. It
has been reported to be a 'venotonic' (increases venous tone) and to decrease capillary
'leakage' in many scenarios. A double blind randomised trial published in 1994 had
shown its efficacy in treating the clinical symptoms of CVD without any significant side
effects.160
The aim of my study was to measure the effects of micronised purified flavonoid
fraction (S5682, Daflon 500 mg, Servier, France) on expression of soluble markers of
endothelial activation in CVD
161.
 GMP-140= P-Selectin = CD 62L (Granulocyte Membrane Protein)122
Table 15 Distribution of the patients according to their CEAP stage and anatomical localisation
of CVD. There is equal number of patients with and without skin changes (n=10). Two patients
had reflux localised to 'minor' tributaries that did not relate to either of the two major superficial
systems. Perforator incompetence is not listed separately because none of the patients had
isolated perforator incompetence.
Material & Methods
Ethics committees’ consent for the study was obtained from UCL Medical School
Committee for medical ethics. This study was performed under the terms of a clinical
trials exemption certificate (CTX). Twenty patients with chronic venous disease,
clinical stage 2-4 were recruited from the vascular clinic at the Middlesex Hospital.
Patients who consented were asked to attend the department on three separate occasions
at two weeks before treatment, the day of starting treatment and after finishing
treatment. A medical history was taken and clinical examination performed. This
included a systemic as well as venous examination. Patients had a full blood count,
serum urea and electrolyte/ liver function tests. All patients were assessed clinically
according to the clinical classification of the CEAP system. People with (Duplex
proven) varicose veins only (C2), with associated oedema (C3), skin changes (C4) and/
or healed ulceration (C5) of > 4weeks were included. Active ulceration (C6) would
have interfered with activation of leucocytes and were thus not included.
All patients had a venous Duplex examination and photoplethysmography within the
previous eight weeks to establish venous and to localise it anatomically. The minimum
extent of Duplex examination in my patients included sapheno-femoral junction, long




C2 3 - - 3
C3 4 3 - 7
C4 7 2 1 10
TOTAL 14
(2M:12F)
5(3M:2F) 1 (M) 19 (20 inc.
1DVI)123
perforators and other reflux sites as picked up by colour Doppler. Patients were assessed
for other possible diagnoses including arterial disease. Ankle-Brachial pressure ratios
were performed whenever there was clinical suspicion. All patients wore class II
support stockings and continued to do so during the study.
Patient Selection
The inclusion criteria for the study were (1) Age above 18 years (2) patients affected
with CEAP stage C2 to C4 (3) C5 with a healed ulcer for at least 4 weeks (4)
psychological stability & motivation.
The exclusion criteria were directed at (i) patients who have conditions that would
change the status of leucocyte/ endothelial activation, (ii) subjects who were taking
compounds similar to flavonoids to avoid bias and (iii) patients who had other major
systemic illnesses.
These criteria were (1)History of alcohol or drug abuse (2) known history of allergy or
intolerance to diosmin or any other venotonic agent (3)active venous ulceration
(4)diabetes mellitus (5)impaired hepatic function (ALT or AST 3 fold above the normal
limit) or Impaired renal function (serum creatinine > 120 µmol/l) (6) any concomitant
active disease or abnormality in laboratory test (judged as clinically significant by the
investigator) (7) patients treated with other vasoactive drugs within the 15 days prior to
inclusion (8) patients with an acute/ chronic inflammatory or infectious disease (9) deep
venous thrombosis within the past 12 months (10) superficial venous thrombosis within
3 weeks (11) patients using steroids, NSAIDs, other 'vaso-active' drugs, Vitamins A, C
&E or anti-coagulants (12) previous poor compliance to treatment (13) participants of a
trial within past 3 months were excluded. (14) pregnancy, breast-feeding or lack of
active contraception also excluded the patient.
DAFLON 500 mg BD (Servier France) was administered orally for 60 days.
Evaluation of venous symptoms employing a visual analogue scale was performed
before and after treatment. Specimens (30mls each) were taken from foot veins before
and after standing the patient supported for 30 minutes.124
Collection of Specimens
A 18G canula (Vasculon 2, Viggo-Spectramed, Helsingborg, Sweden) was placed in the
distal long saphenous vein or dorsal foot vein of one leg. The canula was flushed with
heparinized saline solution. The patient then stood supported against the side of the
couch for 30 minutes without moving the calf muscles (it was previously shown by the
authors by direct pressure measurement that this raises the venous pressure in the
superficial veins of the leg to between 70 and 80 mm Hg. after which 2 ml of blood was
taken and discarded from the canula, and a further 10 ml was collected into two tubes
containing ethylenediamine<TK;4 tetraacetic acid and one tube containing citrate<TK;1
(Vacutainer, Becton Dickinson Vacutainer Systems Europe, BP No 37-38241 Meylan
Cedex, France).Blood samples were carefully placed directly into the sample tubes after
removing the stoppers to prevent excessive cell agitation.
ELISA tests for soluble markers
Details about the ELIS techniques are mentioned in the chapter on methodology. Blood
for Elisa tests for soluble plasma markers was collected in EDTA bottles. The
specimens were spun at 20,000 rpm for 10 minutes to separate the plasma and promptly
frozen at -20c before analysis. The Markers measured were E-selectin, P-selectin,
VCAM, ICAM-1, VW Factor and Lactoferrin. Commercial kits (ICAM-1/ VCAM/ E-
selectin/ P-selectin by R&D Systems 4-10 The Quadrant, Barton Lane, Abingdon, Oxon
OX14 3YS, UK; VW factor kit by Diagnostica Stago 9 rue des Freres Chausson 92600
ASNIERES-SUR-SIENE France; Lactoferrin assay by OXIS International Portland
Oregon USA) were used for these analyses.
Assay of VEGF165 protein was performed using a sandwich ELISA technique. A
‘Quantikine’ kit supplied by R&D systems (4-10 The Quadrant, Barton Lane,
Abingdon, Oxon OX14 3YS, UK) was used. Plasma levels were read from standard
curves obtained by plotting mean absorbance for standards supplied with the kit. The
test used measures levels of VEGF165. This is one of the four 4 transcripts encoding
mature monomeric VEGF (viz. VEGF121, VEGF165, VEGF189, VEGF206). VEGF121 and
VEGF165 are diffusible proteins that are secreted into the medium. The other two are
mostly bound to heparin containing proteo-glycans in the matrix. Results obtained for
naturally occurring human VEGF and the recombinant VEGF121 showed linear curves





























Figure 25. Changes in plasma levels of ICAM-1 and VCAM-1 in patients with CVD before (A)
and after (B) sixty days treatment with micronised purified flavonoid fraction. A logarithmic
scale has been used because of the differences in the absolute levels of the two molecules. P
levels are Wilcoxon ranked sum test. The thick lines join the respective median levels. Vertical







































Figure 26 Shows the differing changes in plasma Lactoferrin in patients with (C4) and without
(C2-3) skin changes before (A) and after (B) sixty days treatment with micronised purified
flavonoid fraction. Probability levels are Wilcoxon ranked sum test. The much increased plasma
Lactoferrin activity is lowered significantly in patients with skin changes127
RESULTS
There were equal numbers of patients with and without skin changes (n=10). Seven
patients in each group had superficial venous insufficiency (SVI) only. Of the remaining
six patients the majority (5) had combined SVI and deep venous insufficiency (DVI).
Most patients either had long saphenous (GSV) involvement (n=9) or combined GSV
and short saphenous (SSV) involvement (n=7). Two patients had CVD involving
neither of the two major superficial anatomic systems. These patients had other
superficial veins (e.g. lateral superficial vein of the thigh) involvement without reflux in
the mentioned major superficial systems. Median age was 58 years (range39-82). These
are shown in Figure 25 Figure 26 and Table 18. The statistical tests are used as shown.
Non-parametric tests were used because of the non-normal distribution of the data.
Significant reduction (p=<0.05) was seen in plasma levels of VCAM & ICAM-1
activity following therapy. Reduction in the level of ICAM-1 32% (141 ng/ml: 73
ng/ml) & VCAM, 29% (1292 ng/ml: 717 ng/mls were seen). A statistically significant
reduction in plasma Lactoferrin (in C4 patients) was observed. The levels of reduction
in endothelial markers ng/ml: 560 ng/ml) occurred in the skin-changes group. The levels
of VW factor also decreased (p=<0.05)in patients with skin changes but not in simple
venous disease. Changes (p=>0.05) in E-selectin levels (decrease) & P-selectin levels.
Lactoferrin levels were appreciably reduced following therapy in patients with skin
changes only. This probably represents damping of leucocytic activity.
Results for VEGF are shown in figures 4.5.1, 4.5.2 and tables 4.5.2 & 4.5.3. The lines in
the figures represent the values of the concentration of the VEGF molecule. The bold
lines represent the median values. The vertical lines represent inter-quartile ranges. The
X-axes show the values before and after treatment. The Y-axes represent the value of
the concentration of the respective molecule. The statistical tests are used as shown.
Non-parametric tests were used because of the non-normal distribution of the data. The
median compliance rate with DAFLON treatment was 98%, (count of returned tablets).
Seven patients experienced minor side effects (loose motions 3, headache 2, and
faintness 1). All were transient and preferred to complete the study.128
Patients with clinically obvious skin changes (C4) had plasma levels of VEGF that were
considerably greater than those in patients without skin changes (C2 & C3) (tables 1 and
2). There were two patients with consistently high levels of plasma VEGF in the C2/C3
group. I are following these up to look for development of clinically obvious skin
changes. I found a decrease in the levels of plasma levels of VEGF in patients with
CVD after treatment with purified. micronised flavonoid fraction treatment. The




Table 16 Median plasma VEGF levels (pg/ml) in patients with (C4) and without skin changes
(C2/C3). The respective values before and after sixty days treatment with flavonoids are shown.
This table shows the combined values in each group before and after a 30-minute period of
standing up. Values in parentheses are inter-quartile ranges. The statistical tests are used as
shown. Non-parametric tests were used because of the non-normal distribution
Before Treatment After Treatment




All patients 47(17-101) 29(8-56)129
Table 17 Median values of plasma levels of endothelial activation markers and plasma
Lactoferrin in patients with CVD. Data obtained for patients with simple CVD (C2-3) and those
with dermatological changes (C4) is shown. The values are before and after a sixty day



















(Wilcoxon) 0.156 0.09 0.231













(Wilcoxon) 0.1 0.74 0.59













(Wilcoxon) 0.61 0.54 0.027130
Table 18 Median values of plasma levels of endothelial activation markers and plasma
Lactoferrin in patients with CVD. Data obtained for patients with simple CVD (C2-3) and those
with dermatological changes (C4) is shown. The values are before and after a sixty day




















(Wilcoxon) <0.001 <0.001 0.88













(Wilcoxon) 0.001 0.001 0.012













(Wilcoxon) 0.001 0.003 0.039131
Table 19 Comparison of mean visual analogue symptom scores in all patients before and after
60-day treatment with 'purified micronised Flavonoid Fraction'. Although decrease was seen in
all the parameters, only the decrease in 'Heaviness' reached statistical significance. (Values in
parentheses are standard deviation).
Pain Heaviness Cramps Paresthesiae Oedema
Before Treatment 8.2 (3.3) 7.7 (2.6) 8.1 (2.8) 5 (3.3) 6.8 (3.2)
After Treatment
8.2 (3.3)
6.4 (2) 6.8 (3.4) 4.8 (2.8) 5.8 (2.4)
P Value
(Wilcoxon) 0.094 0.004 0.07 0.19 0.057132
Figure 27 Figure 4.3.1 Shows comparisons of plasma VEGF levels in patients before and
after 60 days of flavonoid treatment. Values shown are before (A) and after (B) a 30-
minute period of standing. The bold lines join the two respective median values,
differences between these values were not significant. Vertical bars represent inter-
quartile ranges.













































the much increased granulocyte activity in these patients compared to those with simple
CVD. The effect on E-selectin levels was also seen more in the C4 group. Unknown
effects on platelet activity might explain the slight rise seen in P-selectin following
therapy. These effects may explain the differing phenomena seen with VW factor
following therapy (minor rise in VW factor in C3 patients and fall in C4 group).
The reduction in endothelial/ leuocyte activation may block the initial adhesion of these
cells to the endothelium and decrease the amount of tissue damage. The effect seems to
be equivalent in patients with and without skin changes. (Several patients with skin
changes reported partial resolution of their LDS. with 60 days of treatment).
Improvement in clinical scores of all the parameters was seen in the patients treated
with purified Flavonoid fraction. This study demonstrates the possibility of using
leucocyte activation as a marker for therapy in CVD.
I did not make any distinction between patients with superficial venous insufficiency
and those with deep venous insufficiency in interpreting the results. Previous studies
from this department did not report on any difference between these two groups
130 for a
similar clinical stage. I compared equivalent clinical stages (C) that are representative
of the severity of CVD. Some of these markers especially VW-factor are not very
sensitive indicators of endothelial activation. Some like P-selectin and VW factor are
almost certainly affected by other local phenomena like platelet activation. The
physiological significance of these soluble markers remains an issue of debate. They
may represent protease cleavage from cell surface subsequent to endothelial stimulation.
They may also represent molecules released to block receptors and to prevent their
attachment to the endothelium. Despite these they are widely used as markers of
endothelial activation.
It is only relatively recently that the effectiveness of therapy for CVD is being tested
with objective parameters. It has been shown that colour duplex ultra-sonographic and
air-plethysmographic criteria improve in patients one month following surgical therapy.
This improvement was shown to be maintained at two years
162. It would be interesting
to measure the mid to long-term effect of therapy on endothelial markers. Another study
of the effect of compression therapy/sclerotherapy on the microangiopathy (Leu &134
Bollinger et al)
163 showed non-significant changes post therapy. The parameters studied
were capillary microscopy, Doppler flux-metry and tcPo2 measurement. Elevated levels
of VCAM-1, VW Factor, E-selectin, ICAM-1 and Lactoferrin have been reported in
patients with CVD compared to controls
151. However my study is the first to
demonstrate a measurable change in these parameters in CVD following therapy. This
shows the feasibility of using the soluble markers of endothelial activation as a
parameter to measure the response to various forms of treatment.
Experimental blockade of adhesion molecules either with soluble ligands or with
specific monoclonal antibodies has a significant effect on inflammation and immune
mediated tissue damage
164,165. The observation that some markers are specifically
lowered following therapy in patients with skin changes demonstrates the possibility of
flavonoids to ameliorate the symptoms of CVD.
DISCUSSION
I observed a decrease in some soluble endothelial activation markers in patients with
CVD following sixty days therapy with oral purified flavonoid fraction. In particular
VCAM-1 and ICAM-1, adhesion molecules important in endothelial interaction with
neutrophil, monocytes and and/ or arrest some of the skin damage that occurs in CVD.
Inflammatory mechanisms have been implicated in the valvular damage seen in CVD
153
and these compounds may have a role in ameliorating this damage as well. These
aspects merit further study.
Further studies are needed to assess further the role of soluble endothelial markers in
prognosticating the clinical course of CVD. The role of purified micronised flavonoid
fraction and similar compounds also needs to be re-examined in the context of non-
surgical treatment for CVD.
Experimentally flavonoids have been shown to have several anti-inflammatory actions.
My study is the first to demonstrate a mode of action for these compounds in the
clinical setting. In the hamster cheek pouch Daflon significantly inhibited the
macromolecular permeability increasing effect of histamine, bradykinin and LTB4.
Flavonoid-treated animals also tended to have a lower number of leucocytes adhering to135
the venular endothelium.
166 In addition Flavonoids could decrease the production of free
radicals
167, alter cytokine release
168. They can alter the composition of the venous wall
169 and have some haemorrheological effects.
170 This study demonstrates the effect of
micronised purified flavonoid fraction on decreasing leucocyte de-granulation and
endothelial activation. The effects of these compounds on Duplex ultra-sonographic
parameters and on resolution of lipodermatosclerosis need to be quantified in
prospective studies. The lack of side effects of these compounds makes them especially
attractive as medications for CVD.
These anti-inflammatory effects of purified micronised flavonoid may be important in
their clinical effects in CVD. It is possible that different doses & treatment duration may
be needed for various indications. The role of flavonoids in resolving skin changes
needs to be quantified. I observed that it is feasible to use changes in the level of
leucocyte surface adhesion molecules as markers of response to treatment in CVD.
Other modalities of treatment may also be assessed using these parameters. The finding
of large differences between patients with clinically obvious skin changes and those
without is of considerable relevance. I have previously reported many inflammatory
processes that I have observed in the skin and blood of patients with venous disease, but
none has shown major differences between patients with skin changes and those
without. These findings mirror closely the observations of capillary proliferation
originally made by Burnand
171. He found that capillary proliferation correlated closely
to the development of clinical skin changes referred to as lipodermatosclerosis (LDS).
The fact that plasma VEGF levels are greatly elevated in patients with clinical skin
changes of CVD implies that VEGF is involved in the development of the skin changes.
The proliferation of the skin capillaries is associated with the development of
perivascular fibrin cuffs. The significance of these remains unclear, however, VEGF
promotes extravasation of large molecules by its action on the capillary endothelium.
This may be one of the factors leading to deposition of fibrin and other large molecules
and provides an explanation for the mechanism of formation of fibrin cuffs.
Abnormally increased and prolonged exposure to VEGF could have local deleterious
effects. VEGF is strongly expressed by epidermal keratinocytes during wound healing,136
in psoriasis, in skin with ultra-violet burns, lesions of rheumatoid arthritis and in bullous
diseases such as erythema multiforme and bullous pemphigoid. All of these disorders
are characterised by increased micro-vascular permeability and angiogenesis. I have
shown previously up-regulation of VEGF expression in the skin and plasma of patients
with CVD
172. The expression of this molecule in the skin is more marked in patients
with CEAP clinical stage C4 disease than in less severe forms of venous disease without
skin damage
134. The clinical syndrome of lipodermatosclerosis comprises a wide
spectrum ranging from hyperpigmentation to inflammatory changes and fibrosis. It is
possible that growth factors may play different roles at various stages but this has not
been studied in detail. The role of VEGF may be different after the onset of ulceration.
The large difference between VEGF levels in C2/C3 and C4 patients could represent
different stages of development of the dermatological changes. In the initial stages
leucocyte mediated damage could be the predominant event. Later on the repair
processes may become more important and may co-exist with continuing skin damage.
There were two patients with higher levels of VEGF in the C2/C3 group. One
explanation for this could be that these had incipient skin changes that were more
advanced than was clinically apparent or these patients may be particularly susceptible
to the development of lipodermatosclerosis. I had previously shown increased plasma
levels of VEGF in patients with CVD
15. If further studies indicate that high plasma
levels of VEGF indicate impending skin changes, it could provide us with a useful tool
for establishing the prognosis. Similarly if it could be demonstrated that absence of a
fall in VEGF levels following therapy predicts a higher chance of recurrence, this could
be used as a marker of success of the treatment.
I acknowledge that the current data cannot demonstrate whether this finding is the cause
or consequence of the skin changes. However, plasma VEGF levels might then be used
as a surrogate for assessing lipodermatosclerosis by clinical means. Measurement of
LDS in a quantitative way is notoriously difficult, and results in wide variance of the
resulting data
173. VEGF blocking has shown some promise experimentally in
oncological therapy
174 175. Linomide and VEGF-blocking anti-bodies have been used
for this purpose. Tamoxifen has been shown to have some anti-angiogenic activity. The
role of this type of treatment in patients with CVD remains to be explored and will137
depend upon the availability of anti-angiogenic drugs of substantially lower toxicity
than those generally used in tumour my chemotherapy.
In this investigation I assessed the effect of a purified flavonoid fraction preparation
(500) mg on the plasma VEGF levels. This drug is widely used in continental Europe
for the treatment of the symptoms of chronic venous disease, including uncomplicated
varicose veins where is ameliorates the symptoms of discomfort associated with varices
176. Recent animal studies have suggested that it has an effect on leucocyte: endothelial
adhesion, protecting the endothelium from damage in models of reperfusion injury.
177 I
found that plasma VEGF decreases considerably in patients with skin changes following
sixty days therapy with oral purified micronised fraction. The authors acknowledge that
the significance of lower plasma VEGF following therapy remains unclear. No
significant effect was seen in this study in patients without skin changes. However, the
plasma levels of VEGF detected in these patients were at the lower level of the
sensitivity of the assay, and biological variation and well as insensitivity of the test may
have resulted in failure to find a difference.
Concluding Remarks
In conclusion Plasma VEGF levels are much higher in these patients as compared to
those with uncomplicated CVD. These levels are higher than those in controls. Plasma
VEGF levels decrease in patients with CVD induced skin shanges following treatment
with purified micronised flavonoid fraction. The increase in some endothelial activation
markers studied was dampened by the administration of purified micronised flavonoid
fraction for sixty days in patients with CVD. This suggests that these compounds may
down-regulate the activated endothelium in these patients. My study demonstrates the
feasibility of using changes in levels of soluble endothelial markers as parameters for
assessing the response to therapy in CVD.138
4.3 Results of Operative Treatment for Leg Ulcers
Due to Superficial Venous Disease
Many different treatment modalities could achieve healing in leg ulcers due to CVD.
Recurrence of these ulcers is, however, a major problem. Theoretically leg ulcers due to
superficial venous disease only may be cured permanently by appropriate surgery.
Definitive diagnosis and therapy in venous disease is becoming increasingly possible.
178
There are few reports, however, of their long-term results.
179 Reports that do have a
longer follow-up are lacking in the accuracy of the data, mainly because venous duplex
ultrasound has not been widely used until relatively recently.
Sapheno-femoral junction (SFJ) ligation and stripping of the long saphenous vein
(GSV) was the commonest procedure (>70%). Recurrent veins operations were 15%.
Perforator incompetence was reported in only 4%. The mean follow-up period was 52
months (range 12-108 months). >40 % had to use stockings permanently for
troublesome symptoms.
INTRODUCTION
The prevalence of leg ulcers in one study of 92,100 subjects aged > 40 years was
0.38%.
180 In another study of 463 legs with active ulceration venous insufficiency was
detected in 332 patients (72%).
181 In these patients venous insufficiency was the
dominant causative factor in 54% of cases. Until quite recently all legs with venous
pigmentation/ulceration were dubbed ‘post-phlebitic’. Many authors categorically
denied the role of superficial venous disease in venous ulceration.
183 In fact a
substantial proportion of leg ulcers are associated with superficial disease alone.
182
Definitive diagnosis and therapy is becoming possible in many more cases than was
previously the case.
183 Duplex scanning has revolutionised diagnosis of venous
disorders affecting the lower limb. Measurements of the site and duration of venous
reflux can be accurately and reliably charted.
184 Theoretically once the haemodynamic
derangement is recognised it should be possible to cure the limb. In practice this is
possible only in a limited number of cases
185.The reports of success with deep venous139
reconstruction show mixed results. Disease confined to the superficial venous system on
the other hand may be ideal for surgical correction.
It is widely accepted that patients with superficial incompetence and normal deep veins
can achieve good outcomes.
186 There are few reports of the long term outcome of
superficial venous surgery for leg ulceration.
187 Most of the reports include relatively
short follow-up periods. Reports that do have a longer follow-up are lacking in the
accuracy of the data, mainly because ultra-sound imaging was not available until
relatively recently. Since 1987 all patients with suspected lower limb venous disease
have been investigated with Duplex ultra-sound at the Middlesex Hospital Vascular
Laboratory. I
carried out a retrospective study to assess the outcome of management based on duplex
ultra-sound findings.
MATERIAL & METHODS
The vascular laboratory records were examined to locate patients who were examined
for lower limb venous duplex investigation. Patients with venous ulceration attributable
to superficial venous disease were selected for inclusion in the study. These included
patients whose disease was predominantly superficial but who also had an element of
deep disease which was not considered to be the dominant element.
I examined the Middlesex vascular laboratory records to locate patients with venous
ulceration attributable to superficial venous insufficiency (SVI). Outcome of surgery
was assessed for patients who had surgery performed at least one year previously. Out
of 88 such patients, I was able to contact 52. Telephone interviews or questionnaires
were used to assess the status of the ulcer, the use of stockings and the subjective
symptoms from the affected leg.
Outcome of surgery for ulceration due to superficial venous disease was assessed for
patients who had surgery performed at least 12 months previously. All of these patients
had superficial venous disease confirmed by means of Duplex ultrasonography and
Photoplethysmography (PPG). Patients with any deep venous problems were excluded
from the study. Patients with perforator disease (above/ below knee) were included.140
Non-parametric tests were used because of the non-normal distribution of the data.
Probability statistics are those for differences between surgical and conservative groups.
Out of 88 patients scanned before & after surgery for SVI with leg ulcers since 1989 at
the vascular Laboratory of the Middlesex Hospital, London, I was able to contact 52.
Telephone interviews or questionnaires were used to assess the status of the ulcer, the
use of stockings and the subjective symptoms from the affected leg.
SFJ ligation and stripping of the GSV was the most frequently performed operation
((>70%). Recurrent veins were the indication for 15% of the operations. Perforator
incompetence was reported in only 4%. Female patients accounted for 61% of the
operations. The mean follow-up period was 52 months (range 12-108 months). Initial
healing rates were >85% with surgical treatment. Only 40% initial healing was achieved
with conservative treatment.
RESULTS
These results are shown diagrammatically in Figure 28 & in Table 21. Clinical
recurrence rates are relatively high at >30% in the operative group. Nearly one third of
the patients still had ulcers at varying intervals of 1-8 years following treatment. Both
patients who healed on conservative treatment remained ulcer free. Around 50% of all
the patients still had symptoms from their veins. These ranged from cosmetic
recurrences to re-ulceration.
Most of the patients who had surgery (>80%) used graduated elastic stocking in the pre-
operative and short-term post-operative period. >40 % had to use them permanently to
avoid troublesome symptoms. Some patients could not use graduated elastic stockings
because of the size of the limb or other factors.141
Table 20 Distribution of the patients according to sex and anatomical site involvement
 Perforator reflux was not an isolated involvement in these patients.
Table 21 shows the rate of initial healing and persistence of ulcers at the time of surgery
in patients with ulceration due to superficial venous disease only. There was a higher
recurrence rate in the group without surgery. Mean follow-up period since initial duplex
examination 52months.
Anatomical Site








13 1 4 1 1 2 -
Female (33)
Mean Age (44-76)
25 4 2 2 1 3 -
Total (52) 38 5 6 3 2 5 -
Healed ulcers Recurrence Stockings Persisting
Symptoms
Surgery (41) 37† (90%) 9‡ (22%) 35§ (85%) 19¥ (46%)
Conservative (11) 6† (55%) 2‡ (18%) 7§ (64%) 6¥ (55%)
All (52) 43 (83%) 11 (21%) 42(81%) 25(48%)












A B C D
Figure 28 shows the outcome at the time of the study of the 41 surgically treated patients
included in the study. This shows that circa 32% of patients had ulceration either from
non-healing or from healing/recurrence/ non-healing. About 60% had primary healing
without recurrence following surgery preceded by Duplex ultrasonography.
A=Maintained initial Healing
B=No Healing
C=Recurrence/ No Secondary Heealing
D= Recurrence/Secondary Healing143
DISCUSSION
The primary haemodynamic derangement in SVI is reflux. The majority of DVI have
reflux as the major mechanism as well. On the other hand the mechanism in some in
secondary DVI is obstruction. Quoted results for deep venous reconstruction are better
with primary DVI
188 than with secondary DVI.
The role of the superficial venous system has been underestimated in the past. In a
study of 300 limbs in 153 patients were examined by Duplex ultrasonography with
colour-flow imaging for the presence of venous reflux Ninety-eight limbs had skin
changes, which included hyper-pigmentation, lipodermatosclerosis, atrophie blanche
and ulceration. Of this group, 2 per cent had no evidence of venous reflux on duplex
scanning, 39 per cent had deep vein incompetence, 57 per cent had superficial vein
incompetence and 2 per cent had isolated medial perforating vein reflux. Of 25 limbs
with ulceration, 13 had superficial and 12 deep vein reflux. A total of 202 legs, which
included 20 normal control limbs, had no skin changes; 22.3 per cent of these had no
venous reflux, 8.4 per cent had deep vein incompetence, 65.3 per cent had superficial
incompetence and 4.0 per cent had isolated medial calf perforating vein
incompetence
189. Isolated deep venous reflux was present in only 12 limbs (15%). A
combination of deep and superficial venous reflux was found in 25 limbs (32%), and in
42 limbs (53%) there was only superficial venous reflux.
There is some suggestion that superficial venous surgery may improve both the venous
haemodynamics as well as the microangiopathy associated with CVI. A recent study
confirmed improvement in physiological parameters following varicose vein surgery
107.
In 11 patients followed up prospectively the Venous filling index, ejection fraction,
residual volume fraction and the venous filling index were shown to improve
significantly at mean follow-up of 4 and 6 months post-operatively. In another study the
laser doppler flux and tcP02 were shown to improve following sclerotherapy and
compression treatment in 15 patients with moderate to severe disease.
190
There were higher healing rates following surgery preceded by Duplex Ultrasonography
compared conservative treatment. However the recurrence rates and the number of
ulcers at the time of the study were not different. Previous experience with surgery has144
been similar.
191 In another published paper
162 the results of surgical treatment of eleven
limbs showed a complete and maintained response at 16.4 months mean follow up.
High initial rates of ulcer healing are obtainable with surgery for duplex ultrasound
confirmed superficial venous disease. However, recurrence rates may be substantial in
the long term. This suggests that either the altered venous haemodynamics are not
corrected at the initial operation and/ or these patients develop an irreversible
microangiopathy of the leg skin.
Results of Conservative Treatment
192
Most venous ulcers can be expected to heal when patients are enrolled in a nurse-
managed/physician-supervised ambulatory ulcer clinic. Strict compliance with the
treatment protocol may significantly decreases the time to healing and prolonged the
time to recurrence
193. In another prospective study 105 consecutive patients with leg
ulcers were recruited (aetiology: 77% venous, 4% arterial, 9.5% mixed, 9.5% other). 70
(67%) had a history of previous ulceration. 83 patients could be followed up for 1 year.
The healing rate for the whole group was 41 (49%) after 3 months and 61 (73%) after 1
year. The corresponding figures for the 67 venous patients are 44 (66%) and 52 (78%)
respectively. From 61 healed ulcers 18 (30%) reoccurred during the 1st year. At the
primary examination several factors were investigated which might have influenced the
healing rate. Age, ulcer-size, the duration of the ulcer, lateral localisation, absence of
foot-pulses and lymphoedematous skin changes on the forefoot could be shown to have
negative influence on healing.
Results of Surgical Treatment
191
In one study of surgical treatment of leg ulcers the results of treatment of 159
consecutive limbs presenting with a clinical diagnosis of venous ulcer in 140 patients
(70 male, aged 28-90 years, median 66 years) were reviewed. Of the patients, 61% were
referred because of severe pain and 53% of the ulcers had been present > 2 years.
Patients were evaluated clinically and by duplex ultrasound, with selective use of
venography, photoplethysmography, arteriography and latterly duplex scanning.
Seventy-one limbs had surgery to the superficial veins, 18 limbs had arterial
reconstruction, and 10 limbs had skin grafting alone. There was one operative death
after arterial reconstruction but none after venous surgery. Patients were followed up for145
1-5 years (median 3 years). Of those who had been treated surgically, healing was
achieved in 88%, and ulcers healed in 52% of those treated non-operatively. In all, 18%
of the ulcers recurred in each group. These results show a favourable association
between appropriate venous and arterial surgery and the healing of venous ulcers, with
relief of pain. They support a policy of thorough evaluation and appropriate surgical
treatment in these patients.
My study reports mid to long term results in a population of patients with venous ulcers
who have Duplex confirmed superficial venous disease only. It would be informative to
perform repeat Duplex examinations on these patients and compare those that are
completely cured to those with recurrent ulceration and recurrent symptoms.
In one published paper
162 the results of surgical treatment of eleven limbs that had
been subjected to Duplex scanning, venography and Air plethysmography (APG) were
studied. All of these patients had GSV disease as the superficial component. All the
patients had deep venous disease in addition. The mean follow up was 16.4 months. All
the ulcers healed in this study and remained healed for the duration of the follow-up.
The mean clinical score decreased from 10.1 to 1.45. However all the subjects in this
study had evidence of deep venous insufficiency in addition. No mention was made of
any conservative measures employed or if the patients continued to use support
stockings post-operatively
194 In addition the vast majority of patients had reflux only in
the proximal deep vein segments. These are now known to be unimportant unless >1.0
minute in duration
§§ and are probably of significance only if they are associated with
distal reflux. Some deep venous reflux is associated as a secondary phenomenon with
advanced superficial disease.
195 Thus evidence of any deep venous reflux should be
critically evaluated and not taken as an absolute contra-indication to surgery per se
196.
Recurrence rates were high in my series. Larger series of conservative management
have shown similar results to the operative management. In one series 188 patients with
recently healed leg ulceration were followed for at least 18 months. Overall cumulative
recurrence rate was 26% after 1 year and 31% at 18 months.
197 Some series had
suggested that >80 % of patients do not require any long-term support stockings after146
surgery.
186It seems likely that patients who have non-healing or recurrent ulcers have
either had an inadequate operation and/or have a microangiopathy locally that persists
despite correction of the venous reflux. It would not be amiss to discuss here the
problem of recurrent veins, which is intimately related to failure of ulcers to heal.
Recurrent varicose veins are a common problem and can be difficult to deal with. In a
recent study involving a survey of > 150 patients, more than 10 % had to visit their GP
post-operatively with recurrent veins within six months of their operation.
198 Patients’
satisfaction rates with varicose vein surgery are generally low and vary amongst
different series.
199 This may be because different surgeons vary in the importance given
to the meticulousness of operative technique of VV surgery.
Concluding Remarks
High initial rates of ulcer healing are obtainable with surgery for superficial venous
disease. Although about a third recurred in my study and a similar number still had an
ulcer more than a year after their operation. The ESCHAR study also showed significant
recurrence rates although the healing rates had an advantage in the surgical group
196.
This suggests that either the altered venous haemodynamics may not have been
corrected at the initial operation and/ or these patients had developed a microangiopathy
not reversible with operative treatment alone. They may have had a predisposition to
ulceration that is not changed by surgery alone. Careful technique is essential. The
exact nature of the microangiopathy and the inflammatory mechanisms involved needs
to be addressed simultaneously. Further studies to continue follow-up of patient
prospectively using the CEAP classification are warranted.
200 Equally important are
further studies into the micro-circulatory aspects of the disease. A study that would
observe the effect of operative treatment on markers of leucocyte and endothelial
activation may help in elucidating the effect on the microcirculation. The next section
deals with this aspect.147
4.4 The Effect of Operative Treatment on Leucocyte &
Endothelial Activation in CVD – A Prospective Study
The inflammatory response seen in chronic venous disease (CVD) involves leucocyte
and endothelial adherence, cell activation and cell migration. This involves adhesion
molecule expression by endothelial cells, leucocyte activation and local cytokine
activity. The endothelium is activated and histologically the capillaries are proliferative
and convoluted (possible VEGF effect) in skin affected with changes of CVD.
Endothelial cell activation by cytokines or thrombin leads to increased adhesion
molecule expression. These include ICAM-1 (binds neutrophil/ lymphocytes) and
VCAM-1 (binds lymphocytes/ monocytes). This may lead to increased MHC-II (T-cell
response) and GMP- 140 (binds platelets) expression. Binding of platelets increases the
availability of platelet activating factor and further accelerates the expression of
adhesion molecules.
Lactoferrin (LF), also known as lactotransferrin (LTF), is a globular multifunctional
protein with antimicrobial activity (bacteriocide, fungicide) and is part of the innate
defense, mainly at mucous membranes. Lactoferrin is found in milk and many mucosal
secretions such as tears and saliva. Lactoferrin is also present in secondary granules of
neutrophils and also is secreted by some acinar cells. Lactoferrin can be purified from
milk or produced recombinantly. Human colostrum has the highest concentration,
followed by human milk, then cow milk. Lactoferrin belongs to the transferrin family
proteins (TF, melanotransferrin, ovotransferin, etc.). Its molecular mass is 80,000 u (80
kDa). Lactoferrin antimicrobial activity is due partly to its high affinity for Fe (ferric
state). LF proteolysis produces lactoferricin, kaliocin-1 small peptides with
antimicrobial activity.Lactoferrin receptors have been found on brush-border cells,
PMN, monocytes, and activated lymphocytes. Lactoferrin is a good inducer of IL-6 and
TNF-alpha production. It mayalso act as an opsonin.
Objective parameters are increasingly replacing purely subjective assessment of the
outcome of these patients. Duplex scanning has revolutionised diagnosis of venous148
disorders affecting the lower limb. Measurements of the site and duration of venous
reflux can be accurately and reliably charted.
201 Theoretically once the haemodynamic
derangement is recognised it may be possible to cure the limb. In practice this is
possible only in a limited number of cases.
202.Many growth factors are important in the
reparative response. Vascular endothelial growth factor (VEGF) has been shown to be
up regulated in the patients with CVD. This molecule may be of importance in the
perpetuation of the skin changes in CVD as is discussed later. Reports of success with
deep venous reconstruction show mixed results. Disease confined to the superficial
venous system on the other hand would be ideal for surgical correction.
The aim of this study was to assess the effect of removing varicose veins on patients
with uncomplicated varicose veins as well as those with lipodermatosclerosis. Changes
in circulating levels of soluble ‘endothelial markers’, Lactoferrin (surrogate for
leucocyte activity) & VEGF were monitored to reflect changes in leucocyte and
endothelial activation.
MATERIAL & METHODS
Ethics committee consent for the study was obtained from University College London
(UCL) Medical School Committee for medical ethics. Clinical component of the CEAP
(Clinical, etiologic, Anatomical, Pathological) classification was used to stratify
patients.
134 Patients with CVD, clinical stage 2-4 were recruited from the vascular clinic
at the Middlesex Hospital. These patients were given a full clinical examination by a
surgeon experienced in managing patients with CVD. A medical history was taken and
clinical examination performed. This included a systemic as well as venous
examination.
All patients had a full blood count, serum urea and electrolyte/ liver function tests. All
patients had a venous Duplex examination within the previous eight weeks to establish
venous reflux and to localise it anatomically. All the deep and superficial veins in the
lower limbs were examined. Venous reflux greater than 0.5 sec was considered
significant. Patients who consented were asked to attend the department on three
separate occasions. These were immediately pre-operatively and at four weeks and six
months post-operatively.149
Patient Selection
The inclusion criteria for the study were (1) Age above 18 years (2) patients affected
with CEAP stage C2 to C4 (3) C5 with a healed ulcer for at least 4 weeks (4)
Involvement of the superficial venous system only (5) consenting for operative
treatment (6) consenting to the study.
Exclusion criteria for the study were used to eliminate factors that could distort
leucocyte activation status. (1) History of alcohol or drug abuse (2) known history of
allergy or intolerance to diosmin or any other venotonic agent (3) active venous
ulceration (4) diabetes mellitus (5) impaired hepatic function (ALT or AST 3 fold above
the normal limit) Impaired renal function (serum creatinine > 120 µmol/l) (6) any
concomitant debilitating active disease or abnormality in laboratory test (judged as
clinically significant by the investigator) (7) patients treated with other vasoactive drugs
within the 15 days prior to inclusion (8) patients with an acute/ chronic inflammatory or
infectious disease (9) deep venous thrombosis within the past 12 months (10) superficial
venous thrombosis within 3 weeks (11) patients using steroids, NSAIDs, other 'vaso-
active' drugs, or anti-coagulants (12) pregnancy or breast-feeding.
Blood was collected from the patients in the morning.No vigorous exercise was
permitted prior to specimen collection. Patients with skin changes were fewer (n=5)
than patients without skin changes (n=15). Most patients either had long saphenous
(GSV) involvement with reflux at the groin (n=13) or short saphenous (SSV)
involvement (n=4). Two patients had superficial venous disease (SVD) involving the
GSV through other feeding sources like the mid-thigh perforator.
Collection of Specimens
Blood was collected via an 18G canula (Vasculon 2, Viggo-Spectramed, Helsingborg,
Sweden) placed either in the distal long saphenous vein or dorsal foot vein of the
affected leg. The canula was flushed with heparinized saline solution. 2 ml of blood was
taken and discarded from the canula, and a further 10 ml was collected into two tubes
containing ethylenediamine- tetraacetic acid and citrate (Vacutainer, Becton Dickinson
Vacutainer Systems Europe, BP No 37-38241 Meylan Cedex, France) respectively. The
stoppers were removed before adding blood to prevent excessive cell agitation.150
The Markers measured were E-Selectin, VCAM, ICAM-1, VW Factor, Lactoferrin and
VEGF. Commercial kits were used for these tests (ICAM-1/ VCAM/ E-selectin/ P-
selectin/ Lactoferrin by R&D Systems 4-10 The Quadrant, Barton Lane, Abingdon,
Oxon OX14 3YS, UK; VW factor kit by Diagnosica Stago 9 rue des Freres Chausson
Table 22 shows the patients according to their CEAP stage and anatomical localisation of CVD.
Most patients had stage C2 or C3 diseases (n=15). Two patients had reflux localised to mid-
thigh perforators and localised segments of the GSV (‘Other’ category). Perforator
incompetence is not listed separately because none of the patients had isolated perforator
incompetence.
92600 ASNIERES-SUR-SIENE France; were used for these analyses). Assay of
VEGF165 protein was performed using a sandwich ELISA technique. A ‘Quantikine’
kit supplied by R&D systems (4-10 The Quadrant, Barton Lane, Abingdon, Oxon
OX14 3YS, UK) was used. Plasma levels were read from standard curves obtained by
plotting mean absorbance for standards. The VEGF test used measures levels of
VEGF165. This is one of the four transcripts encoding mature monomeric VEGF (viz.
VEGF121, VEGF165, VEGF189, VEGF206). VEGF121 and VEGF165 are diffusible
proteins that are secreted into the medium. The other two are mostly bound to heparin
containing proteo-glycans in the matrix. Results obtained for naturally occurring human
VEGF and the recombinant VEGF121 showed linear curves that were parallel to the
standard curves obtained using the ‘’Quantikine’’ kit standards. Please see methodology
section for a more detailed description.
Statistical methods
The statistical tests are used as shown. Non-parametric tests were used because of the
non-normal distribution of the data. Because of the non-Gaussian distribution the
descriptors used are the median and interquartile range. The levels of statistical
GSV SSV GSV/ SSV OTHER Total
C2 3 2 - 1 6 (3F: 3M)
C3 7 2 - - 9 (6F: 3M)
C4 3 - 1 1 5 (2F: 3M)
Total 13 4 1 2 20 (3F: 3M)151
significance were obtained using the Wilcoxon matched-pairs signed-ranks test for
within group differences.
RESULTS
These results are shown diagrammatically in Table 23 as well as in Figure 29,Figure 30,
Figure 31. There was a statistically significant decrease in the plasma Lactoferrin levels
at six months. This decreased from 864 (IQR 662-1260) to 519 (IQR 306-911) ng/ml
(p=0.03)). This was an absolute decrease of 40% in the median levels compared to
preoperative levels. There was no significant change in Lactoferrin levels at 2 months.
Siginificant increase in the levels of sVCAM-1 (43%) was observed at six months when
compared to pre-operative levels. The change in levels was observed from 280ng/ml
(IQR 200-390) to 399ng/ml (IQR 324-418) over the respective time periods.
Changes in plasma VEGF levels (65: 83:134 pg/ml) failed to reach statistical
significance in this study. Although there was a trend towards rising levels, significant
spread in the results may account for the lack of statistical significance. There were no
siginificant changes in the levels of either VW factor or ICAM-1 levels (75: 78:79 [p=
0.12] & 208: 175: 199 [p=0.62]. This was true both at four weeks as well as at six
months.152
Table 23 Changes in the levels of plasma markers of endothelial activation, lactoferrin and
VEGF at four weeks and six months following surgery. Bold values represent medians, values
in parentheses are inter-quartile ranges.
Yellow=statistically significant changes. The actual differences in the E-Selectin levels are too small to be
meaningful.
 These values (Wilcoxon) are for the differences between the values obtained pre-operatively
and at four weeks post-operatively.
These values (Wilcoxon) are for the differences between the values obtained pre-operatively













Pre-Operative 75 (63-90) 208 (176-223) 65 (37-178) 49 (34-57) 280 (200-390) 864(662-1260)
Four Weeks 78 (51-96) 175(133-307) 83 (74-137) 40 (38-49) 240 (215-290) 870(605-1717)
P value
 0.27 0.84 0.25 0.53 0.41 0.7
Six Months 79 (67-87) 199 (137-243) 134 (38-2940) 51(40-72) 399 (324-418) 519(306-911)
P value 0.12 0.62 0.15 0.01 0.01 0.03153
Figure 29 Shows changes in the plasma activity of VW factor before (A) four weeks (B) and six
months (C) following surgery. VW factor is expressed by endothelial cells and is up regulated in
endothelial activation in addition to its role as a pro-coagulant. There no statistically significant
change at six months.
The lines in the figures represent the values of the concentration of the relevant molecule. The bold lines
represent the median values. The vertical lines represent inter-quartile ranges. The X-axes show the
values pre-operatively, 4 weeks post-operatively and six months post-operatively. The Y-axes represent






































Figure 30 The response of plasma levels of sICAM-1 to operative therapy in the short to
medium term. There is no significant change either at 4 weeks or 6 months post-operatively.
The lines in the figures represent the values of the concentration of the relevant molecule. The bold lines
represent the median values. The vertical lines represent inter-quartile ranges. The X-axes show the
values pre-operatively, 4 weeks post-operatively and six months post-operatively. The Y-axes represent































Figure 31 shows changes in plasma levels of lactoferrin at 4 & 6 months post surgery.
Lactoferrin levels represent leucocyte degranulation. There is a statistically significant decrease
at 6 months.
The lines in the figures represent the values of the concentration of the relevant molecule. The bold lines
represent the median values. The vertical lines represent inter-quartile ranges. The X-axes show the
values pre-operatively, 4 weeks post-operatively and six months post-operatively. The Y-axes represent






































I observed an initial rise and a subsequent decrease to below starting levels in the levels
of lactoferrin in the plasma. On the other hand the markers of endothelial activation and
VEGF continued to show a trend towards increase at six months post-operatively. The
exact medical significance of this amount of change in endothelial activation is open to
further work. This decrease may reduce the initial adhesion of these cells to the
endothelium and thus decrease the amount of tissue damage. These effects seem to be
equivalent in patients with and without skin changes. Other possible confounding
effects (e.g. the time of the year the samples were taken ) also have to be
acknowledged.
Presently there are no reliable markers either to assess the effectiveness of treatment of
chronic venous disease (CVD) or to help in its prognosis. Many patients are worried
about the long-term sequelae of their venous disease and do not want surgery merely for
appearance's sake. Markers of venous disease include clinical, hand held Doppler,
duplex ultrasound, plethysmography (air, photo, strain gauge), capillary microscopy and
tonometric criteria. Many assessments are subjective and may be unreliable. Duplex
examination after therapy may indicate success in the short term but may not predict
future recurrences or the course of skin complications.
Chronic venous disease (CVD) and its sequelae are a major cause of morbidity in the
Western world.
203, Previous studies from this department have shown increased
leucocyte activation in patients with CVD. Leucocyte mediated inflammatory
mechanisms have been a focus of attention in CVD This report is the first to show the
response of this activation to any form of therapy. Moyses et al reported sequestration
of leucocytes in the circulation of the lower limb following venous hypertension in
1978.
204. Bollinger et al showed that there were areas of very low skin blood flow in
legs affected with CVD. These areas diminished on application of compression
stockings.
205 Blood flow in the microcirculation is dependent on i. The arterio-venous
gradient ii. The viscosity of the blood and iii. The vascular resistance. The white cells
contribute importantly to the vascular resistance by being about 2000 times less
compliant than the red cells. Thus ‘sludging’ of the WBCs can seriously affect the157
micro-circulatory haemodynamics. This is thought to be at least in part attributable to
leucocyte-induced damage mediated through cytokines.
Coleridge-Smith et al put forward the hypothesis of leucocyte trapping due to reduction
in capillary blood flow because of an increase in venous pressure in 1988.
206 A study
published by the same group in 1997 showed that venous hypertension results in
sequestration of the more activated population of neutrophils and monocytes in the
microcirculation of the leg in patients with CVD. These cells bind to the endothelium
and may not emerge from the limb when venous hypertension is reversed.
130 The
physical interaction between the leucocyte and the micro-vascular endothelium is
important for its function in the microvasculature.
207
Patients with chronic inflammatory and septic states show increased leucocyte priming.
This is also observed in patients with CVD. The primed cells show increased surface
CD62L and CD11B
130. CD62L is involved in the initial 'rolling' movement of the
leucocyte along the endothelium. CD11B is the molecule responsible for firmer
adhesion and subsequent diapedesis. There is some evidence of inflammatory
mechanisms being important in damage to the venous valves seen in CVD
153.
Experimental blockade of adhesion molecules either with soluble ligands or with
specific monoclonal antibodies has a dramatic effect on inflammation and immune
mediated tissue damage
164. The observation that some markers are specifically lowered
following therapy in patients with skin changes demonstrates the possibility of
flavonoids to ameliorate and/ or implicated in the valvular damage seen in CVD
153 and
these compounds may have a role in ameliorating this damage as well. These aspects
merit further study.
Inflammatory processes are regarded as important in the pathogenesis of skin changes
seen in CVD
130. Increased leucocyte presence has been shown in the skin and the vein
wall itself. In the chronic stages there is a reparative tissue response that exists
alongside the inflammatory response
131. Many growth factors are involved in the
reparative response208. Vascular endothelial growth factor (VEGF) is one of the
molecules involved physiologically in the angiogenesis of healing. It is a very potent
micro-vascular permeability-increasing factor initially associated with tumour158
angiogenesis209. It is a glycoprotein secreted by a variety of cells including smooth
muscle cells, monocytic cells and keratinocytes210. Its expression is dependent on
increased mRNA synthesis and increased transcription
211. Any tissue injury, especially
hypoxic injury could be a potent stimulus for its expression.
Abnormally increased and prolonged exposure to VEGF could have local deleterious
effects. VEGF is strongly expressed by epidermal keratinocytes in psoriasis, skin with
ultra-violet burns, lesions of rheumatoid Arthritis and in bullous diseases such as
erythema multiforme and bullous pemphigoid.
212 There is a characteristic increased
micro-vascular permeability and angiogenesis.
I used a model of surgery for varicose veins to study the effect of operative management
on CVD in general. The effects on microcirculation for any given clinical (CEAP) grade
of severity are similar for superficial as well as deep disease. Superficial venous disease
is currently considered to be of equal importance in the prevalence of CVD. In a study
of 98 limbs with skin changes due to CVD (hyper-pigmentation, lipodermatosclerosis,
atrophie blanche and ulceration) 57 per cent had superficial vein incompetence only
189.
Following any successful treatment for CVD, a reduction in leucocyte activation would
be expected. Because of the paucity of the number of surgical procedures performed for
deep venous insufficiency, it would not have been practical to include patients with DVI
in this study.
The relatively short follow-up in this study also precludes any study of the effect of
recurrence on endothelial/ leucocyte activation markers. The clinical effect of this
amount of reduction in the levels of LAMs has yet to be elucidated scientifically.
Despite no controls in the present study I were able to demonstrate the effect of
operative treatment on the abnormal leucocyte activation seen in CVD in the short to
medium term.
SVI is an important factor in many cases of chronic venous insufficiency. The long-term
effects of SVI may be equally severe compared to DVI. The role of the superficial
venous system has been underestimated in the past. Superficial venous surgery has been
shown to improve venous haemodynamics associated with SVI. In a study of 11
patients followed up prospectively, ejection fraction, residual volume fraction and the159
venous filling index were shown to improve significantly at mean follow-up of 4 and 6
months post-operatively. The microangiopathy associated with CVD may also improve
following therapy. Laser Doppler flux and tcP02 were shown to improve following




162 the results of surgical treatment of eleven limbs with leg ulcers due
to SVI was studied. The mean follow up was 16.4 months. All the ulcers healed in this
study and remained healed for the duration of the follow-up. The mean clinical score
decreased from 10.1 to 1.45. More recent studies of the efficacy of surgical treatment
alone exist.
213 Longer follow-up results of such series are required to show many late
recurrences.
Changes in the level of VEGF may have some clinical significance. Proliferation of
micro-vessels in the skin and accumulation of peri-capillary fibrin cuffs in CVD has
been recognised for some time
214. The significance of these cuffs remains unclear.
VEGF selectively promotes extravasation of Fibrinogen
215. VEGF blocking has shown
some promise experimentally in oncological therapy
216 217. Linomide and VEGF-
blocking anti-bodies have been used for this purpose. Tamoxifen has been shown to
have some anti-angiogenic activity. The role of such therapy in CVD remains to be
explored. Ancillary therapy in CVD to reduce recurrence or accelerate healing of skin
lesions in selected cases may be a possibility in the future.
Evidence of decreased plasma lactoferrin may be explained on removal of segments of
veins that were causing venous stasis and leucocyte activation. at six months further
corroborates these findings. Increase in levels of plasma VEGF (if real) may be
postulated to be a continuing process of vascular remodelling in these patients. It is
unknown at the moment if clinical recurrences of veins or persistence/ worsening of
skin changes are preceded by increase in the levels of these markers.
Concluding Remarks
In summary operative treatment of varicose veins leads changes in endothelial
activation markers that are mostly difficult to interpret. Many of the markers of
endothelial activation were increased at six months post-surgery. Plasma VEGF showed160
a similar trend. This may be explainable on some form of vascular remodelling that
may occur after operative treatment to varicose veins. These phenomena may or may
not be related to the recurrence of varicose veins or the non-healing of venous
hypertension induced skin changes.161
4.5 Effect of Skin Compression
On the microcirculation
The effect of compression on the microcirculation in patients with CVD as well as CVD
combined with occlusive peripheral arterial disease is important. Laser Doppler ‘flux’ has
been used in the past for this purpose. This measures flow in both the nutritional vessels of
the skin as well as the deeper thermoregulatory plexuses.
Compression in patients with combined venous and arterial disease
More than 20% of patients with venous leg ulceration have associated arterial disease
218.
It is conventional practice to avoid the application of high levels of compression in patients
with arterial disease because of the possibility of causing ischaemia of the leg resulting in
gangrene. No systematic investigation of this problem has been undertaken and no simple
measure is currently available which allows an assessment of a particular patient when
considering the use of compression treatment, other than the measurement of Doppler
ankle indices.
Conventional capillary microscopy is of limited use in the skin of the leg. It is usually
employed in the nail fold where capillary loops run horizontally in the skin. Elsewhere the
nutritional capillaries pass from deep to superficial, running perpendicularly to the skin
surface, and flow velocities cannot be measured. A device termed a laser capillary
anemometer uses Doppler shift in a laser beam to assess the flow in a single capillary. The
device incorporates a capillary microscope through which capillary loops may be
visualized. The laser beam is then employed to assess blood flow velocity. Skin capillaries
may be counted and measured, as well as their flow estimated.
The aim of my study was to use laser Doppler fluxmetry and capillary microscopy / laser
capillary anemometry to assess the leg skin microcirculation in patients and controls
during the application of compression in order to measure the response of the nutritional
circulation of the skin.162
Table 24 Characteristics of the patients with mixed arterial and venous disease. Most patients
had SVI and proximal arterial occlusive disease.
MATERIAL & METHODS
Patients were investigated by colour doppler ultrasonography and photoplethysmography
to confirm that venous disease was responsible for the skin changes and to define the
extent of arterial disease. All patients had ankle and brachial pressures measured using
Doppler ultrasound and the ankle: brachial pressure index was calculated. Patients with
ischaemic rest pain were excluded from the study.
Initially the subjects lay supine. At least 5 representative capillaries were studied in each
limb. Images of the capillaries were recorded on videotape for subsequent morph metric
analysis. The laser anemometer and fibre-optic laser Doppler system was used to measure
the mean flow velocity over a 1-minute interval. Compression was then applied in 10 mm
Hg increments up to a pressure of 100 mm Hg. Further images and flow velocity readings
were taken. The measurements were repeated with the subjects standing supported, using a
high stool or couch to maintain comfort and balance. Recordings were made in the same
region of the limb as before.
Blood flow velocity during compression
A capillary microscope/laser anemometer was modified so that the skin is viewed through
an acrylic window. Details of the instrument are mentioned in the section on methodology.
The microscope, which is of small dimensions, was mounted on a pivoted frame so that it
may be applied to the lower limb with the patient lying supine or in the sitting position.
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The frame was designed so that a variable force may be applied to the skin and measured
with the aid of a strain gauge incorporated into the microscope mounting system. The
system was designed to apply pressures of up to 100 mm Hg to the viewing window of the
microscope, allowing the skin microcirculation to be viewed and measured whilst under
compression. A conventional fibreoptic laser Doppler probe was incorporated into the
system to assess the effect of this system on previously reported effects of compression




The study was conducted in an environmental chamber at 22
oC. Patients were acclimatized
for 20 minutes before the start of the experimental protocol. In each patient and volunteer
the supra-malleolar skin 5 cm proximal to the medial malleolus was investigated.
RESULTS
A group of 15 patients with skin changes due to venous disease (lipodermatosclerosis or
haemosiderosis) or healed and unhealed venous ulcers (CEAP classification: clinical
groups 4, 5 Proximal arterial= Ileo-Femoral disease, Distal Arterial= Popliteal and distal
disease, C1-C4 etc refer to the CEAP clinical classification), 15 patients with moderate
lower limb arterial disease (ABPI <0.8 and >=0.5), 12 patients with combined venous
disease (CEAP classification: clinical group any) and moderate arterial disease (ABPI <0.8
and >=0.5) and 15 control subjects was studied. The results obtained from all three groups
of patients are shown in the following figures.. Also show the data obtained from the
control group. The most marked response to treatment was seen in the patients with CVD.
The lines in the figures represent the median values of the relevant velocities. The
vertical lines represent inter-quartile ranges. The X-axes show the velocities in the
capillaries.
The Y-axes represent the value of the compression applied to the limb. The statistical
tests used are non-parametric tests because of the non-normal distribution of the data.
Maximal velocities were seen well into the 60-70 mm Hg compression levels. In patients
with arterial disease only pressure above 20-30 mmHg was poorly tolerated with flows164
rapidly declining above these pressure levels. The patterns in the mixed disease sub-group
did not strictly lie in between the arterial and venous groups. In the mixed group of
patients reached a maximum at 20 mm compression. Blood flow was barely detectable at
100mmHg. Thus compression at higher levels than 30-40mm was poorly tolerated.
Capillary velocity reached a maximum at 40mm compression. Although blood flow was
still not abolished at 100mmHg, the velocity was greatly reduced. Higher pressures were
tolerated with the patient in the upright position among all the groups.165


























































Figure 32 Shows a comparison between data from mixed disease with patients suffering from
either arterial OR venous disease (all in supine position). Blue lines represent CVD; red lines
represent arterial disease while green lines represent the group with mixed disease.
Patients with CVD (a) show a very marked and enhanced response to compression peaking at
about 40-60mm of pressure
Patients with arterial disease (b) show a marked cut-off in velocity at just 30mm especially in
the supine position. There is no tendency to peak but rather a decreasing trend in velocity with
increasing pressure.
The line representing the mixed group (c) does not strictly lie between the arterial and the
venous groups but does show a more sustained response to compression.
Velocity= mm/s167



























































Figure 33 Shows a comparison between data from mixed disease with patients suffering from
either arterial OR venous disease (all in upright position). Blue lines represent CVD; red lines
represent arterial disease while green lines represent the group with mixed disease.
Patients with CVD (a) show a very marked and enhanced response to compression peaking at
about 60mm of pressure
Patients with arterial disease (b) show a cut-off in velocity at higher than the supine position.
There is no tendency to peak but rather a decreasing trend in velocity with increasing pressure.
Velocity= mm/sCOMPRESSION
Pressure 0 mm 10 mm 20 mm 30 mm 40 mm 50 mm 60 mm 70 mm 80 mm 90 mm 100 mm
Control








































































































Table 25 Shows a comparison between data from mixed disease with patients suffering from either arterial OR venous disease (all in upright position).
Patients with CVD show a very marked and enhanced response to compression peaking at about 60mm of pressure Patients with arterial disease show a
cut-off in velocity at higher than the supine position. There is no tendency to peak but rather a decreasing trend in velocity with increasing pressure. The
data representing the mixed group does not strictly lie between the arterial and the venous groups but does show a more sustained response to
compression. Again higher levels of pressure are tolerated as compared to the supine position.
Velocity= mm/s170
COMPRESSION 0 mm 10 mm 20 mm 30 mm 40 mm 50 mm 60 mm 70 mm 80 mm 90 mm 100 mm
Control 0.655 0.705 0.735 0.83 0.88 0.83 0.78 0.675 0.625 0.605 0.56
















































































Table 26 Represents data obtained with the patient supine. Median flow velocities (mm/sec) in all fourgroups of patients are shown. Velocities at
varying levels of compression from 0-100 mm Hg. Increments of 10 mm were used for this study. Values in parentheses represent inter quartile ranges.
Correlate arterial pressure with foot compression pressureDISCUSSION
Previously it has been widely assumed that the application of compression to the lower
limb restores valvular competence to venous valves
219,220,221,222. Objective assessment of this
assumption using duplex ultrasonography has failed to show that valvular competence is
restored by the application of moderate levels of compression, known to be effective in the
treatment of venous ulceration
223. However studies suggest that moderate levels of
compression do augment the calf pump mechanism and may lead to improvement in air
plethysmographic criteria. On the other hand only moderate levels of compression may
work in ulceration due to CVD. Stockings, which exert 20 - 30 mm Hg, heal venous ulcers
and prevent their recurrence.
The method we used utilises pressure applied to an acrylic disc. Although these
measurements may be not show pressure transducer measurements underneath a pressure
garment. The method was used to allow direct measurement of the underlying capillaries.
Nevertheless it appears that compression therapy at lower levels increases the flow of
blood through the skin microcirculation. This was true even in patients with mixed disease
and arterial disease. Lower levels of compression may be useful in patients with mixed
arterial and venous disease.
In a previous study from this department the effects of compression on the
microcirculation of the limb were investigated using laser Doppler fluxmetry. It was found
that increased flow of blood through the microcirculation of the skin occurred with
compression levels as low as 20 mm. Therefore compression stockings may work
principally by increasing the blood flow velocity through the capillaries and venules skin.
This may modify the interaction of the blood, in particular the leucocytes, with the
endothelium of the microcirculation preventing stagnation, leucocyte adhesion and acting
as an anti-inflammatory treatment. (It has been shown that WBC trapping in the leg was
decreased by compression stockings).
224
A study of the microcirculation using laser Doppler fluxmetry to assess skin blood flow
found that compressing the leg skin in patients with venous disease resulted in a 50%
increase in laser Doppler flux when only 20 mm Hg of compression was applied
105. When
patients sat with their limbs dependent up to 60 mm Hg compression could be applied172
before laser Doppler flux began to decrease. This suggests that much of the efficacy of
compression may be attributable to its effect on the microcirculation. It has been confirmed
that compression stockings achieve the same effect on laser Doppler flux in the skin
225.
The fibre-optic method of laser Doppler fluxmetry used in these studies measured flow in
both the nutritional vessels of the skin as well as the deeper thermoregulatory plexuses
below, particularly from the sub-papillary plexus
226.
Direct measurement of blood flow in skin capillaries in my study permitted an assessment
of whether compression influences these vessels, and whether where the efficacy of
compression occurs and how treatment might best be optimised.
More than 20% of patients with venous leg ulceration have associated arterial disease. If
the patient has arterial disease as well as venous incompetence it becomes difficult to
gauge the extent of compression therapy that may be applied safely. Excessively high
levels of compression may harm the patient by causing ischaemic necrosis of the skin over
bony prominences. Although ABPI may dictate the maximum levels of compression that
may be used it does not provide any guide to an optimum compression level.
Studies done by Abu-Own’s study suggest that the increased flux associated with skin
compression involves both increased velocity as well as increased concentration of moving
blood cells. I did not measure the either change in diameter of the capillaries with
increasing compression or the number of visible capillaries. These may be important
parameters, however; the present study was concerned with the effect of compression on
blood flow.
Concluding Remarks
Skin compression increases the capillary blood velocity in the sub-papillary plexus in
patients with mixed disease. Thus compression therapy does seem to help in these
patients, however, maximum velocities are reached at relatively smaller pressures
especially in the supine .position. The fact that maximum velocities in these patients are
reached at 20 mm in supine and 40 mm in sitting positions suggests that lower levels of
compression may be useful in these patients.173
The outcome of this investigation may indicate the optimum levels of compression likely
to be effective in the management of chronic venous disease and in combined venous and
arterial disease. This may help in the design of more effective methods of compression for
the treatment of patients with venous disease. It may indicate whether compression is
helpful in the lying position as well as when the patient is standing or sitting. Laser




Previously many inflammatory processes have been reported in the skin and blood of
patients with venous disease. Burnand
227 found that capillary proliferation correlated
closely to the development of clinical skin changes (lipodermatosclerosis, LDS). There
are no studies showing major differences between patients with skin changes and those
without. Reports of changes in the microcirculatory processes following therapy are also
few.
VEGF & Inflammatory markers
I demonstrated high plasma levels of vascular endothelial growth factor (VEGF) among
patients with chronic venous disease (CVD). The finding of large differences between
patients with clinically obvious skin changes and those without may be of relevance.
Although, measurements of plasma levels may not accurately represent the actual tissue
levels expressed in the tissues. The data from this study show that both groups of
patients showed similar elevations in plasma VEGF compared to controls. This suggests
that this growth factor is induced in patients with venous disease as a response to tissue
damage caused by venous hypertension
My studies showed for the first time that there is a decrease in some soluble endothelial
activation markers in patients with CVD following sixty days therapy with oral purified
flavonoid fraction. This demonstrated a quantifiable change in endothelial activation .
VCAM-1 and ICAM-1 (adhesion molecules important in endothelial interaction with
neutrophil, monocytes and lymphocytes) were decreased significantly following
therapy. This effect was seen in all patients irrespective of their clinical stage.
Lactoferrin levels were appreciably reduced following therapy mainly in patients with
skin changes. Changes seen in endothelial activation markers following surgery are hard
to interpret. This may represent damping of the much increased granulocyte activity in
these patients compared to those with simple CVD. The effect on E-selectin levels was
also seen more in the patients with skin changes in the leg. As yet unknown factors may
be responsible for the differing phenomena seen with VW factor following therapy (rise
in VW factor in C3 patients and fall in C4 group). A rise in VW factor expression may
indicate both an acute inflammatory phase as well as a pro-thrombotic tendency. A
decreased expression may imply the reverse.176
Inflammatory markers & Surgery for Varicose veins
Despite advances in doppler ultrasound, surgery for varicose veins causing leg ulcers
may not always result in leg ulcer healing. In my review of long-term outcome in 32
patients initial healing rates were >85% with surgical treatment. Only 40% initial
healing was achieved with conservative treatment. Recurrence rates are relatively high
at >30% in the operative group. About half of all the patients continued to be
symptomatic from their veins. Most of the patients who had surgery (>80%) used
graduated elastic stocking in the pre-operative and short-term post-operative period. >40
% had to use them permanently to avoid troublesome symptoms. Some patients could
not use graduated elastic stockings because of the size of the limb or other factors.
I have shown that operative treatment led to an initial increase and a subsequent
decrease to below starting levels of lactoferrin in the plasma. As acknowledge
previously, changes seen in endothelial activation markers following surgery are hard to
interpret. On the other hand ICAM-1, vWF and VEGF continued to show a trend
towards increase at six months post-operatively. The significance of this amount of
change in endothelial activation is open to further work. These effects seem to be
equivalent in patients with and without skin changes.
Effects of Compression on the Micro-circulation
I showed that compression therapy at lower levels in patients with mixed venous and
arterial disease increases the flow velocity of blood through the skin microcirculation. It
may be reasoned that compression therapy at a lower level may be useful even in
patients with mixed arterial and venous disease. Patients with CVD showed the most
change in cpillary blood velocity in response to compression. Maximal velocities were
seen well into the 60-70 mm Hg compression levels. In patients with arterial disease
only pressure above 20-30 mmHg was poorly tolerated with flows rapidly declining
above these levels.
In patients with mixed arterial and venous disease, capillary velocity reached a
maximum at 20 mm compression. Thus compression at higher levels than 30-40mm
was poorly tolerated. Capillary velocity reached a maximum at 40mm compression.177
Higher pressures were tolerated with the patient in the upright position among all the
groups.
Discussion of methodology
In the study that showed increased levels of VEGF in patients with CVD the control
subjects were slightly younger than either of the study groups. I investigated the
influence of age on the VEGF levels in my control subjects and could find no
correlation. A Medline search of the world literature did not reveal influence of age on
plasma VEGF levels at the range involved in my study. The median VEGF levels in my
control subjects are similar to those measured by the manufacturers of the analysis kit in
their human controls. Nevertheless I admit that the age differences between patient and
control groups leave the possibility that some of the differences I have observed may be
accounted for by age differences.
No distinction was made between patients with superficial venous insufficiency and
those with deep venous insufficiency in interpreting the results. Previous studies from
this department did not observe any difference between these two groups
130 (for a
similar clinical stage). I compared equivalent clinical stages (C), which are
representative of the severity of CVD. Although some of these markers like VW-factor
are also acute phase reactants, they are widely used to estimate endothelial cell
activation. Nonetheless they are widely used for estimating endothelial/ leucocyte
activation. Various roles have been ascribed to circulating plasma levels of adhesion
molecules. They represent protease cleavage from cell surface subsequent to endothelial
stimulation.
The primary haemodynamic derangement in SVI is reflux. Most primary DVI has reflux
as the major mechanism as well. On the other hand the mechanism implicated in some
cases of secondary DVI may be obstruction. Models of surgical treatment of varicose
veins causing ulcers have produced similar results even with segmental (& possibly)
total deep venous insufficiency (ESCHAR trial).
228 196
My study of mid to long-term results of surgery for varicose veins causing venous
ulcers reports on the outcome in a cross-sectional study. Superficial venous disease is178
currently considered to be as important as deep venous insuficiency in the pathogenesis
of CVD. For example, in a study of 98 limbs with skin changes due to CVD (hyper-
pigmentation, lipodermatosclerosis, atrophie blanche and ulceration) 57 per cent had
superficial vein incompetence only
189.
Following any successful treatment for CVD, a reduction in endothelial/ leucocyte
activation would be expected. Clinical studies performed recently of surgery for both
superficial as well as superficial and partial/ total deep venous reflux have shown
possible beneficial effect in all groups.
.196 229 230 The relatively short follow-up in this
study also precludes any study of the effect of recurrence on markers (or vice versa).
The clinical significance of this amount of reduction that I have shown in the levels of
markers has yet to be elucidated. Despite there being no controls in the present study I
was able to demonstrate the effect of operative treatment on the abnormal leucocyte
activation seen in CVD in the short to medium term. The results were compared with
historical controls.
My study on effect of compression on the skin microcirculation suggested that
compression therapy at lower levels increases the flow of blood in mixed arterial and
venous disease. It may be reasoned, that lower levels of compression may be useful in
patients with mixed arterial and venous disease.
Previous Studies
Increased VEGF expression has been shown previously in the skin of patients with
CVD
172. It was observed that VEGF upregulation is seen both in patients with as well as
those without skin changes. The expression was more marked in patients with
lipodermatosclerosis. It was thought that the VEGF was the main factor in causing the
neo-angiogenesis in CVD. The precise stimulus to the increased VEGF stimulation was
not studied. Local tissue hypoxia is a potent stimulus for the release of VEGF. Hypoxia,
although not thought to be the man tissue damaging event in CVD, may nevertheless
exist.
231 Mixed aetiology ulcer s may have more pronounced hypoxia. Non-hypoxic
tissue damage may lead to release of VEGF as well through little understood
mechanisms.179
Recurrence of Venous Leg Ulcers
Most studies show that venous ulcers can be expected to heal when patients are enrolled
in a nurse-managed/physician-supervised ambulatory ulcer clinic.
Photoplethysmography-derived venous refill time of 10 seconds or less predicts delayed
healing. Strict compliance with the treatment protocol significantly decreases the time to
healing and prolonged the time to recurrence
232. However recurrence of ulcers is a
problem in a substantial proportion of patients.
In a prospective study 105 consecutive patients with leg ulcers were recruited (causes:
77% venous, 4% arterial, 9.5% mixed, 9.5% other). 70 (67%) had a history of previous
ulceration. 83 patients could be followed for 1 year. The healing rate for the whole
group was 41 (49%) after 3 months and 61 (73%) after 1 year. The corresponding
figures for the 67 venous patients are 44 (66%) and 52 (78%) respectively. From 61
healed ulcers 18 (30%) reoccurred during the 1st year. At the primary examination
several factors were investigated which might have influenced the healing rate.
In a recently published paper
162 the results of surgical treatment of eleven limbs that
had been subjected to Duplex scanning, venography and Air plethysmography (APG)
were studied. All of these patients had GSV disease as the superficial component. All
the patients had deep venous disease in addition. The mean follow up was 16.4 months.
All the ulcers healed in this study and remained healed for the duration of the follow-up.
The mean clinical score decreased from 10.1 to 1.45. However all the subjects in this
study had evidence of deep venous insufficiency in addition. No mention was made of
any conservative measures employed or if the patients continued to use support
stockings post-operatively. It was not mentioned if the contra-lateral limb was screened
for deep vein reflux detectable without any apparent clinical consequences.
233 In
addition the vast majority of patients had reflux in the proximal deep veins. The
ESCHAR study does address many of these issues and is referred to in the introductory
section.
Superficial venous surgery has been shown to improve venous haemodynamics
associated with SVI. In a study of 11 patients followed up prospectively, the Venous
filling index, ejection fraction, residual volume fraction and the venous filling index180
were shown to improve significantly at mean follow-up of 4 and 6 months post-
operatively. Laser doppler flux and tcP02 were shown to improve following
sclerotherapy and compression treatment in one study of 15 patients with moderate to
severe SVI.
190 In another published paper the results of surgical treatment of eleven
limbs with leg ulcers due to SVI was studied. The mean follow up was 16.4 months. All
the ulcers healed in this study and remained healed for the duration of the follow-up.
The mean clinical score decreased from 10.1 to 1.45. More recent studies of the efficacy
of surgical treatment alone exist.
234 Longer follow-up results of such series are required
to show many late recurrences.
Leucocyte Activation
Previous studies from this department have shown increased leucocyte activation in
patients with CVD. Leucocyte mediated inflammatory mechanisms have been a focus
of attention in CVD. Moyses et al reported sequestration of leucocytes in the circulation
of the lower limb following venous hypertension in 1978.
235. Bollinger et al showed
that there were areas of very low skin blood flow in legs affected with CVD. These
areas diminished on application of compression stockings
205. Blood flow in the
microcirculation is dependent on i. The arterio-venous gradient ii. The viscosity of the
blood and iii. The vascular resistance. The white cells contribute importantly to the
vascular resistance by being about 2000 times less compliant than the red cells. Thus
‘sludging’ of the WBCs can seriously affect the micro-circulatory haemodynamics. This
is thought to be at least in part attributable to leucocyte-induced damage mediated
through cytokines.
Coleridge-Smith et al proposed the hypothesis of leucocyte trapping due to reduction in
capillary blood flow because of an increase in venous pressure in 1988.
236 A study
published by the same group in 1997 showed that venous hypertension results in
sequestration of the more activated population of neutrophils and monocytes in the
microcirculation of the leg in patients with CVD. These cells bind to the endothelium
and may not emerge from the limb when venous hypertension is reversed.
130
Effects Of Compression on the Microcirculation
The exact mechanism of action of compression therapy in CVD remains unknown. The
increase in flux through skin associated with compression therapy in CVD has been put181
forward its possible mechanism of action A study of the microcirculation using laser
Doppler fluxmetry to assess skin blood flow found that compressing the leg skin in
patients with venous disease resulted in a 50% increase in laser Doppler flux when only 20
mm Hg of compression was applied.
105 When patients sat with their limbs dependent up to
60 mm Hg compression could be applied before laser Doppler flux began to decrease. This
suggests that much of the efficacy of compression may be attributable to its effect on the
microcirculation. It has been confirmed that compression stockings achieve the same effect
on laser Doppler flux in the skin.
237 The fiber-optic method of laser Doppler fluxmetry
used in these studies measured flow in both the nutritional vessels of the skin as well as the
deeper thermoregulatory plexuses below, particularly from the sub-papillary plexus.
238
In my studies direct measurement of blood flow in skin capillaries permitted an
assessment of whether compression influences these vessels, and where the efficacy of
compression occurs This may have implications for optimsising and individualising
treatment. More than 20% of patients with venous leg ulceration have associated arterial
disease. If the patient has arterial disease as well as venous incompetence it becomes
difficult to gauge the extent of compression therapy that may be applied safely.
Excessively high levels of compression may harm the patient by causing ischaemic
necrosis of the skin over bony prominences. Although ABPI may dictate the maximum
levels of compression that may be used it does not provide any guide to an optimum
compression level. My study attempted to rationalize the use of compression.
Abu-Own’s study suggests that the increased flux associated with skin compression
involves both increased velocity as well as increased concentration of moving blood
cells. My study did not concern change in diameter of the capillaries with increasing
compression or the number of visible capillaries. These may be important parameters,
however; the present study was concerned with the effect of compression on blood flow.
It has been previously been assumed that the application of compression to the lower
limb restores valvular competence to venous valves
239,240,241. Objective assessment of
this assumption using duplex ultrasonography has failed to show that valvular
competence can be restored by the application of moderate levels of compression,
known to be effective in the treatment of venous ulceration
242. However studies suggest182
that moderate levels of compression do augment the calf pump mechanism and may
lead to some improvement in air plethysmographic criteria. It is known that stockings,
which exert 20 - 30 mm Hg, heal venous ulcers and prevent their recurrence. A
previous study from this department investigated the effects of compression on the
microcirculation of the limb using laser Doppler fluxmetry. It was found that increased
flow of blood through the microcirculation of the skin occurred with compression levels
as low as 20 mm. Therefore compression stockings may work at least partly by
increasing the blood flow velocity through the capillaries and venules skin. This
modifies the interaction of the blood, in particular the leucocytes, with the endothelium
of the microcirculation preventing leucocyte adhesion and acting as an anti-




VEGF is important both in angiogenesis and oedema formation.
243 VEGF acts via two
different tyrosine kinase membrane receptors, which have been identified on vascular
endothelial cells
244. VEGF has an important part to play in the healing process.
However, abnormally increased levels over a prolonged period of time can have local
deleterious effects. It leads to increased micro-vascular permeability and angiogenesis.
Up-regulation of VEGF expression in the skin and plasma of patients with CVD
15 has
been demonstrated previously.
The expression of this molecule in the skin is more marked in patients with CEAP
clinical stage C4 disease than in less severe forms of venous disease without skin
damage
134. It is acknowledged that the current data cannot demonstrate whether this
finding is the cause or consequence of the skin changes. There is a possibility of using
plasma VEGF levels as a surrogate for assessing lipodermatosclerosis by clinical means.
Measurement of LDS in a quantitative way is notoriously difficult, and results in wide
ranging discrepancies of the resulting data.
245
Epidermally derived VEGF is likely to be a factor in the angiogenesis of
lipodermatosclerosis. This increased expression of VEGF is seen even before any skin
changes develop. I have shown increased serum levels of VEGF in my study in patients183
with venous disease. Studies that measure the expression of VEGF mRNA levels may
more conclusively prove the actual site of origin of the protein.
VEGF seems to act both acutely over a period of a few minutes as well as chronically
(over a few hours) to increase micro-vascular permeability.
246 VEGF promotes the
extravasation of fibrinogen and deposition in the tissues as fibrin. This could represent a
mechanism for the formation of the ‘Fibrin Cuffs’ that are characteristically found in
CVD.
247 There is no concrete evidence that these cuffs have a causative role. They are
probably an association in the chronic inflammatory process.
Previous work had shown that leucocyte activation occurs within 30 minutes of
experimental venous hypertension using the same model as employed in this study. This
can be shown both in control subjects as well as those with venous disease. This is
associated with evidence of endothelial activation and I believe these are the
mechanisms that initiate the skin damage caused in CVD. This may initiate a repair
process that involves increased expression of VEGF by keratinocytes and vascular
smooth muscle cells. This causes the neo-vascularization essential to any tissue repair
process. The neo-vasculature is permeable to large molecules when compared to normal
capillary endothelium and allows the perivasular accumulation of large molecules
accounting for the ‘fibrin cuff’ originally reported by Browse and Burnand. Such
perivascular cuffs are of course common in many inflammatory conditions.
The physical interaction between the leucocyte and the micro-vascular endothelium is
important for its function in the microvasculature.
248 Patients with chronic
inflammatory and septic states show increased leucocyte priming. This is also observed
in patients with CVD. The primed cells show increased surface CD62L and CD11B
130.
CD62L is involved in the initial 'rolling' movement of the leucocyte along the
endothelium. CD11B is the molecule responsible for firmer adhesion and subsequent
diapedesis. There is some evidence of inflammatory mechanisms being important in
damage to the venous valves seen in CVD.
153
Experimental blockade of adhesion molecules either with soluble ligands or with
specific monoclonal antibodies has a dramatic effect on inflammation and immune184
mediated tissue damage
164,249. The observation that some markers are specifically
lowered following therapy in patients with skin changes demonstrates the possibility of
flavonoids to ameliorate and/ or arrest some of the skin damage that occurs in CVD.
Inflammatory mechanisms have been implicated in the valvular damage seen in CVD
153
and these compounds may have a role in ameliorating this damage as well. These
aspects merit further study.
The clinical syndrome of lipodermatosclerosis comprises a wide spectrum ranging from
hyperpigmentation to inflammatory changes and fibrosis. It is possible that growth
factors may play different roles at various stages but this has not been studied in detail.
The large difference between VEGF levels in C2/C3 and C4 patients could represent
different stages of development of the dermatological changes. In the initial stages
leucocyte mediated damage could be the predominant event. Later on the repair
processes may become more important and may co-exist with continuing skin damage.
If further studies indicate that high plasma levels of VEGF indicate impending skin
changes, it could provide us with a useful tool for establishing the prognosis. Similarly
if it could be demonstrated that absence of a fall in VEGF levels following therapy
predicts a higher chance of recurrence. This could potentially be used as a marker of
success of the treatment.
It has been demonstrated that Hyaluron oligosaccharides (OHA) in the intercellular
matrix modulate the invasive and proteolytic properties of bovine micro-vascular
endothelial cells and synergize specifically with VEGF in the induction of angiogenesis
in vitro. The synergism between OHA and VEGF probably plays a role in the regulation
of angiogenesis. This could be exploited therapeutically in situations that would benefit
from modulation of new blood vessel growth.
VEGF has been associated with stimulation of Nitric Oxide (NO) production. The
signaling cascade is thought to involve inducible NO synthase (iNOS).The pathways
involve Guanylate cyclase and cGMP dependent protein kinase. Experimentally
administration of VEGF was found to cause severe hypotension in animals. The hypo
tension is thought to be mediated by production of NO and is reversible with185
appropriate blocking therapy with N (G)-monomethyl-L- arginine (L-NMMA)
250-251.
NO can also explain the hyper-permeability induced by VEGF. An excessive release of
nitric oxide can be caused by this mechanism. In contrast to its usual beneficial role in
small doses, this free radical may contribute to local tissue damage in larger amounts.
Ulcer Healing & Superficial Vein (Varicose Vein) Surgery
Superficial venous surgery has been shown to improve the venous haemodynamics
associated with CVI. The majority of patients with combined superficial and deep
incompetence can be selected for SVS on the basis of AVP measurement with
tourniquets. SVS can improve segmental deep incompetence and PRI in those properly
selected
107. In a study of 11 patients followed up prospectively the Venous filling index,
ejection fraction, residual volume fraction and the venous filling index were shown to
improve significantly at mean follow-up of 4 and 6 months post-operatively. In another
study the laser Doppler flux and tcP02 were shown to improve following sclerotherapy
and compression treatment in 15 patients with moderate to severe disease.
190
Larger series of conservative management have shown similar results to the operative
management. In one series 188 patients with recently healed leg ulceration were
followed for at least 18 months. Overall cumulative recurrence rate was 26% after 1
year and 31% at 18 months
197. Some series had suggested that >80 % of patients do not
require any long-term support stockings after surgery.
It is quite possible that patients who have non-healing or recurrent venous ulcers have
either had an inadequate operation and/or have a microangiopathy locally that persists
despite correction of the venous reflux.
Presently there are no reliable markers either to assess the effectiveness of treatment of
chronic venous disease (CVD) or to help in its prognosis. Many patients are worried
about the long-term sequelae of their venous disease and do not want surgery merely for
appearance's sake. There are also no reliable markers to indicate which patients will
develop skin changes/ ulceration. Presently available markers of venous disease include
clinical, hand held doppler, duplex ultrasonography, plethysmography (air, photo, strain
gauge), ambulatory venous pressure, capillary microscopy and tonometric criteria.
Many assessments are subjective and may be unreliable. Duplex examination after186
therapy may indicate success in the short term but may not predict future recurrences or
the course of skin complications.
My study of the effect of operative treatment on markers attempted to answer some of
these questions. The initial increased lactoferrin (at four weeks) in my study imay be
due to the effect of operative trauma on the leucocytes. The subsequent decline in
lactoferrin may be due to the corrected venous hypertension. Changes in the level of
VEGF may have some clinical significance.
The decrease in lactoferrin seen at six months post-operatively may be explained on
removal of segments of veins that were causing venous stasis and leucocyte activation.
Changes in levels of plasma VEGF may be explained by a continuing process of
vascular remodelling in these patients. It is unknown at the moment if clinical
recurrences of veins or persistence/ worsening of skin changes are preceded by increase
in the levels of these markers.
My study of the effect of compression on the microcirculation indicates the possible
optimum levels of compression likely to be effective in the management of chronic
venous disease and in combined venous and arterial disease. This may be helpful in the
design of more effective methods of compression, especially for the treatment of
patients with combined venous & arterial disease. It may indicate whether compression
is helpful in the lying position as well as when the patient is standing or sitting.
Further Studies
Experimental blockade of adhesion molecules either with soluble ligands or with
specific monoclonal antibodies has a dramatic effect on inflammation and immune
mediated tissue damage
164, 252. The observation that some markers are specifically
lowered following therapy in patients with skin changes demonstrates the possibility of
flavonoids to ameliorate and/ or implicated in the valvular damage seen in CVD
153 and
these compounds may have a role in ameliorating this damage as well. Other modalities
of modifying adhesion molecule activity may have a role in CVD. These aspects merit
further study.187
VEGF; Therpeutic Implications
VEGF blocking has shown some promise experimentally in oncological therapy
253 254.
Linomide and VEGF-blocking anti-bodies have been used for this purpose. Tamoxifen
has been shown to have some anti-angiogenic activity. The role of such therapy in CVD
remains to be explored. Ancillary therapy in CVD to reduce recurrence or accelerate
healing of skin lesions in selected cases may be a possibility in the future.
Further studies are needed to assess further the role of soluble endothelial markers in
prognosticating the clinical course of CVD. The role of purified micronised flavonoid
fraction and similar compounds also needs to be re-examined in the context of non-
surgical treatment for CVD.
Monitoring Response to Therapy
It is only relatively recently that the effectiveness of therapy for CVD is being tested
with objective parameters. It has been shown that colour duplex ultra-sonographic and
air-plethysmographic criteria improve in patients one month following surgical therapy.
This improvement was shown to be maintained at two years
162. It would be interesting
to measure the mid to long-term effect of therapy on endothelial markers. Another study
of the effect of compression therapy/sclerotherapy on the microangiopathy (Leu et al)
163
showed non-significant changes post therapy. The parameters studied were capillary
microscopy, Doppler flux-metry and tcPo2 measurement. Elevated levels of VCAM-1,
VW Factor, E-selectin, ICAM-1 and Lactoferrin have been reported in patients with
CVD compared to controls
130. However my study is the first to demonstrate a
measurable change in these parameters in CVD following therapy. This shows the
feasibility of using the soluble markers of endothelial activation as a parameter to
measure the response to various forms of treatment.
Role of Flavonoids in CVD
The effects of flavonoids on Duplex ultra-sonographic parameters and on resolution of
lipodermatosclerosis need to be quantified in prospective studies. The lack of side
effects of these compounds makes them especially attractive as medications for CVD.
Experimentally flavonoids have been shown to have several anti-inflammatory actions.188
My study is the first to demonstrate a possible mode of action for these compounds in
the clinical setting.
Comments
To summarise all these observations a possible scenario for the sequence of events in
skin injury in CVD may be the following. Damage to the tissues is caused by abnormal
leucocyte activation. The injury itself may stimulate a VEGF response. Activated
platelets or macrophages present at the site of injury may have a role in stimulating
VEGF release. The abundant macrophages in skin exposed to CVD are a potential
source of VEGF as well. These could be within the basement membrane or extra-
cellular matrix. Components of the extra-cellular matrix like heparin proteo-glycans are
also exposed by injury. These are known to facilitate migration and tube formation by
endothelial cells. -
255 Re-synthesis of extra-cellular matrix components and migration of
pericytes may represent a mechanism of dampening the angiogenic stimulus.
256
I have shown that increase in some endothelial activation markers studied was
dampened by the administration of purified micronised flavonoid. This suggests that
these compounds may down-regulate the activated endothelium in these patients. This
study demonstrates the feasibility of using changes in levels of soluble endothelial
markers as parameters for assessing the response to therapy in CVD.
Plasma VEGF activity decreases in patients with skin changes dues to CVD following
treatment with purified micronised flavonoid fraction. VEGF protein levels may be
much higher in some of these patients as compared to those with uncomplicated CVD.
The role of confounding factors like seasonal variations etc. has to be considered. The
role of circulating VEGF as a marker for skin complications in these patients needs to
be explored further.
In my study of ulcer recurrence following varicose vein surgery high initial rates of
ulcer healing were seen with surgery. About a third recurred in my study and a similar
number still had an ulcer more than a year after their operation. These findings have
been corroborated by further clinical studies like the ESCHAR study. This suggests that
either the altered venous haemodynamics were not corrected at the initial operation and/189
or these patients had developed a microangiopathy not reversible with operative
treatment alone. They may have a predisposition to ulceration that is not changed by
surgery alone. Every effort should be made to make varicose vein surgery anatomically
and haemodynamically precise. The exact nature of the microangiopathy and the
inflammatory mechanisms involved may need to be addressed simultaneously. Further
studies to continue follow-up of patient prospectively using the CEAP classification are
warranted.
134 Equally important are further studies into the micro-circulatory aspects of
the disease.
Operative treatment of varicose veins leads to an initial increase in lactoferrin followed
by a decrease to below pre- operative levels at six months. This may indicate success
of operative treatment in ameliorating the leucocyte/ endothelial activation responsible
for the complications of CVD. Longer-term follow up is indicated to observe the effect
of recurrent varicose veins on leucocyte activation (or vice versa) in these patients over
a period. Many of the markers of endothelial activation were increased at six months
post-surgery. These results are harder to interpret meaningfulluy. Plasma VEGF showed
a similar, but more marked trend. This may be explained on some form of vascular
remodelling that may occur after operative treatment to varicose veins. The change in
VEGF levels may have a similar explanation. These phenomena may or may not be
related to the recurrence of varicose veins and/ or the non-healing of venous
hypertension induced skin changes.
The laser anemometer is a research tool that my help in the design of better methods of
compression. Skin compression increases the capillary blood velocity in the sub-
papillary plexus in patients with mixed disease. Thus compression therapy does seem to
help in these patients, however, maximum velocities are reached at relatively smaller
pressures especially in the supine position. The fact that maximum velocities in these
patients are reached at 20 mm in supine and 40 mm in sitting positions suggests that
lower levels of compression may be useful in these patients. Further work needs to be
done to observe if compression pressures for patients for individualised therapy are
deducible from this method.190
PART VI
CONCLUSIONS191
The studies included in this thesis support the hypothesis that there are measurable
changes in leucocyte/endothelial activation and microcirculatory stasis in CVD in
response to therapy. Increased plasma ‘Vascular endothelial growth factor’ (VEGF) in
patients with CVD was also clearly demonstrated. Further studies may show if a
correlation between clinical status/ prognosis and these parameters exists. These
parameters may be used as objective measures of response to treatment. Increased
endothelial/ leucocyte activation seems to respond favourably to therapy in CVD.
Plasma levels of VCAM, ICAM-1, vW factor Lactoferrin are markers of increased
microcirculatory activity. The increased endothelial activation and neutrophil activation/
degranulation seem to be ameliorated by pharmacological compounds (purified
flavonoid fraction) that have been shown to be of symptomatic benefit in CVD. Plasma
levels of VCAM, ICAM-1 are significantly reduced following therapy with oral purified
micronised flavonoid fraction. In addition levels of VW-factor and Lactoferrin are
reduced significantly in patients with C4 disease.
Following varicose vein surgery a statistically significant change was seen in the level
of plasma lactoferrin levels. However at 6 months plasma E-Selectin and VCAM were
higher to some degree than pre-operative levels. Changes in VEGF levels failed to reach
significant levels. As mentioned the latter results may be harder to interpret.
Compression therapy seems to increases the skin blood flow velocity in patients with
pure CVD as well as in those with mixed arterial and CVD. This may lead to increased
shear at the venular/ capillary endothelial interface. This may decrease leucocyte/
endothelial interaction and possibly help in ameliorating the effects of CVD. In my
model of acrylic disc skin compression I demonstrated the increased velocity of blood
in the subpapillary plexus. I also showed that lower levels of compression (20 mm Hg)
are effective in increasing velocity in patients with mixed disease. I have demonstrated
in this thesis that the sluggish microcirculatory flow, endothelial activation, VEGF
activity & increased neutrophil degranulation activity been described previously in
chronic venous disease show changes in response to various forms of therapy.192
Critique of the Research Presented In the Thesis
Although the research presented in the thesis was performed some time ago the
inflammatory aspects of CVD remain topical issues. They are the subject of much
debate and ongoing discussion. CVD continues to be a cause of much morbidity as well
as a drain on NHS resources.
The microcirculatory changes in chronic venous disease were described in the early
1980s and 1990s. Thus they are not new findings. However, there were relatively few
studies recording the changes in these parameters in response to treatment. The
techniques used for measurement of the markers of endothelial activation were well
established ELISA techniques. The CAM capillary anaemometer was a new instrument
looking at the velocity of blood in specific sub-papillary nutritive vessels.
It is acknowledged that the understanding of the VEGF molecule has progressed
considerably recently. The original classification is VEGF A (the main VEGF), B, C
and PlGF. The results of the study measure the main molecule (VEGF A) and are
relevant
. These were the first todemonstrate increased VEGF in chronic venous
disease.
It is also acknowledged that larger studies may show differing seasonal temporal, sexual
and age-related changes in plasma levels of VEGF in chronic venous disease. Many of
the studies include relatively few patients. The scope of this work, however, was to
perform initial studies to look at the levels in a population of subjects with/ without
clinical chronic venous disease. Further larger studies would be useful and informative
in this regard.
Positive Conclusions from this Work
I demonstrated a decrease in Lactoferrin levels at six months following surgery (36%).
My report regardin increased plasma VEGF in patients with CVD was the first such
 In alternative classifications the term 'VEGF' covers a number of proteins from two families, that result
from alternate splicing of mRNA from a single, 8 exon, VEGF gene. The two different families are
referred to according to their terminal exon (exon 8) splice site - the proximal splice site (denoted
VEGFxxx) or distal splice site (VEGFxxxb). In addition, alternate splicing of exon 6 and 7 alters their
heparin binding affinity, and amino acid number (in humans: VEGF121, VEGF121b, VEGF145,
VEGF165, VEGF165b, VEGF189, VEGF206).
PlGF= Placenta Growth Factor193
published report. This may explain the link between the white cell activation and
‘fibrin’ cuff theories (i.e. white cell activation in inflammation triggers VEGF release
that is a well known permeaboility factor allowing extravastion of Fibrin).
I demonstrated decrease in plasma leels of VEGF, ICAM-1, VCAM, vW Factor &
Lactoferrin after 60 days treatment with oral Flavonoids. I also showed that the sub-
papillary capillary blood velocity increases during the range of pressures used
therapeutically.These velocities were highest at about 60 mm Hg in CVD and about
40mm Hg in mxed disease. These findings may help explain some of the mechanisms
by which compression treatment may work.
Practical Clinical Applications
The study involving Flavonoid confirmed improvement in some markers of endothelial
activation. It also confirmed some clinical benefit. Since these were initial studies,
larger studies were awaited before there was more generalised prescription of
Flavonoid. These compounds do continue to be prescribed by some clinicians in this
country. Whether or not different (& stronger!) anti-inflammatory agent (e.g. NSAIDS)
would be effective in this clinical setting remains to be proven
.
As suggested it may be a possible application of this data to determine whether the
treatment (surgical/ pharmacological/ physical) being applied is effective. However the
scope of these studies would not allow such conclusions to be made. It may also be
possible to test devices that allow bespoke best compression levels for individual
subjects.
The study of response of capillary velocity to skin compression is indicative that
patients with mixed disease may indeed benefit from a lower level of compression
Publications & Citations
 Both NSAIDS (non-selective/ COX-2) as well as corticosteroids are eicosanoid inhibitors. They may be
ant-inflammatory at different stages. Systemic therapy with a useful benefit/ risk ratio has not been
demonstrated in chronic venous disease. NSAIDS are currently mainly used for acute thrombophlebitis
and sometimes in acute inflammatory exacerbations of lipodermatosclerosis. Local steroid creams are in
widespread use for venous eczema.194
Several presentations/ publications resulted directly from the work in this thesis. Three
of the papers were published in widely circulated, high quality, peer reviewed journals
(Journal of Vascular Surgery/ European Journal of Vascular & Endovascular Surgery).
Copies of these have been appended at the end of the thesis. One other published article




It is acknowledged that an added study of effect of compression on plasma markers of
endothelial/ leucocyte activation would have been useful in comparing this response to
that seen with pharmacotherapy and surgery. Constraints of the project did not allow
that to happen but it would have been a very informative study to perform.
The study of the outcome of treatment was meant to try and quantify possible outcomes
after surgical treatment of duplex proven varicose vein disease in subjects with leg
ulcers. Because of the long-term results required a prospective study was not possible in
the constraints of the project. Larger population longer term results may now become
available through centrally maintained web based registeries.
Studies into the role of VEGF monitoring in patients with chronic venous disease
looking at a larger population may be useful and informative.
As suggested it may be a possible application of this data to determine whether the
treatment being applied is effective. However the scope of these studies would not allow
such conclusions to be made.
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APPENDIX II
Classification of chronic venous disease (C, E, A, P) (Original)
……………………
Limbs with chronic venous disease should be classified according to clinical signs (C),
cause (E), anatomic distribution (A), and path physiologic condition (P). The
classification system detailed below and summarized in Table I was developed in 1994
by an international consensus conference on chronic venous disease held under the
auspices of the American Venous Forum.
Clinical classification (C0-6)……
(It replaces clinical classes 0 to 3 outlined in the 1988 version of ‘Reporting Standards
in Venous Disease’. This updated method of classifying chronic venous disease is
designed to provide the additional details necessary to accurately compare limbs in
medical and surgical treatment trials.
((………………………………………………………………………
Any limb with possible chronic venous disease is first placed into one of seven clinical
classes (C0-6) according to the objective signs of disease listed.
Venous-dilation…………………………………………………………………………….
Mild chronic venous insufficiency (CVI) is signified by the occurrence of a
submalleolar venous flare. Greater degrees of venous dilation are apparent by both
observation and
palpation. Telangiectasiae are defined as dilated intradermal venules less than 1 mm in
Size. Reticular veins are defined as dilated, nonpalpable; sub dermal veins 4 mm in size
or less. Varicose veins are defined as dilated palpable subcutaneous veins generally
larger than 4 mm.
Oedema.
The presence of oedema indicates more functionally advanced venous disease than the
presence of venous dilation alone. In individual case reports and when otherwise
applicable, the location and extent of oedema should be noted and objectively
documented with circumferential limb measurements.204
Table 27 Classification of chronic lower extremity venous disease
Skin
pigmentation…………………………………………………………………………..
Pigmentation changes and other cutaneous manifestations of chronic venous disease
(venous eczema, lipodermatosclerosis) are important signs of severe chronic venous




The location and measurements of any venous ulcer should be described, and the
presence absence of granulation tissue should be noted. The presence of healed venous
ulceration manifested by cutaneous scarring should be noted
Limbs in higher categories have more severe signs of chronic venous disease and may
have some or all of the findings defining a less severe clinical category. Each limb is
further characterized as asymptomatic (A), for example, C0-6,A, or symptomatic (S), for
example,
C0-6,S. Symptoms that may be associated with telangiectacic, reticular, or varicose veins
include lower extremity aching, pain, and skin irritation. Therapy may alter the clinical
category of chronic venous disease. Limbs should therefore be reclassified after any
form of medical or surgical treatment.
Classification of chronic lower extremity venous disease
C Clinical signs (grade0-6), supplemented by (A) for asymptomatic and (S) for
symptomatic presentation
E Etiologic Classification (Congenital, Primary, Secondary)
A Anatomic Distribution (Superficial, Deep, or Perforator, alone or in combination)
P Path physiologic Dysfunction (Reflux or Obstruction, alone or in combination)205
Table 28 Clinical classification of chronic lower extremity venous disease
Anatomic classification (AS,D,P). …………………………………………………….
The anatomic site(s) of the venous disease should be described as superficial (AS), deep
combination. For reports requiring greater detail, the involvement of the superficial,
deep, and perforating veins may be localized by use of the anatomic segments listed .
Measurement by superficial venous canulation of the foot venous pressure at rest in the
upright position and the change in pressure on walking has historically represented the
"gold standard" for the overall objective assessment of chronic venous disease.
25 It is
now recommended that reports of patients with chronic venous disease be accompanied
by sufficient objective measurements of venous haemodynamics and anatomy to
document adequately the individual patho-physiologic changes, reflux, obstruction, or
both, accompanying chronic venous disease. Phlebographic or vascular laboratory
studies can (AD), or perforating (AP) vein(s). One, two, or three systems may be
involved in any objectively assess the presence of venous outflow obstruction (PO), as
well as the presence of venous reflux (PR) in the superficial, communicating, and deep
venous systems.
Clinical classification of chronic lower extremity venous disease
Class 0 No visible or palpable signs of venous disease
Class 1 Telangiectasiae, reticular veins, malleolar flare
Class 2 Varicose veins
Class 3 Edema without skin changes
Class 4 Skin changes ascribed to venous disease (e.g., pigmentation, venous
eczema, lipodermatosclerosis)
Class 5 Skin changes as defined above with healed ulceration
Class 6 Skin changes as defined above with active ulceration206
Table 29 Etiologic classification of chronic lower extremity venous disease
Patho-physiologic classification (PR,O). ……………………………………….
Clinical signs or symptoms of chronic venous disease result from reflux (PR),
obstruction (PO), or both (PR,O). Ascending phlebography defines areas of obstruction,
recanalization, and collateral vein formation. Descending phlebography demonstrates
competency of venous valves by assessing the magnitude of contrast reflux.
Comparisons of different reports of with the venous segments outlined in Table IV.
Currently, duplex ultrasonography performed with the patient in an upright position and
with the limb
examined in a non Wight bearing position, in combination with proximal deflation of a
venous occluding blood pressure cuff,
24 is the best-documented noninvasive method of
quantifying reflux, by measuring reflux duration in specific axial superficial or deep
venous segments. Duplex scanning is also suggested as a means of identifying reflux in
individual communicating
veins.…………………………………………………………………...
Table 30 Patho-physiologic classification of chronic lower extremity venous disease
Table 1.8. Etiologic classification of chronic lower extremity venous disease
Congenital
(EC)
The cause of the chronic venous disease has been present since birth
Primary
(EP)
Chronic venous disease of undetermined cause
Secondary
(ES)
Chronic venous disease with an associated known cause
(postthrombotic, posttraumatic, other)




Reflux and obstruction (PR,O)207





Greater (long) saphenous vein
2 Above-knee
3 Below-knee
4 Lesser (short) saphenous vein
5 Non-saphenous
Deep veins (AD6-16)











15 Tibial (anterior, posterior or peroneal)




Table 31 Segmental localiszation of chronic lower extremity venous disease
The modified CEAP classification was proposed
257, the clinical classification according
to this is presented in table form below. To improve the assignment of designations
under E, A, and P a new descriptor, n, is now recommended for use where no venous
abnormality is identified. This n could be added to E (En, no venous cause identified),
A (An, no venous location identified), and P (Pn, no venous pathophysiology
identified). The authors of the ‘new’ CEAP stress that CEAP is a descriptive208
classification, whereas venous severity scoring and quality of life scores are instruments
for longitudinal research to assess outcomes.
The authors also recommend that the level of investigation in CVD can be logically
organized into 1 or more of 3 levels of testing, depending on the severity of the disease:
They also suggest that this be reported in the staging.
Level I: office visit, with history and clinical examination, which may include use of a
hand-held Doppler scanner.
Level II: noninvasive vascular laboratory testing, which now routinely includes duplex
color scanning, with some plethysmographic method added as desired.
Level III: invasive investigations or more complex imaging studies, including ascending
and descending venography, venous pressure measurements, computed tomography
(CT), venous helical scanning, or magnetic resonance imaging (MRI).
C0No visible or palpable signs of venous disease.
C1Telangiectasies or reticular veins.
C2Varicose veins; distinguished from reticular veins by a
diameter of 3 mm or more.
C3Edema.
C4Changes in skin and subcutaneous tissue secondary to CVD, now divided into 2 subclasses to better define the
differing severity of venous disease:
C4aPigmentation or eczema.
C4bLipodermatosclerosis or atrophie blanche.
C5Healed venous ulcer.
C6Active venous ulcer.
The C clinical stages of the ‘new’ CEAP classification209
APPENDIX III
Enzyme-Linked Immunosorbant Assays (ELISA)
ELISA is an alternative solid-phase readout system (and mostly took over from radio
immunoassay ) in which antibodies or antigen are covalently coupled to an enzyme
instead of a radioisotope so that bound enzyme activity is measured instead of
radioactivity. Some of the enzyme labels are shown in table1. In practice the safety and
convenience of non-radioactive materials and the commercial availability of plate
readers that can measure the absorbance of 96 wells in 1 minute account for ELISAs
growing popularity. Since both ELISA and RIA are governed by the same
thermodynamic constraints, and the enzyme can be detected in the same range of
molarity as commonly used radioisotopes. The sensitivity and specificity are
comparable. I consider four basic strategies for using FLISA assays to detect specific
antibody, antigen or cross-reacting antibodies.
As shown in figure 26, the indirect antibody method is the simplest way to detect and
measure specific antibody in an unknown antiserum. Antigen is non-covalently attached
to each well of a plastic micro titre dish. For this purpose it is fortunate that most
proteins bind nonspecifically to plastic. Excess free antigen is washed off and the vials
are incubated with an albumin solution to block the remaining nonspecific protein
binding sites. The test antiserum is then added, and any specific antibody binds to the
solid-phase antigen. Washing removes unbound antibodies. Enzyme-labelled anti-
immunoglobulin is added. This binds to specific antibody already bound to antigen on
the solid phase bringing along covalently attached enzyme. Unbound antiglobulin-
enzyme conjugate is washed off; then substrate is added. The action of bound enzyme
on substrate produces a coloured product that is detected as increased absorbance in a
spectrophotometer.
Although this method is quick and very sensitive it is often difficult to quantify. Within
a defined range the increase in optical density is proportional to the amount of specific
antibody (added in the first step). However the amount of antibody bound is not
measured directly. Instead, the antibody concentration of the sample is estimated by
comparing it with a standard curve for a known amount of antibody. It is also difficult210
Figure 34 shows diagrammatically various types of ELISA tests. Each of the four rows













































to determine affinity by this method, since the solid-phase antigen tends to increase the
apparent affinity. A single preparation of enzyme-linked antiglobulin can be used to
detect antibodies to many different antigens. Alternatively class specific antiglobulins
can be used to detect how much of a specific antibody response is due to each
immunoglobulin class. Obviously reproducibility of the assay depends on uniform
antigen coating of each well that can vary. The specificity depends on using purified
antigen to coat the wells.
Figure 34 also shows the competition technique for detecting antigen. Soluble antigen is
mixed with limiting amounts of specific antibody in the first step. Then the mixture is
added to antigen-coated wells and treated is described. Any antigen-antibody complexes
formed in the first step will reduce the amount of antibody bound to the plate and hence
will reduce the absorbance measured in the final step. This method permits the estimate
of affinity for free antigen which is related to the half-inhibitory concentration of
antigen. In addition, some estimate of cross-reactivity between the antigen in solution
and that on the plate can be obtained.
The figure also shows the sandwich technique for detecting antigen. Specific antibody is
used to coat the micro-titre wells. Antigen is then bound to the solid-phase antibody.
Finally, a second antibody linked to enzyme, is added. This binds to the solid-phase
antigen-antibody complex carrying enzyme along with it. Excess second antibody is
washed off and substrate is added. The absorbance produced is a function of the antigen
concentration of the test solution, which can be determined from a standard curve.
Specificity of the assay depends on the specificity of the antibodies used to coat the
plate and detect antigen. Sensitivity depends on affinities as well as the (amount of the
first antibody bound to the well that can be increased by using affinity-purified
antibodies in the coating step. The binding of both antibodies of the sandwich depends
on divalency of the antigen, or else the two antibodies must be specific for different
antigenic determinants on the same antigen molecule. If the antibodies are two different
monoclonal antibodies that both bind to the same monomeric antigen. This technique
can be used to ascertain whether212
Figure 35 is a photogtraphhotograph of a typical 96 well ELISA plate.
Turnover rate is the number of moles of product released per munite per mole of enzyme at the
designated temperature…………
………………………
… Figure 36 Enzymes used in ELISA tests…
Enzyme Source Molecular Weight Turnover rate*
Alkaline
Phosphatase
Calf Intestine 140,000 420,000
13-Galactosidase E Coli 540,000 324,000




Peroxidase Horseradish 40,000 220,000
Urease Black Bean 540,000 450,000213
the two antibodies can bind simultaneously to the same molecule or whether they
compete for the same site or sites close enough to cause steric hindrance. The sandwich
technique for detecting antibody cross-reactivity is also depicted. The wells are coated
with antigen I, followed by the adsorption of specific antibody for antigen 1. Excess
antibody is washed off, and enzyme-labelled antigen 2 is added. If bound antibody
cross-reacts with both antigen I and antigen 2 then enzyme-labelled antigen 2 will
adsorb onto the solid phase. This will be measured as increased absorbance of the
enzyme-catalyzed reaction. This method has been used to assay the cross-reactivity of
anti-idiotype antisera for two preparations of idiotype or for detection of anti anti-
idiotype. Other arrangements of antibody and antigen are also possible. Extra layers of
detecting agents can amplify sensitivity but also tend to raise the background and
introduce variability.
An example of the first method described above is the election of human antibodies to
influenza virus. Alternate columns were coated with influenza virus or bovine 'albumin.
Serum is added at 1/10 dilution to the top two wells of each box and serially diluted in
four fold steps from top to bottom. The last coloured well indicates the titre, whereas the
absence of colour in the albumin-coated wells indicates the specificity. A second use of
this method is for screening culture supernatants in the production of hybridoma
antibodies. The sensitivity and peed of the ELISA method make it possible to screen
large numbers of wells for the production of specific antibody. (Clones selected by this
method tend to have high antigen affinities, perhaps due to dissociation of low-affinity
antibodies during the wash steps.
An important caution when using native protein antigens to coat solid phase surfaces
(Figure 34) is that binding to surface can alter the conformation of the protein. For
instance using conformation specific monoclonal antibodies to myoglobin it was found
that binding of myoglobin to a surface altered the apparent affinity of some antibodies
more than others.214
APPENDIX IV
CAM 1 Capillary Anemometer
Optical System
A schematic for the CAM1 is shown in Figure 37. A 7 mW 780 nm laser diode is
focused by lenses l1 and objective l2. The position of l1 is adjusted so that the waist of
the laser beam is in the object plane of the CCD camera and the photodetector. The
position of mirror m1 is adjusted so that the laser beam is in the centre of the image.
The position is set so that the photodetector is aligned with the image of the laser beam
focal point. For maximum contrast between red blood cells and the surrounding
tissue, green light of 525 nm is used for illumination for the CCD camera.
Beam splitter bs1 separates the laser light from the green ccd image. The 50:50 beam
splitter bs2 splits the backscattered laser radiation via mirror m2 onto the detector. Laser
power at the focal point is typically 0.8 to 1 mW with an elliptical spot of about 5 m by 10 m. zw
Figure 37 Schematic drawing of signal processing in the CAM-1
small fraction of the laser light will be backscattered by blood cells and collected by
lens l1. Lens l1 will also collect laser light reflected from the surrounding tissue. Laser
light backscattered by a moving blood cell will shift the frequency of the light. The
magnitude of the shift will depend on the angle of scatter and the angle of the blood cell
velocity. Since the CAM1 collects the reflected light along the same path as the incident
light, the frequency shift will only depend on the relative angle, q, between the incident
beam and the velocity, V.
dwg #215
Figure 38 A schematic presentation of the CAM-1 capillary microscope/ laser Doppler
anemometer
--Electronic system
The CAM1 electronics is shown in Figure 37. Output from the photo-detector is
amplified then bandwidth limited. The bandwidth is limited to 68 Hz to 50 kHz, which
corresponds to a velocity range of 0.02 to 14.6 mms -1. An analogue to digital converter
(ADC) on an interface card in a personal computer, digitses the signal for processing by
the CAM1 software. The ADC samples the signal with 12 bit resolution. The software
allows the Doppler ‘bandwidth’ to be set to 6.25, 12.5, 25, or 50 kHz, corresponding to
an ADC sample rate of 12.5, 25, 50, and 100 kHz, and velocity full scale ranges of 1.8,
3.7, 7.3, and 14.6 mm.s -1 . The bandwidth into the ADC is fixed, only the ADC sample
rate is changed. The ‘bandwidth’ is therefore determined by the ADC sample rate. Since
the ‘bandwidth’ will always be set to eliminate clipping of the calculated velocity
signal, anti-aliasing filters are not necessary. Data is captured in 512 x 12 bit sample
blocks. The interval between blocks can be adjusted but is set by default to 20 blocks216
per second. The maximum rate is determined by the processing power of the computer,
although it is not possible to faster than 24.4 Hz at the lowest bandwidth setting (6.25
kHz) due to the time required to acquire the 512 samples.
Signal Processing
A radix-4 fast Fourier transform (FFT) is performed on each block of 512 samples.
When squared this produces a power spectrum with 256 points. On the lowest
‘bandwidth’ this gives a resolution of 7.2 m.s -1, and 0.057 mm.s -1 on the highest
bandwidth. Two methods are provided for determining the velocity from the Doppler
shift power spectrum (DSPS). The large low frequency components are from the
amplitude and phase variations as the blood cells pass through the laser beam. For larger
vessels, in which the blood flow may have a velocity profile, there will be a wide range
of shifts from the low velocities at the edge, to the maximum velocity at the centre.
The first method works well with small capillaries that usually produce a well defined
narrow peak in the DSPS. In this method the software searches for a peak in the DSPS.
A user-defined threshold is used to ignore the background noise. ft is set to the
maximum frequency component that exceeds the threshold. The maximum power is
then searched for in a section of the PSDS between ft/2 and ft. The capillary blood cell
velocity (CBV) can then be calculated from fp and equation 1
.
The second method detects the highest frequency component ft that exceeds the user
defined threshold. This is more suitable to the DSPS of larger vessels as shown.
However this later method can be sensitive to the threshold level set by the operator,
and the signal strength, if the cut off at fp is not steep.
 = 2nV cos  (where n is refractive index here taken as 1.33;  is wavelength here taken as 780nm)
217
Figure 39 shows a photograph of the CAM-1 capillary anemometer. The lower photograph
shows a detail of the acrylic disc used for exerting graduated pressure on the skin.218
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